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Autografts are the orthopedic “gold standard” for repairing bone voids.
Autografts are osteoconductive and do not elicit an immune response, but they are in
short supply and require a second surgery to harvest the bone graft. Allografts are
currently the most common materials used for the repair of segmental defects in hard
tissue. Unlike autografts, allografts can cause an undesirable immune response and the
possibility of disease transmission is a major concern. As an alternative to the above
approaches, recent research efforts have focused on the use of composite materials made
from hydroxyapatite (HA) and bioresorbable polymers, such as poly-L-lactide (PLLA).
Recent results have shown that the surface hydroxides on HA can initiate the ring
opening polymerization (ROP) of L-lactide and other lactones creating a composite with
superior interfacial strength.
This thesis demonstrates that the surface of porous biologically derived HA
substrates, such as coralline HA and trabecular bone, can be used to initiate the ROP of
L-lactide and other lactones from the vapor phase. This process increases the strength of
the porous scaffold through the deposition of a thin, uniform polymer coating, while
maintaining the porous structure.

The kinetics of the chemical vapor deposition

polymerization (CVDP) are described using a quartz crystal microbalance (QCM). The
reaction temperature and monomer vapor pressure are found to affect the rate of the
polymerization. Also described in this thesis is the preparation of a porous polymer
scaffold that mimics the structure of demineralized bone matrix (DBM).

This

demineralized bone matrix simulant (DBMS) is created using anorganic bovine bone as a
template to initiate the polymerization of various lactones, followed by the removal of the
HA scaffold. This material retained its shape and exhibits mechanical properties superior
to DBM. Finally it is shown that HA can be used to initiate the ROP of ε-caprolactam
and the biocompatibility of various HA/bioresorbable polymer composites are described
through the use of cell cultures run in collaboration with a research group specializing in
immunology.

iv
Dedication

This dissertation is dedicated to my parents, Robert and Denese. Without your
support, guidance, and sacrifices this would not have been possible. I thank you for
encouraging and supporting me and my siblings in our pursuit of higher education.

Love,
Kristopher

v
Acknowledgements
I would like to acknowledge and thank everyone was has helped and supported
me as I have completed my dissertation. First and foremost, I would like to thank
Crystal, my parents, Robert and Denese, my brothers and sisters, Braden, Grant,
Whitney, Jordan, Mattison, and the rest of my family and friends for the support over the
past several years.
I would especially like to thank my advisor, Professor Jody G. Redepenning, for
his support, guidance, and encouragement. He has helped me develop and evolve as an
independent thinker and has provided the opportunity to work on a fascinating research
project. I would also like to extend my thanks to my doctoral committee Dr. Christian
Binek, Dr. Wonyoung Choe, Dr. David Hage, and Dr. Robert Powers for their support.
I would also like to thank my current and former lab members, Dr. Nathan
Stafford, Dr. Chun Juan Zhang, Dr. Jeremy Karr, Dr. Rajesh Rajasekaran, Dr. Troy
Wiegand, Dr. Chris Schwartz, Paul Goodman, Ben Wymore, Haoming Li, and Lukasz
Guaza for their help. Additionally I would like to thank Dr. Andrei Sokolov for his help
with sputtering and lithography, Dr. Natale J. Ianno for his help with sputtering and
questions regarding the quartz crystal microbalance, Dr. You (Joe) Zhou and Dr. Han
Chen for their help with scanning electron microscopy, Dr. Mark Beatty and Bobby
Simetich for their help with mechanical testing, and Les Marquart for his help in the
machine shop. Also I would like to acknowledge Dr. Paul Wooley, director of research
at Orthopaedic Research Institute at Via Christi Hospital in Wichita, KS, Dr. Haiying Yu,
and Zheng Song for performing the cell culture studies.

vi
The funding that made this research possible was provided by the United States
Army Medical Research and Materiel Command (USAMRMC) and the University of
Nebraska Department of Chemistry. Additional thanks to Biomet, Inc. for donating Pro
Osteon and coral samples and Premium Protein Products for donating bovine femurs.

vii
Figures, Equations, and Tables
Title

Page

Equation 2.1

37

Figure 2.1

41

Figure 2.2

42

Equation 2.2

44

Figure 2.3

49

Figure 2.4

50

Figure 2.5

51

Figure 2.6

53

Figure 2.7

54

Figure 2.8

56

Figure 2.9

57

Figure 2.10

59

Figure 2.11

60

Table 2.1

61

Figure 2.12

63

Figure 2.13

65

Figure 2.14

67

Figure 2.15

70

Table 2.2

71

Table 2.3

72

Equation 2.3

74

viii
Title

Page

Equation 2.4

74

Equation 2.5

74

Equation 2.6

74

Equation 2.7

74

Equation 2.8

75

Figure 2.16

77

Figure 2.17

78

Figure 2.18

80

Figure 2.19

82

Figure 2.20

84

Figure 2.21

85

Table 2.4

86

Figure 2.22

88

Figure 2.23

90

Figure 2.24

91

Figure 2.25

93

Figure 2.26

95

Figure 2.27

97

Figure 2.28

98

Figure 2.29

99

Figure 2.30

101

Figure 2.31

102

ix
Title

Page

Figure 2.32

103

Figure 2.33

104

Figure 2.34

105

Equation 3.1

120

Equation 3.2

120

Equation 3.3

121

Equation 3.4

121

Equation 3.5

121

Equation 3.6

122

Figure 3.1

123

Figure 3.2

125

Figure 3.3

126

Figure 3.4

128

Figure 3.5

130

Figure 3.6

132

Equation 3.7

133

Equation 3.8

134

Equation 3.9

134

Equation 3.10

134

Equation 3.11

134

Equation 3.12

134

Equation 3.13

135

x
Title

Page

Equation 3.14

135

Figure 3.7

136

Table 3.1

137

Equation 3.15

138

Equation 3.16

138

Equation 3.17

138

Figure 3.8

139

Figure 3.9

140

Equation 3.18

141

Equation 3.19

141

Figure 3.10

142

Figure 3.11

143

Figure 3.12

146

Figure 3.13

147

Table 3.2

149

Figure 3.14

150

Figure 3.15

151

Figure 3.16

153

Figure 4.1

167

Figure 4.2

169

Figure 4.3

173

Figure 4.4

174

xi
Title

Page

Table 4.1

176

Figure 4.5

177

Figure 4.6

179

Figure 4.7

181

Table 4.2

182

Figure 4.8

184

Figure 4.9

185

Figure 4.10

186

Figure 4.11

188

Figure 4.12

189

Figure 4.13

190

Table 4.3

191

Figure 5.1

202

Equation 5.1

204

Equation 5.2

204

Figure 5.2

205

Equation 5.3

206

Equation 5.4

206

Equation 5.5

206

Figure 5.3

207

Figure 5.4

208

Equation 5.6

209

xii
Title

Page

Equation 5.7

209

Figure 5.5

210

Equation 5.8

211

Equation 5.9

211

Equation 5.10

211

Equation 5.11

211

Equation 5.12

211

Figure 5.6

212

Equation 5.13

213

Figure 5.7

216

Figure 5.8

218

Figure 5.9

219

Figure 5.10

221

Table 5.1

223

Figure 5.11

225

Table 5.2

226

Figure 5.12

227

Figure 5.13

228

Equation 5.14

229

Figure 5.14

230

Figure 5.15

231

Table 5.3

232

xiii
Title

Page

Figure 5.16

234

Table 5.4

235

Figure 5.17

236

Figure 5.18

238

Figure 6.1

252

Figure 6.2

253

Figure 6.3

255

Equation 6.1

257

Table 6.1

258

Figure 6.4

260

Figure 6.5

262

Figure 6.6

263

Figure 6.7

264

xiv
Table of Contents
Chapter

Title

1

Introduction……………………………………………..

1

2

Chemical Vapor Deposition Polymerization of
Common Biocompatible Monomers and Polymers
Initiated by the Nucleophilic Surface of Biologically
Derived Porous Substrates……………………………...

34

Kinetic Analysis of Common Biocompatible Monomers
and Polymers with Chemical Vapor Deposition
Polymerization Initiated by Zinc Oxide at Various
Temperatures using a Quartz Crystal Microbalance……

116

Preparation and Characterization of a Demineralized
Bone Matrix Simulant (DBMS) Prepared from
Composites of Anorganic Bovine Bone and
Polylactones or Polylactams…........................................

163

Preparation and Characterization of Anorganic Bone
(AB)/Poly-ε-Caprolactam (PCLM) Biocomposites…….

201

Preliminary in vitro Biocompatibility Studies for
Anorganic Bone/Bioresorbable Polymer Composites.....

244

3

4

5
6

Page

1
Chapter One
Introduction
The repair and replacement of hard tissue is a challenge that has intrigued humans
throughout history.

Neolithic man was known to perform trephination, the surgical

creation of a hole in the cranium.1 Pre-Incans in Peru not only performed trephination
but also cranioplasty, the repair of defects in the skull.

Several skulls have been

discovered with shells, gourds, and silver or gold plates implanted.2, 3 For broken bones
that would not heal through splinting and fitting together, the Aztecs recommended using
an intramedullary graft of wood.4 The first bone graft procedure was performed in 1501
by an Iranian surgeon, Muhammad Baha’ al-Dawla. He reported the surgical treatment
of osteomyelitis of the skull through the removal of a portion of the sick bone and
replacing it with a piece of bone from a dog.5,
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The outcome of that surgery is not

known, and Job van Meekeren is often credited with the first successful bone graft
procedure in 1668.7 A defect in a Russian man’s skull was repaired by van Meekeren
with a piece of bone from a dog. The church considered this unchristian and the man was
excommunicated. The recipient of the graft asked to have it removed, but by that point
his skull had healed.8 The first clinical autograft was performed in 1820 by Philips von
Walter in Germany.9 The first allograft was performed in 1880 by William Macewen
from Scotland,10 but it wasn’t until 1915 and the publication of F.H. Albee’s work on
bone graft surgery that bone transplantation became more routinely preformed.11
Today, the repair and replacement of hard tissue remains an important issue.
Since the beginning of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom
(OIF), more than 34,300 (19%) of troops have been wounded. Musculoskeletal injuries
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make up 70% of war wounds and 55% are to the extremities. Fractures are 26% of
combat injuries, and 82% of all fractures are open fractures.12, 13 Many of these injuries
are caused by improvised explosive devices (IEDs). The average wound caused by an
IED requires five surgeries, resulting in an estimated 30,000 surgeries.14 Fortunately, the
survival rate of these injuries is now 90%, higher than any previous conflict. This can be
attributed to improvements in body armor, military tactics, improved medical techniques,
and rapid evacuations.15 With the majority of the trauma occurring in OEF and OIF
being orthopedic-related, the United States army has placed an emphasis on improving
treatment and outcomes of these injuries. The first mission statement listed on the United
States Army Institute of Surgical Research Orthopaedic Trauma Research Program
(USAISR OTRP) website is “Improved Healing of Segmental Bone Defects: Develop a
treatment for fractures likely to become non-unions due to the size of the defect,
concomitant neural/vascular injury, or lack of soft tissue coverage. Tissue engineering or
regenerative medicine approaches to discover treatments that are capable of working in
the face of contamination / infection are desired.”16
This issue is no less important to the civilian population. As the U.S. population
ages, the need to repair damaged bone and tissues due to osteoporosis and other diseases
increases. It is estimated that in 2010, 52 million Americans over the age of 50 had
osteoporosis or low bone mass.17 In 2005 alone there were more than 2 million fractures
due to osteoporosis, costing a total of $17 billion.18 In total there are more than 6.5
million fractures a year in the U.S., of which approximately 15% are difficult to heal.
This includes both delayed unions and nonunions.19 Although not as prevalent, bone and
joint cancer affects 0.08% of the U.S. population, with a relative survival rate of 66.3%.20
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The survivors are left with large defects in the bone due to the resection of the tumor,
which often require the use of a bone graft to aid in the repair.21, 22
The vast majority of bone trauma can be healed through the common treatment of
fixation. This involves the alignment, immobilization and stabilization of the bone so the
fracture can heal. For simple fractures, this can be achieved using external slings, splints,
or casts. More complex open or comminuted fractures may require the use of external
fixators. This involves placing pins or wires into the bone above and below the fracture
site that are connected to clamps and rods on the outside of the skin. The three most
common external fixators are the standard pin fixator, the ring fixator, and the hybrid
fixator. No secondary surgery is required to remove the external fixators. Internal
fixation can also be used for complex or comminuted fractures. This is achieved through
the use of metal wires, pins, screws, plates, and intramedullary mails or rods. Although
some devices are left in, a second surgery is often required to remove the device.23 In
cases where the device is left in, the healed bone is not as strong as the preinjury bone
due to the differences in flexural properties between the bone and the supporting device.24
This is known as stress-shielding and can lead to bone atrophy.25 In addition, even
though the fixation device is biologically inert, it is not integrated into the bone. This
results in phase boundaries between the bone and the device, which increases the chances
of future fractures at the site.26, 27
Some traumatic bone injuries lead to segmental bone defects. A segmental bone
defect is defined as a gap or fracture in the bone that is too large to be repaired through
the normal mechanism used to fuse the two segments.28-30 The minimum size of this
defect, known as the critical size defect, is loosely defined as 2-2.5 times the diameter of
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the affected bone.

31, 32

Actual critical size defects vary to some extent based on a variety

of factors, including species, defect location, biomechanical conditions, and age, among
others.33 The result is a permanent gap in the bone that requires a graft composed of a
bioinert or biocompatible material to aid in the healing process.
An ideal bone graft should not produce an immune response but should provide
mechanical support, be osteoconductive and osteoinductive, promote osteogenesis, and
eventually be osseointegrated. An osteoconductive graft is one that permits bone growth
on its surface and into its pores.34 It has been argued that the minimum graft porosity
needed for regenerating bone is 100 µm,35,

36

with the optimum macroscopic porosity

being between 100 and 500 µm.37, 38 The pores promote vascularization and aid in the
transport of materials and waste.

Osteoinduction is defined as the stimulation of

osteoprogenitor cells to differentiate into osteoblasts in an extraskeletal site. A bone graft
is considered osteogenic if it contains cells that help form new bone.39 Osseointegration
is defined as direct contact between the living bone and implant through the ingrowth of
new bone into the graft.34 Gradually the graft is replaced by the new bone in a process
known as creeping substitution.40
The material that is the closest to containing all of these properties, and is
considered the “gold standard” of bone grafts, is autograft bone. An autograft is defined
as bone from one area of the skeleton that is transferred to a different location within the
same individual.

Ironically, autograft bone does not exhibit the so-called optimum

porosity described above.

Common autograft preparations include nonvascularized

cortical, vascularized cortical, and cancellous bone. Cortical bone is typically harvested
from the fibula, rib, or tibia and is used in defects of greater than 5 to 6 cm that require
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structural support. Cancellous bone is harvested from the iliac crest and is useful in voids
where structural support is not needed. Nonvascularized cortical grafts are
osteoconductive but contain little osteoinductive or osteogenic properties.39 Necrosis and
resorption are seen early after transplantation, while new bone growth proceeds at a much
slower pace.41

Vascularized cortical grafts are capable of overcoming the problems

associated with necrosis in the early stages in nonvascularized grafts. Studies have
shown that after 24 weeks both types of cortical autografts are similarly incorporated, but
there is a larger amount of necrotic tissue in the nonvascularized graft.42 Cancellous
autografts are osteoconductive and again provide limited osteogenic properties.39 Their
advantages include rapid revascularization and quick integration times when compared to
cortical bone.42 The advantages of autografts are optimum incorporation, no disease
transmission, and histocompatibility, meaning tissue rejection is not an issue; but there
are major disadvantages as well. Perhaps the greatest issue is donor site morbidity.
Many studies have reported complications when harvesting bone from the iliac crest,43, 44
as well as lingering pain.45, 46 Additionally, the supply of autograft bone is limited.39
One alternative to an autograft is an allograft. An allograft comes from a donor
that is the same species as the recipient. Compared to autografts, there is a very large
supply of allograft material and donor site morbidity is not an issue;47 however, there are
several problems with fresh allografts. The first is disease transmission. Second, fresh
allografts provoke an immune response that threatens the incorporation or destruction of
the graft.48-54 The antigens of the major histocompatibility complex (MHC) are primarily
responsible for the immune response.

55

This response can be reduced if the tissue of the

host and graft are properly matched,49-51 but preservation has been shown to be most
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effective in reducing the immune response, improving the incorporation, and reducing
disease transmission.56 Preservation is typically achieved by freezing the material below
-60 oC or by using freeze drying.57 Although these processes reduce immunogenicity and
antigenicity, they also destroy the osteoprogenitor cells and reduce the osteoinductive
properties, leaving behind an osteoconductive scaffold.

The revascularization and

incorporation of the allograft is generally slower compared to autografts, but the process
is similar.58

Complications that can cause failure of the allograft include infection,

delayed healing, fractures, significant resorption, or a “walling off” of the allograft.59-64
The immune response is thought to be the primary cause of these complications.
Infection rates have been reported to be as high as 14%, but this is not a result of the
transfer process. Instead, it is due to the large amount of necrotic tissue that remains in
the graft for an extended period of time.56, 65, 66 Nonunion has been seen in 11% of cases
using frozen allografts.67 Fractures occur in about 16% of cases, typically two to three
years after implantation.62, 68 The fractures are thought to occur where revascularization
and new bone growth are absent. There are numerous long term studies on the outcome
of bone allografts.60, 69, 70 One noteworthy recent study showed a good or excellent result
in 77% of patients treated with a massive allograft after the removal of a tumor.71
Allograft bone is also often processed as demineralized bone matrix (DBM).
DBM was originally produced as a solution to preservation problems in countries where
power outages are common.57,

72, 73

DBM is prepared by the removal of the mineral

phase of the bone, hydroxyapatite (HA). The demineralization process leaves behind an
organic matrix consisting of noncollagenous proteins, bone growth factors, and
collagen.57, 74, 75 The resulting organic matrix is osteoconductive and osteoinductive but
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has no structural strength.

57, 76

Because it has no mechanical strength, it is often used in

powder or putty form. The complex mechanism by which DBM stimulates new bone
growth is dependent on many factors, including the extent of demineralization, particle
size, donor related effects, preparation of the matrix, and degradation of the matrix during
demineralization.75,

77, 78

Due to these many variables, the clinical outcome is often

difficult to predict. DBM does not elicit an immune response.72
Another less viable alternative to the options summarized earlier is a xenograft. A
xenograft is defined as tissue from a member of one species that is transplanted into a
member of a different species. The major attraction of xenografts is their large supply.
Over the last few decades bone from numerous species has been transplanted into man.
The results have generally been poor.79

Much like allografts, the fresh xenograft

produces an immune response that results in inflammation, sequestration, and resorption
of the graft.80-82

Freeze-dried samples show no decrease in the undesirable

immunological response.83,

84

Another problem when using xenografts is disease

transmission. One example is when bovine bone is used as the grafting material. It is
important to limit exposure to the prion protein (PrPSc) which is responsible for bovine
spongiform encephalitis in cows and Creutzfeldt-Jakob disease in humans.

Current

products produced from bovine bone are deproteinized through either chemical treatment
or sintering at high temperatures, leaving behind the inorganic HA matrix.79

This

deproteinized bovine bone (DBB) has reduced mechanical strength.85, 86 Biodegradability
of these materials differs depending on whether they were sintered or not.86 Additionally,
religious and ethical concerns with transplantation of tissue from other species can pose a
problem.87, 88
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The disadvantages associated with using autografts and allografts have led to
research into alternative materials that still possess many of the properties desired in an
ideal bone graft substitute. A large amount of research has focused on using a bioactive
ceramic, synthetic hydroxyapatite (Ca10(PO4)6(OH)2).89, 90 HA has a similar composition
to the mineral portion of bone. Biological HA is prone to ion substitution and is usually
calcium deficient and always carbonate substituted. Therefore, an appropriate way to
write the formula for biological HA is (Ca, M)10(PO4, Y)6(OH, X)2, where M represents
cations besides Ca2+ (Mg2+, Na+, K+, Sr2+, Ba2+); Y represents carbonates, acid phosphate,
and sulfates; and X represents F-, Cl-, and carbonates.91 HA can be prepared as dense or
macroporous forms. Dense HA is defined as having a maximum porosity of 5% by
volume, with micropores of about 1 µm in diameter.92 It is prepared through a three step
process: preparation of the HA powder, compacting or compressing into the desired
shape, and sintering. HA can be prepared through precipitation,93, 94 hydrolysis, solidstate, or hydrothermal reactions.92, 95 The powder is then compressed at a pressure of 60
to 80 MPa and heated to 950 to 1300 oC.95 Alternative hot-pressing techniques, in which
heat and pressure are applied at the same time, can be used.96

Dense HA is

biocompatible,92 osteoconductive,97-100 and exhibits good interfacial strength between the
bone and the implant.101, 102 But dense HA is a typical fragile and brittle ceramic. It has a
Young’s modulus of 35-120 GPa, a bending strength of 38-250 MPa, a compressive
strength of 120-900 MPa, and a tensile strength of 38-300 MPa. The listed range of
values is due to the different conditions used to prepare the dense HA. All of these
values are comparable to bone, but dense HA has a low fracture toughness (KIC = 0.8-1.2
MPa m1/2), a Weibull’s modulus of 5-18, and a decelerated crack propagation coefficient
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that is 26-80 in a dry atmosphere and 12 to 49 in a humid atmosphere. These mechanical
parameters make dense HA highly susceptible to slow crack growth and make it
unreliable under load. Implants with a Weibull’s modulus of 10-20 are expected to fail in
several months, meaning dense HA is not suitable for load bearing applications. 91, 92, 95 In
addition to inadequate mechanical properties, dense HA is slowly resorbed in the
body.103, 104
An alternative to using a synthetic dense HA implant is to use a synthetic porous
HA implant. There are several methods available to produce porous, synthetic HA
scaffolds.105 One method involves mixing HA powders with volatile particles that burn
off when sintered at high temperatures. This method usually produces closed pores.106, 107
Another method involves mixing HA with water-soluble porogens. This method does not
require sintering and produces an interconnected porous structure.108 A third method
produces porous HA by a technique called foaming. Gas evolving reactions are carried
out within the HA slurry, causing it to foam.

Monomers in the foam are then

polymerized and the entire mixture is sintered.109-111 Other synthetic methods include
phase mixing112 and the polymeric sponge method.113, 114
When dense HA scaffolds and porous HA scaffolds are compared, far more
fibrous tissue is found within the porous implant and at earlier stages after surgery.115
There are two reasons the porous HA provides better conditions for new bone growth
than dense HA. First, porous HA allows migration and proliferation of osteoblasts and
mesenchymal cells to take place.
pores.116

In addition, vascularization can occur within the

Second, porous HA provides greater mechanical stability between the

surrounding bone and the implant.117 As stated earlier, Hulbert and Klawitter argue that
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the minimum pore size required for regenerating bone is 100 µm. This corresponds well
with the average size of the pores in the haversian system, which have diameters between
100 and 200 µm.35, 36 In addition to pore size, interconnectivity is also important.118-123
Interconnected pores allow cells to penetrate into the scaffold and vascularization to take
place throughout so that bone growth occurs within.124-127 Although larger pores and
greater interconnectivity produce more bone ingrowth, the mechanical strength decreases
as these properties increase.105, 128, 129 For example, increasing the pore volume from 10
to 20% results in a decrease in the mechanical strength by a factor of four.130, 131, 132 The
porosity also increases the surface area of the HA implant, which leads to greater
resorption than dense HA.133
The materials described above are attempts to mimic the bone structure produced
by nature.134 An alternative to producing synthetic structures is to use materials already
provided by nature.

One example of a natural porous substrate is coral.

Coral is

composed of calcium carbonate, usually in the mineral form aragonite. The two genera
of coral that receive the most attention are Porites and Goniopora because of their
structural similarities to human bone. Porites has a void volume of 66%, a pore size of
230 µm, and an interconnecting pore size of 190 µm. Goniopora has a pore size of 600
µm and an interconnecting pore size of 220 to 260 µm.135 Although the unaltered coral
can be used as a bone graft scaffold, it is usually considered inadequate due to its high
dissolution rate and poor longevity and stability.134 It is possible to convert the calcium
carbonate in coral to hydroxyapatite via hydrothermal exchange while maintaining the
macroscopic structure.136 The new material is often called coralline hydroxyapatite and
has been shown to be an effective osteoconductive scaffold for the generation of new
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bone.

122, 137-140

Conversion to 100% HA is possible, but the reaction can also be

terminated early to produce a material with a calcium carbonate core and a thin HA layer.
Scaffolds that are not completely converted to HA dissolve faster than scaffolds
composed completely of HA.97
Porous HA can also be derived from bovine bone. This scaffold is produced by
removing the organic material, generally through the use of one of two methods. The
first method involves using highly caustic solutions to dissolve and hydrolyze the organic
material. The second method involves removal of the organic material through heating at
high temperatures.89, 90, 141-143

These methods can be used to produce anorganic bone

with a porous scaffold that is identical in structure and composition to the original bone
while exhibiting good osteoconduction.144-147
Bioresorbable polymers have also been used in a variety of ways for bone fixation
and repair. Among synthetic polymers, polyesters have been extensively researched.
This class of polymers includes poly-L-lactide (PLLA), polyglycolide (PGA), poly-εcaprolactone (PCLN), poly-p-dioxanone (PD), and copolymers of these polymers. The
attractiveness of these polymers lies with their ability to undergo hydrolysis at the ester
linkage, eventually leading to the complete breakdown of the implanted material.148 The
degradation mechanism is regarded as bulk erosion, as evident by the large molecular
weight decrease that precedes the release of the monomer.149 Currently, these materials
are most commonly used in sutures, rotator cuff repair, and as fixation plates and screws
for non-load bearing applications.150-156

The downside to solid implants composed

completely of PLLA is slow bone ingrowth, fibrous encapsulation of the implant, and
localized acidosis due to polymer degradation.157-161 In addition, such solid polymer
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devices remain in the recipient for several years and can actually inhibit the healing
process.162 One study saw local inflammatory reactions and intraosseous cysts in the
bone where bioresorbable polymer implants were placed.163 Recent work has focused on
creating highly porous scaffolds to promote bone growth.

These porous polymer

matrixes can be created by a variety of methods, including fiber bonding, solvent
casting/particulate leaching, gas foaming, and phase separation.164-166

The polymer

scaffolds often exhibit good osteocompatibilty167 and osteoconductivity.168

Local

acidosis is generally not a problem with highly porous scaffolds because they have a low
polymer mass per unit volume and, in general,161 the buffering capacity of biological
fluids is able to compensate for the acidic products of the degradation. Furthermore, the
movement of these fluids dilutes and diffuses the products away from the implant site.160,
169, 170

Of concern when using bioresorbable polymer scaffolds is the mechanical strength

over time.

The bulk degradation mechanism can lead to a large decrease in the

mechanical properties over a short period of time because of the large surface area of the
porous scaffold.167

The mass and strength loss depend on many factors, including

polymer properties, implant configuration, in vitro test conditions, and in vivo
conditions.148,

171, 172

Ideally the degradation rate and mechanical strength loss

compliments the healing rate of the bone to prevent failure of the device.173
Unfortunately, ceramic and polymer implants alone don’t accurately mimic the
structure of bone. Bone is composed of an organic matrix (30-35% by weight), made up
of mainly type I collagen, with an inorganic mineral phase (65-70% by weight) dispersed
throughout. The inorganic material, HA, provides the mechanical strength and rigidity,
while the organic matrix provides flexibility and elasticity.174 To more closely mimic the
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unique structural characteristics of bone, researchers have investigated using HA as a
filler within a matrix of a bioresorbable polymer. The polymer helps to overcome the
brittleness of the HA, and the ceramic improves the mechanical properties and
osteoconductivity of the polymer matrix.175-178

Several studies have examined the

efficacy of PLLA/HA composites in animal models.179-186 One study where PLLA/HA
composites were implanted in the tibias of rabbits found bony ingrowth into the implant.
The polymer was absorbed gradually over time and no adverse reactions were seen.180
Early composites were formed by taking a high molecular weight polymer and combining
it with HA through various methods, such as solvent solution casting, melt mixing, and
mechanical pressing.187

Although the results were promising, a lack of interfacial

bonding and adhesion between the two phases limited the mechanical strength of the
composite materials.188-191 Because the HA was not bonded to the polymer, the interface
served as a point of failure and failure propagation.192 To overcome this problem, several
researchers have attempted to modify the surface of HA to improve the interfacial
bonding between the HA and the polymer matrix.193-195
Typically, the ring opening polymerization of lactones is performed using tin(II)
octoate (Sn(oct)2) as a catalyst and an alcohol as an initiator. This polymerization occurs
via coordination insertion with the final polymer having an alcohol and ester end group,
which prevents the polymer from bonding to the surface of HA.196-201 Recently an
alternative method for the production of HA/polymer composites has been developed.
This method uses the nucleophilic hydroxides on the surface of HA to initiate the ring
opening polymerization of various lactones. This polymerization process is anionic.202-204
In the resulting composite, the bioresorbable polymer is directly bonded to the surface of
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the HA.

This improved interfacial interaction between HA and the bioresorbable

polymer produces a composite with superior mechanical properties. One recent study
used an anorganic bone scaffold to initiate the polymerization of L-lactide.

The

monomer polymerized within the porous framework and the resulting composite had a
macroscopic morphology similar to the original bone, with the polymer replacing the
original organic matrix. The composites exhibited compressive strength and an elastic
modulus similar to that of human femoral bone.205
The research presented in this dissertation is based on a continuing effort in our
research group to use the nucleophilic surface of HA to initiate the ring opening
polymerization of L-lactide and other lactones. The resulting composite material can
potentially be used for the repair of hard tissues. Previous work has focused on using
synthetic and biological powdered HA and anorganic cortical bone to initiate the
polymerization of lactones.

These reactions were performed with the HA in direct

contact with the molten monomer and resulted in a nonporous composite. The anorganic
bone/PLLA composites exhibited a macroscopic morphology and mechanical properties
similar to that of the original bone.205-207
My efforts, described in the proceeding chapters, will mainly focus on the
creation of porous polymer/ceramic materials that can potentially be used for hard tissue
repair. Interconnected porosity is a highly desirable trait of bone graft substitutes because
it improves the osteoconductivity of the material by allowing cells to penetrate into the
scaffold and provide vascularization throughout so that bone growth occurs within the
scaffold.124-127 Many attempts have been made to produce a synthetic porous scaffold
that mimics the structure of bone. Alternatively, nature provides numerous porous
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ceramic scaffolds that resemble the structure of bone. These include coral and anorganic
bone. The problem with both synthetic and naturally occurring ceramic porous scaffolds
is the mechanical properties are often ill suited for load bearing applications.
Improvements in the mechanical properties can be made by introducing a polymer
coating onto the scaffold; however, there is not a direct bond between the ceramic and the
polymer, and the coating processes can leave behind uneven polymer films and partially
filled pores. Chapter 2 will describe my efforts to use the nucleophilic surface of various
biologically derived porous substrates to initiate the polymerization of lactones. The
process produces thin, even polymer films and leaves the pores intact. The attachment of
the polymer to the surface creates a better interfacial strength and increases the
mechanical properties of the scaffold.

Chapter 3 examines the kinetics of the

polymerization process through the use of a quartz crystal microbalance.
A different type of porous material is described in Chapter 4. As in previous
work within our group, anorganic bone is used to initiate the polymerization of various
lactones. Removal of the inorganic material leaves a porous polymer substrate. Because
anorganic bone was used as the template, the resulting polymer matrix has a structure
similar to DBM. Unlike DBM, the material maintains its original structure and exhibits
improved mechanical properties.
In addition to the production of the porous substitutes described above, Chapter 5
focuses on using HA and anorganic bone to initiate the polymerization of the lactam εcaprolactam. ε-Caprolactam is structurally similar to ε-caprolactone but contains an
amide group in place of the ester group. Poly-ε-caprolactam (PCLM) degrades slower in
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the body than polylactones, which could be advantageous in load bearing applications
where implant strength is needed over an extended period of time.
Any material that will potentially be implanted into the body for hard tissue repair
must be biocompatible. Chapter 6 describes preliminary results based on cell culture
experiments designed to assess the cytotoxicity and inflammatory response toward the
HA/polymer composites. In summary, the research in this dissertation describes my
efforts to create various biocompatible HA/polymer composites that can potentially be
used for hard tissue repair.
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Chapter Two
Chemical Vapor Deposition Polymerization of Common Biocompatible Monomers and
Polymers Initiated by the Nucleophilic Surface of Biologically Derived Porous Substrates

Introduction and Background
As was described in the introduction, an extensive body of research has examined
the use of ceramics, such as hydroxyapatite (HA), biodegradable polymers, and
composites of the two materials as an alternative to autografts and allografts as bone
grafts for the repair of large defects in bone.

After biocompatibility and

osteoconductivity, perhaps the most important property of a bone graft substitute is
compositional similarity to the bone it is replacing, and its efficacy in mimicking the
macro- and microscopic morphology of bone.1-5 Bone is composed of an inorganic
material, highly substituted hydroxyapatite, within an organic matrix. The porosity of
cortical bone is 3-12% and the porosity of cancellous bone is 50-90%. The pores within
cancellous bone can be as large as 1 mm whereas the voids within cortical bone are much
smaller. For example, the series of interconnected pores that comprise the haversian
canals in cortical bone have a cross-sectional area of 2500-12000 µm2.2
HA is often the material of choice for bone defect repair due to its similar
composition (Ca10(PO4)6(OH)2) to bone. The original sintered HA ceramic grafts were
dense and mechanically strong, but poorly resorbed, brittle, and difficult to handle.6
Several studies have shown a lack of fibrous tissue surrounding implanted dense HA
scaffolds,7, 8 while others have observed fibrous tissue surrounding the implant.9, 10 Often
lacking in these early studies was demonstration of tissue regeneration inside the implant.
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When comparing dense HA scaffolds to porous HA scaffolds, Andrade et al. observed far
more fibrous tissue within the porous implant and at earlier stages after surgery.11 The
pores were found to be desirable for the development of new bone growth for two
reasons. First, they allow the migration and proliferation of osteoblasts and mesenchymal
cells to take place, followed by vascularization within the pores.12 Second, the pores
were found to promote greater mechanical stability between the surrounding bone and the
implant.13 Hulbert and Klawitter showed that the minimum pore size required for
regenerating bone was 100 µm. This corresponds well with the average size of the pores
in the haversian system, which have a diameter between 100 and 200 µm.14,

15

The

optimum range for macroscopic porosity is between 100 and 500 µm.16, 17 In addition to
pore size, interconnectivity of the pores is also important.18-23 Interconnected pores allow
cells to penetrate into the scaffold so that vascularization and mature bone growth can
occur throughout.24-27 Three factors that are considered important when optimizing bone
growth within a porous scaffold are the permeability, tortuosity, and the mean equivalent
diameter of the interconnecting pathways.28 Microporosity (less than 5 µm) and surface
roughness are also important in regard to the bioresorbability of the ceramic bone graft.
The desirable influence of high surface roughness has been attributed to high levels of
adsorbed bone producing proteins and cells, both of which facilitate resorption of the
scaffold.2, 29, 30 Although larger pores and greater interconnectivity produce more bone
ingrowth, the mechanical strength decreases as these properties increase.1,

2, 31

For

example, increasing the pore volume from 10 to 20% results in a decrease of the
mechanical strength by a factor of four.29,

32, 33

The optimum scaffold therefore must

strike a balance between the porosity of the implant and strength. Although scaffolds
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with high porosity may lead to high rates of new bone growth, their poor mechanical
stability can limit their utility to non-load bearing applications.
Synthetic HA scaffolds have been prepared using a variety of methods.1 One
method involves mixing HA powders with volatile particles that burn off when sintered
at high temperatures. This method usually produces closed pores.34, 35 Another method
involves mixing HA with water-soluble porogens. This does not require sintering and
produces an interconnected porous structure.36 A third method produces porous HA by a
technique called foaming.

Gas evolving reactions are carried out within a slurry

containing HA and a polymerizable monomer, causing it to foam. The monomer is then
polymerized and the composite sintered.37-39 Other synthetic methods include phase
mixing40 and the polymeric sponge method.41, 42
The methods described above were designed to produce porous HA scaffolds that
mimic the bone structure provided by nature.43 An alternative to producing synthetic
structures is to use natural materials as templates. One example of a natural porous
substrate is coral. Coral is composed of calcium carbonate, usually in the mineral form
aragonite. The two genera that receive the most attention are Porites and Goniopora
because of their structural similarities to human bone. Porites has a void volume of 66%,
a pore size of 230 µm, and an interconnecting pore size of 190 µm. Goniopora has a pore
size of 600 µm and an interconnecting pore size of 220 to 260 µm.6 Although unaltered
coral can be used as a bone graft scaffold, it is usually considered inadequate due to its
high dissolution rate, poor longevity and poor mechanical properties.43 The calcium
carbonate coral can be converted to hydroxyapatite via hydrothermal exchange while
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maintaining the macroscopic structure.

44

The exchange that takes place is shown in

equation 2.1.

10CaCO3 + 6(NH4)2HPO4 + 2H2O → Ca10(PO4)6(OH)2 + 6(NH4)2CO3 + 4H3CO3

(2.1)

The new material, commonly called coralline hydroxyapatite and has been shown to be
an effective osteoconductive scaffold for the generation of new bone.22,

45-48

Complete

conversion of the calcium carbonate in coral to HA is possible, but the reaction can also
be terminated early to produce a material with a calcium carbonate core and a thin HA
layer. One commercially available product of this composition is Pro-Osteon 500R
produced by Biomet, Inc. Because it is not completely converted to HA, the dissolution
is faster than a scaffold composed completely of HA.49 The hydrothermal conversion can
also be used to convert other marine species such as Australian coral,50 cuttlefish bone
(CFB),51 and gastropod (Abalone) nacre52 from calcium carbonate to HA. CFB is of
interest because it is readily available worldwide. Although the structure of cuttlefish
bone is different from that of bone, it does contain highly ordered layers of
interconnected, 80 µm x 100 µm, pores.51
Another commercial HA scaffold derived from a natural source is modified
bovine trabecular bone. This scaffold is produced by removing the organic material and
then sintering the remaining anorganic bone. An example of a commercially available
product is Endobon produced by Biomet, Inc. (Warsaw, IN).53 The advantage of using
bovine trabecular bone is that its composition is virtually identical to that of human bone,
and it possesses good osteoconduction.54-57
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As was mentioned earlier, the major problem associated with porous ceramic
scaffolds is a decrease in mechanical strength as the porosity increases. One method
aimed at increasing the mechanical strength is filling microscopic pores in the ceramic
with a biodegradable polymer, such as poly-L-lactide (PLLA) or polyglycolide (PGA),
creating a composite polymer/HA material.

The HA scaffold is reinforced and the

limited bioactivity of the polymer is countered by combining the two materials.58-63 Such
polymer coatings should evenly coat the entire substrate while maintaining the open
porous structure. This is traditionally achieved by dipping the scaffold into a solution or
liquid melt of the polymer after which it is removed and dried. Thin polymer coatings can
also be achieved through other methods, including spraying or spin-on processes.62 The
processes described above can result in non-uniform thicknesses, pinholes, and residual
solvent left behind.64 In addition, such techniques do not produce a chemical bond
between the scaffold and the polymer. One might conclude that such a bond would
increase the interfacial strength of the composite, and improve the mechanical properties
of the entire device.
Chemical vapor deposition polymerization (CVDP) is one method capable of
producing thin, even polymer films that can be bonded to the surface on complex
substrates. In CVDP, a monomer precursor is heated in the presence of a substrate. The
monomer enters the vapor phase where it comes into contact with the substrate. At the
substrate surface it adsorbs and one of two results can occur. The monomer can react at
the surface or desorb and reenter the vapor phase. Over time a thin polymer film is
produced that becomes thicker as the reaction proceeds. Because the substrate does not
come into contact with the liquid monomer, excess monomer does not accumulate and
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consequently need not be removed. Additionally one does not have to worry about filling
the pores with liquid monomer through capillary action. Finally, for coatings formed by
CVDP, one can often identify discrete bonds between the surface and the polymer chains
in the coating. In other words, CVDP coatings do not merely cover the surface; they are
attached to it.64
Recently it has been shown that the ring opening polymerization of several
lactones can be initiated by the nucleophilic surface of HA in the absence of any other
solvent or catalysts.65-67

With this result in mind, one can hypothesize that the

polymerization could occur out of the vapor phase. In this chapter I describe the use of
CVDP to create composites of porous HA scaffolds with polylactones and polylactams.
More specifically, the work in this chapter describes the use of various biologically
derived porous scaffolds, including cuttlefish bone, coral, coralline HA, and trabecular
bone, to initiate the polymerization of lactones and lactams via CVDP.
Experimental
Chemicals: Ammonia dihydrogen phosphate (NH4H2PO4, from Sigma Aldrich,
St. Louis, MO), calcium hydroxide (Ca(OH)2, ≥ 95% from Sigma Aldrich), calcium
hypochlorite (Ca(OCl)2 from Sigma Aldrich), cuttlefish bone (CFB, from Petsmart,
Lincoln, NE),

deuterated chloroform (CDCl3, 99.8% D from Sigma-Aldrich), ε-

caprolactam (99%+ from Acros Organics, Geel, Belgium), ε-caprolactone (99% from
Acros Organics), ethylenediamine (99% from Sigma Aldrich), glycolide (GL, 99.9%
from Polysciences Inc., Warrington, PA), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP,
99.5%+,

from

Acros

Organics),

polystyrene

(PolyCALTM

gel

permeation

chromatography (GPC) standards from Viscotek, Worchestershire, U.K.), sodium

40
hypochlorite (Na(OCl)2, 5.25% solution from HyVee, Lincoln, NE), tetrahydrofuran
(THF, HPLC grade from Sigma Aldrich), and 2,2,2-trifluoroethanol (TFE, ≥ 99% from
Sigma Aldrich) were used as purchased from the respective supplier. L-Lactide (from
Purac, Lincolnshire, IL) was sublimed at 90 oC and then transferred into a N2(g)
atmosphere glove box for subsequent use. Anorganic trabecular bone was derived from
bovine femur donated by Premium Protein Products (Lincoln, NE). Goniopora coral, Pro
Osteon 500R, and Pro Osteon 200R were provided by Biomet® in 6 mm x 12 mm
cylinders and 13 mm x 14 mm x 17 mm blocks.
Preparation of cuttlefish bone/poly-L-lactide (PLLA) composites via CVDP:
CFB was hydrothermally converted from calcium carbonate, present in the mineral form
aragonite, to HA. The CFB was placed in a 0.6 M NH4H2PO4 solution. The molar ratio
of calcium from the CFB to phosphorus from the NH4H2PO4 solution was maintained at
10 to 6, the ratio present in HA. The CFB and ammonium phosphate solution were
placed in a Teflon tube, plugged with Teflon plugs and then inserted into a high pressure
reactor (Figure 2.1). The reactor was sealed with a torque wrench, applying 40 ft/lbs to
each screw. The reactor was heated at 200 oC for 9 hr and then allowed to cool to room
temperature. CFB hydroxyapatite (CFBHA) samples were rinsed with water and dried in
air. Prior to reacting with L-lactide, CFBHA samples were heated at either 700 oC for 16
hr or 800 oC to remove organic material. After heating, samples were transferred to a
vacuum desiccator and allowed to cool before being transferred to a N2(g) atmosphere
glove box. In the glove box, L-lactide (approximately 200 mg) was loaded into a Pyrex
glass tube.

The tube typically had a diameter between 7 and 9.5 mm, and was

constructed with an hour glass constriction near the center. This constriction prevented
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Figure 2.1. High pressure reactor used to hydrothermally convert cuttlefish bone (CaCO3)
to hydroxyapatite. It has an outer diameter of 65 mm, an inner diameter of 39 mm, a
height of 36 cm, and a volume of approximately 310 cm3.
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Figure 2.2.
substrates.

Typical reaction vessel used for the CVDP of L-lactide onto porous
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the sample from coming in contact with the liquid monomer in the bottom of the vessel
(Figure 2.2).

The sample was then inserted in the tube, coming to rest above the

constriction. A rubber septum was placed on the open end of the tube and the reaction
tube and contents were then attached to a rotary vane pump. The pressure in the tube
dropped to 20 mTorr over 10-15 min. Once the reaction vessel was evacuated, its bottom
was immersed in liquid N2 to lower the vapor pressure of the monomer. The reaction
tube was then sealed under vacuum using a glass blowing torch. The tube was then
transferred to a convection oven and the reaction was allowed to proceed at 130 oC.
Reaction times were either 10 days or 14 days. The reaction tube was then removed from
the oven. Before it was opened, the bottom of the reaction tube was immersed in liquid
N2 to condense excess L-lactide from the vapor phase into the bottom of the vessel away
from the sample.
Pre-reaction treatment for Goniopora coral and Pro Osteon: Prior to using coral
and Pro Osteon samples to initiate cyclic lactone polymerizations, I investigated a
number of sample pretreatments in search for optimum conditions that would produce a
composite with desired visual and physical properties. The temperature at which the
sample is heated at prior to reacting with L-lactide affects the sample color, its
composition, and subsequent polymerization rates. Heating samples to 400-500 oC turns
the samples from white to brown and eventually grey. This is due to residual organic
material.68, 69 The sample can be returned to white by heating it to 550 oC or greater. At
600 oC the sample, which is primarily the aragonite polymorph of calcium carbonate
(CaCO3), is converted to calcium oxide (CaO) with the concomitant elimination of
carbon dioxide (CO2) (Equation 2.2).
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CaCO3(s) → CaO(s) + CO2(g)

(2.2)

CaO is a strong nucleophile that is capable of initiating the polymerization of L-lactide,
whereas CaCO3 is a weak nucleophile that does not initiate the polymerization. As
described later, the generation of additional nucleophiles leads to an increase in the
observed polymerization rates.
Preparation of Goniopora coral/PLLA composites via CVDP: Cylinder coral
samples with a diameter of 6 mm and a length of 12 mm were treated at a variety of
temperatures prior to being reacted. These include drying at room temperature under
vacuum, drying at 200 oC in air, and heating to 400 oC, 550 oC, and 600 oC in air. The
length of time was varied as well. Samples were dried at room temperature for 16 hours,
at 200 oC for 2 hours, heated to 400 oC for 3 hours, and various lengths of time from 6 to
43 hours at 550 oC and 600 oC. Reaction and sample preparation was the same as
described above. In a typical reaction, between 300 and 400 mg of L-lactide was loaded
into the reaction tube. Reactions were generally carried out at 130 oC, but occasionally as
high as 160 oC. Reaction times varied from 22 hr to 119 hr. Some of the samples were
briefly immersed for 2 hours in liquid L-lactide before being inverted and allowed to
react via CVDP. The reaction tube was then removed from the oven. Post reaction steps
were performed as described above.
Preparation of Pro Osteon 500R and 200R cylinder/PLLA composites via CVDP:
The pre-reaction treatment of Pro Osteon 500R and 200R cylinder samples with a
diameter of 6 mm and a length of 12 mm was limited to two temperatures. One set of
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samples was heated to 400 C for 3 hours and the second set was heated to 600 C for 19
hours in air. Three hours at 400 oC proved to be sufficient to drive off the organic
material while only turning the sample light brown in color. Nineteen hours at 600 oC
converts roughly 85-90% of the CaCO3 to CaO.

The overall reaction and sample

preparation is the same as described above. For 500R samples, 200 mg of L-lactide was
added to the reaction tube. 200R samples heated to 400 oC were placed in reaction tubes
with one of four different amounts of L-lactide: 100 mg, 150 mg, 200 mg, or 250 mg.
For 200R samples heated to 600 oC, 200 mg of L-lactide was added to the reaction tube.
Samples heated to 600 oC were allowed to react at 130 oC for 5 days via CVDP. Samples
heated to 400 oC were reacted for 10 days via CVDP. The termination of the reaction
occurred as described above.
Preparation of Pro Osteon 500R block/PLLA composites via CVDP: Pro Osteon
500R blocks with dimensions of 13 mm x 14 mm x 17 mm were exposed to a variety of
pre-reaction treatments in an attempt to produce a visually appealing product and a
composite with superior compressive strength compared to uncoated Pro Osteon. The
majority of the samples were dried under vacuum at room temperature for 16 hours.
Others were subjected to heating at 500 oC in various environments including air, a
stream of oxygen, and vacuum conditions.

Additionally, chemical treatments were

executed to attempt to remove residual organic material without heating. These chemical
treatments included placing the sample in solutions of calcium hypochlorite and sodium
hypochlorite followed by rinsing in deionized water and vacuum drying at room
temperature.

Polymerizations of cyclic lactones were then carried out as described

above. A large diameter tube was needed to accommodate for these large samples, and a
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minimum of 4 g of L-lactide was added to the reaction tubes. This amount was sufficient
to ensure that adequate monomer was present to fill the void volume of the Pro Osteon if
the reaction proceeded long enough. Typical reaction times were 6 days, but these
periods varied from 3 days to a maximum of 27 days. Some of the samples were briefly
immersed in L-lactide for either 2 hr or 3 days before the CVDP process. For these
samples, a modified procedure was used to remove the samples from the oven while
isolating the coated sample from excess monomer. A hole was cut in the bottom of the
oven and covered while heating samples.

When the reactions were terminated, the

bottom reservoir of the reaction vessel was dropped through the hole and cooled in liquid
N2 while the sample continued to be heated at the reaction temperature. This proved to
be a highly effective method for condensing the vapor phase monomer into the bottom of
the reaction vessel and for making sure that any excess monomer was removed from the
surface of the sample.
Preparation of bovine trabecular bone (TB)/PLLA, poly-ε-caprolactam (PCLM),
polyglycolide (PG), poly-ε-caprolactone (PCLN) composites via CVDP:

Cylindrical

plugs, with a diameter of 6 mm and a length between 12 and 20 mm, of trabecular bone
were cut from the proximal end of a bovine femur. The plugs were placed into a Soxhlet
extractor to remove the majority of the organic material. The solvent mixture used for
the extraction was 80% ethylenediamine and 20 % deionized water (v/v).70 This solvent
refluxed at 119 oC. The samples were extracted for approximately 48 hr. Fresh solvent
cycled through approximately every 10 min.

After the extraction period, the

solvent/organic bone material mixture was replaced with deionized water.

Soxhlet

extraction of the bone with water was continued until the water was neutral pH. The
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water was replaced 3-4 times during this process. The now white, porous trabecular bone
was removed and allowed to air dry. Samples were further heated to temperatures
between 600 oC and 700 oC in air to remove the residual organic material before being
used in a reaction with one of the monomers. The length of this heating was varied from
16 hr to 66.5 hr. Reactions were executed as described above using excess monomer.
CVDP of L-lactide, ε-caprolactam, and glycolide were conducted at 130 oC, 250 oC, and
100 oC, respectively. Termination of the reactions was executed as described above.
Scanning electron microscopy (SEM) images were obtained using a Hitachi
(Tokyo, Japan) S4700 Field-Emission Scanning Electron Microscope (Morrison
Microscopy Core Research Facility, University of Nebraska-Lincoln (UNL)). X-Ray
powder diffraction (XRD) patterns were obtained on a Rigaku (Tokyo, Japan) D-Max/B
θ/2θ Horizontal X-Ray Diffractometer (Nebraska Center for Materials and Nanoscience
(NCMN), UNL). X-Rays are produced by a 2 kW copper target with Kα of λ = 154.4 pm.
Obtained patterns were compared to and confirmed with a database of standard XRD
patterns. NMR spectra were obtained using either a Bruker (Billerica, MA) 300 MHz
NMR or Bruker Avance 400 MHz NMR instrument. Spectral processing was done using
Bruker Topspin 3.0.b.8 (Research Instrumentation Facility, Department of Chemistry,
UNL). Samples were dissolved in CDCl3 and spectra were referenced to the solvent
singlet at 7.27 ppm. Gel permeation chromatography (GPC) was used to determine Mp.
GPC was performed using a Viscotek VE 2001 GPC solvent/sample module (Department
of Chemistry, UNL). The instrument was equipped with a 7.8 mm x 30 cm Jordi-Gel
DVB 10,000 Å organic GPC column that was heated to 35 oC. The detector was a
Viscotek VE 3589 refractive index detector. HPLC grade THF was used as the eluent at
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a flow rate of 1 mL/min.

A series of polystyrene standards were used to create a

calibration plot from which the molecular weight of the sample could be determined.
Mechanical testing was performed using a Single Axis Instron Model 1123 Fatigue
Testing Machine at a crosshead speed of 1 mm/min (College of Dentistry and
Department of Chemistry, UNL).

Instrument control, data acquisition, and data

processing were performed by Blue Hill version 2.23 software (Norwood, MA).
Results and Discussion
CFBHA/PLLA composites via CVDP: Although the structure is quite different
from mammalian bone, CFB does possess layers of channeling pores that are 80 µm wide
and 100 µm tall,51 making it potentially useful as a porous bone graft scaffold. The
porous structure and a top view of the channeling pores are shown in the SEM images in
Figure 2.3. The CFB was converted to morphologically similar HA for two reasons.
First, the primary inorganic component of CFB, CaCO3, is a weak nucleophile that does
not initiate the polymerization of L-lactide. Second, upon being heated to 400 oC, the
CFB loses an average mass of 10 ± 2% and delaminates into individual layers.
Consequently, heating to higher temperatures in hope of generating well-structured CaO
was not feasible. CFB was converted hydrothermally to HA as summarized by Equation
2.1. Confirmation of successful conversion was demonstrated using XRD (Figure 2.4).
As seen in Figure 2.4, the hydrothermal conversion results in complete conversion from
aragonite CaCO3 to HA. The structure after the conversion is maintained as well (Figure
2.5).
Although the CFB and, subsequently, the CFBHA have a porosity of around 90%,
the CFB’s compressive strength of approximately 2.75 MPa71 is not ideal for use as a

Figure 2.3. Scanning electron microscopy images of cuttlefish bone displaying the layered porous
structure and the channeling pores from above.
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Figure 2.4. X-ray powder diffraction patterns showing the conversion of cuttlefish bone from aragonite CaCO3 to
hydroxyapatite.
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Figure 2.5. Scanning electron microscopy images of the porous structure of cuttlefish bone after it was converted to
hydroxyapatite. The structure of the original cuttlefish bone is maintained (see Figure 2.3).
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bone graft scaffold. To strengthen the CFBHA, I attempted to use it to initiate the CVDP
of L-lactide. The goal was to reinforce the structure with a thin polymer layer. The
reaction was carried out at 130 oC for 10 or 14 days. The results of the CVDP can be
seen in the SEM images in Figure 2.6. Although some pores remain open, it appears that
the majority of them are filled with PLLA. The CVDP of L-lactide by CFBHA was
verified by 1H NMR (Figure 2.7). Peak assignments for L-lactide and PLLA were
compared to literature values.72-76 Comparison of the integrated areas of the quartets at
approximately 5.17 and 5.03 ppm provide information on the amount of polymer
compared to monomer in the composite. The quartet at 5.17 ppm is due to the internal
methine proton in the polymer and the quartet at 5.03 ppm is due to the methine proton of
L-lactide. The quartet at 4.36 ppm is due to the methine protons at the hydroxyl end of
the polymer. Doublets at approximately 1.53 ppm and 1.66 ppm are due to the methyl
protons in PLLA and L-lactide respectively. Comparison of these integrated peak areas
shows this particular composite contains approximately 91% polymer. These preliminary
results indicate that the CVDP of L-lactide can be initiated by CFBHA. The reaction
times were too long and the majority of the pores were filled.

It is possible that

shortening the reaction time will prevent this issue. It is also possible that the pore
structure of the CFB does not lend itself well to the CVDP of L-lactide while at the same
time maintaining the original porosity.
Goniopora coral/PLLA composites via CVDP:

As mentioned earlier in the

experimental section, the coral samples are predominantly CaCO3, specifically the
mineral form aragonite. At elevated temperatures (above 500 oC) it is possible to convert
the CaCO3 to CaO through the loss of CO2 (Equation 2.2). This was originally deemed

Figure 2.6. Scanning electron microscopy images of a
cuttlefish bone converted to hydroxyapatite/poly-Llactide composite prepared by chemical vapor
deposition polymerization.
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Figure 2.7. Representative 1H NMR spectrum of a CFBHA/PLLA composite.
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necessary as CaCO3 is a weak nucleophile not capable of initiating the polymerization of
L-lactide and CaO is capable of initiating the reaction.

Figure 2.8 shows the time

dependent mass loss of Goniopora coral upon heating it in air at 600 oC. Between t = 0
hr and approximately t = 20 hr the rate of weight loss proceeds at a constant rate. The
point at t = 0 hr is the mass of coral obtained by thermally pretreating it at 400 oC for 3
hr. As a result of this thermal pretreatment the average percent mass loss of four samples
heated to 400 oC was 2.56 ± 0.29%, where the reported uncertainty is one standard
deviation (SD). This plot shown in Figure 2.8 indicates that at 600 oC, the decomposition
of the aragonite in coral is a zero order reaction for which the weight of the coral
decreases by approximately 2% of the original weight for each hour it is heated. This
zero order process continues until the mass loss nears 44%, at which point nearly all of
the CaCO3 (Formula Weight (F.W.) = 100.09 g/mol) has been converted to CaO (F.W. =
56.08 g/mol).

Figure 2.8 shows that the extent of the conversion process can be

controlled by terminating the heating process at a given time. As expected, heating the
coral at higher temperatures results in a faster rate of conversion and at much lower
temperatures a much slower rate of conversion occurs. For example, two samples heated
at 550 oC for 25 and 43 hours produced a mass loss of 6.07 and 7.36% respectively. At
500 oC for a period of 43 hr, no conversion of CaCO3 to CaO was observed. The
conversion from aragonite to CaO can be observed over time using XRD. Figure 2.9
shows a series of XRD patterns of coral heated at 600 oC for 12 and 24 hr. It also shows
an unheated sample and a coral sample heated to 400 oC for 3 hr.

Although no

conversion of CaCO3 to CaO occurs at 400 oC, the coral originally present in the mineral
phase aragonite, is completely converted to the mineral phase calcite. This was not
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Figure 2.8. Time dependent mass loss of Goniopora coral heated at 600 oC.
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Figure 2.9. X-Ray powder diffraction patterns for Goniopora coral heated at 400 oC for 3 hr and 600 oC for 12
and 24 hr.
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observed when heating at 300 C or below. Heating the sample at 600 C for 12 hr,
results in an approximately 25% mass loss, meaning approximately 55% of its original
CaCO3 is converted to CaO. The peaks at 32, 37.5, and 54 degrees that are absent from
the patterns of the coral samples treated at lower temperatures are due to CaO. For the
sample that was heated for 24 hr at 600 oC, the conversion is complete and the only peaks
present are those of CaO.
The effect heating at 600 oC has on the microporosity of the coral is readily
apparent in SEM images. Figure 2.10 displays SEM images of a coral sample as received
from Biomet, Inc. and a coral sample that has been heated to 600 oC for 24 hr in air. The
development of small pores a few micrometers in diameter can clearly be seen after
heating. Samples heated at this temperature and length were extremely brittle due to the
loss of 44% of the original mass and increase in microporosity.
Although the mechanical properties of the sample suffered upon its conversion to
CaO, this conversion did create a nucleophile suitable to polymerize L-lactide by CVDP,
and hopefully strengthen the sample. SEM images in Figure 2.11 show a coral sample
heated to 600 oC for 24 hours in air and the same coral sample coated with PLLA by
CVDP. The thin, even polymer coating appears smooth when compared to the uncoated
sample. A few of the macroscopic pores appear to be filled with PLLA, most notably in
the upper left corner, but the majority of the pores remained unfilled and the
interconnected porous network is largely preserved.

The influence of thermal

pretreatment and reaction conditions are summarized in Table 2.1. There are two general
trends that can be observed based on this data. First, longer reaction times produced
larger amounts of deposited polymer when samples were pretreated for the same length

Figure 2.10. Scanning electron microscopy images of (left) Goniopora coral as received from Biomet, Inc. and (right)
Goniopora coral heated at 600 oC for 24 hr in air.
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Figure 2.11. Scanning electron microscopy images of (left) coral heated at 600 oC for 24 hours in air and (right) coral heated at
600 oC for 24 hours in air followed by CVDP of L-lactide to PLLA for 24 hours.
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Sample

Time heated at

Reaction

Reaction time

Mass gain (%)

600 oC (hr)

temperature (oC)

(hr)

1

12

130

40.75

91

2

12

130

57

130

3

12

130

70.5

138

4

12

130

70.5

159

5

6

130

24

31

6

15

130

24

73

7

18

130

24

70

8

30

130

24

87

9

24

130

137

120

10

24

160

26

180

Table 2.1. Raw data for several individual coral/PLLA composites heated at 600 oC for
various lengths of time followed by CVDP of L-lactide to PLLA for various lengths of
time.
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of time at 600 C. Second, as the length of the pretreatment was increased, an increase in
the amount of polymer deposited was observed when the reactions were conducted for
the same length of time at 130 oC. Additionally, reactions conducted at 160 oC instead of
130 oC proceeded faster, producing thicker polymer films and greater polymer masses for
reactions run for the same period of time. A representative 1H NMR spectrum for
coral/PLLA composites prepared via CVDP is shown in Figure 2.12. There are only
PLLA peaks present in this spectrum. Note that the absence of extraneous peaks in the
spectrum indicates that it is a relatively pure sample of PLLA. The spectrum indicates
that the sample is >99% PLLA and that no excess monomer can be detected.
The generation of CaO is advantageous because it initiates the polymerization of
L-lactide, but once in the body any excess CaO will readily dissolve forming strongly
basic Ca(OH)2 in the presence of water.77 If the dissolution were to happen quickly, the
structural integrity of the implant might be compromised and there would probably be an
undesirable response to the strong base. Consequently I sought to convert the CaO
generated during the heating of the coral samples at 600 oC back to the original CaCO3
while maintaining the interconnected porous structure. The conversion of CaO to CaCO3
can be accomplished in two steps. The first step involves converting the CaO to Ca(OH)2
and the second involves converting the Ca(OH)2 to CaCO3. Recently, it has been shown
that Ca(OH)2 can be converted to CaCO3 in supercritical CO2 containing small amounts
of water (wet-sCO2).78 I placed my coral derived CaO/PLLA composites in a desiccator
with a vial of water at 50 oC for 20 hr. This step converted the CaO to Ca(OH)2, but I
also observed that the polymer layer on the sample became highly swollen and more
elastic than its original form. The sample was then placed in a supercritical CO2 dryer
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Figure 2.12. Representative 1H NMR spectrum of a coral/PLLA composite.
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with a damp Kimwipe, containing approximately 1 ml of deionized water. The pressure
was increased to 1250 psi and the temperature to 42 oC over a period of 15 min. The
pressure and temperature were then allowed to drop below the critical point. The XRD
pattern in Figure 2.13 confirms that the original CaO was converted back to CaCO3, but
the resulting polymorph was calcite, not the desired aragonite. This process does hold
potential for converting CaO to CaCO3 in composites such as these. The porous structure
is retained after the conversion. The downside of the conversion process is that the
physical characteristics of the polymer (and probably its molecular weight) are altered. It
may be possible to convert uncoated samples, but the brittleness of such samples presents
a different challenge.
Alternatively, it was possible to demonstrate the polymerization of L-lactide using
coral dried at room temperature under vacuum or at 400 oC in air instead of heating the
coral samples to 600 oC and converting them to CaO. Although CaCO3 does not
effectively initiate the polymerization of L-lactide, I investigated the possible use of
hypochlorite or hydroxide remaining from the process used to remove the organic
constituents. The disadvantage would be the rate of the reaction would slow considerably
because of the small number of potential nucleophiles. The advantage would be the
possible avoidance of brittleness I observed upon heating the coral to 600 oC. Two coral
samples were heated at 400 oC for 3 hr to remove water and any other residual organic
material. The mass loss due to this process was 2.69 ± 0.07%. The pretreated samples
were then used to attempt to initiate the CVDP of L-lactide. The reactions were carried
out at 130 oC for 113 hr. I was somewhat surprised by the success of these reactions.
The average percent mass gain was 37 ± 5%, and the peak molecular weight (Mp) of one
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Figure 2.13. X-Ray powder diffraction patterns for a coral/PLLA sample. Coral had been previously
converted to CaO at 600 oC for 24 hours (bottom). It was then converted to Ca(OH)2 (middle) and finally
calcite (CaCO3) (top) using wet-sCO2.
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of these two samples was measured to be 45,000 Da by GPC. SEM images shown in
Figure 2.14 confirm the presence of a smooth PLLA coating. In Figure 2.14 a SEM
image of an uncoated coral sample heated to 400 oC is compared to a SEM image of the
coral sample with a thin, even layer of PLLA. Again, like the coral heated to 600 oC, a
thin, even layer of polymer is deposited via CVDP without filling up the macroscopic
pores.
Additionally, four coral samples, two of which were placed in a solution of
Ca(OH)2 for three days and then rinsed in water, were dried at room temperature under
vacuum for 16 hr. These treated coral samples were then used to polymerize L-lactide
via CVDP. The reaction was carried out at 130 oC for 5 days. At the end of this period,
polymer was observed to have deposited on the coral. The average percent mass gained
for the four samples was 74 ± 3%. The Mp was 5200 ± 600 Da. These four coral/PLLA
samples also underwent mechanical testing.

The average compressive strength was 18

± 3 MPa and the average elastic modulus was 1.2 ± 0.3 GPa. An additional coral sample
was heated to 500 oC for 16 hr and reacted in the same manner as the preceding four
samples. This sample had a 93.22% mass gain, a Mp of 17,700 Da, a compressive
strength of 11.4 MPa, and an elastic modulus of 0.5 GPa. For comparison purposes, one
source in the literature lists the compressive strength for Goniopora coral at 2.64 MPa79
and trabecular bone between 1 and 12 MPa depending on the location of the bone.80
Consequently, these results from my exploratory experiments suggest that these
coral/PLLA composites are approximately 7 times stronger than the original coral and
also mechanically stronger than trabecular bone.

This increase in strength can be

attributed to the deposited polymer reinforcing the coral structure.

It can also be

Figure 2.14. Scanning electron microscopy images of (left) coral heated to 400 oC for 3 hours and (right) a coral/PLLA
composite after CVDP at 130 oC for 113 hr.

67

68
attributed to partially filling the void volume of the sample. As mentioned earlier, the
higher the porosity, the lower the compressive strength for porous ceramic scaffolds. The
coral samples had a void volume of 72 ± 1%. After coating the samples with PLLA, this
void volume was 67 ± 6% filled. Increasing the compressive strength is important, but
the interconnected porosity needs to be maintained for optimum bone ingrowth. These
preliminary results suggest that I have succeeded in improving the compressive strength
without compromising the desired porosity.
Pro Osteon 500R and 200R cylinder/PLLA composites via CVDP: Pro Osteon is
a coralline hydroxyapatite marketed by Biomet, Inc. Instead of completely converting
the entire coral scaffold to HA, only a thin layer of the surface is converted by
terminating the hydrothermal exchange early.44 This maintains the CaCO3 core which is
resorbed faster than HA and also the interconnected porous structure. The 200R and
500R samples differ in their pore size and porosity. Pro Osteon 200R has an average
pore size of 200 µm and an average porosity of 50%. Pro Osteon 500R has an average
pore size of 500 µm and an average porosity of 65%.81

Biomet expressed interest in

improving the mechanical properties of the Pro Osteon bone graft substitute by using the
CVDP method developed in our group. The goal was to increase the strength while
maintaining the interconnected porosity. Based on results of the coral samples described
above, I opted to focus on two different pre-reaction treatments. Heating samples at 400
o

C in air for three hours was previously shown to remove the residual organic material

without converting the sample to CaO. The downside of this treatment is a slight color
change from white to light brown or grey. The second treatment examined was to heat
the samples in air at 600 oC for 43 hours. The samples were white after this period of
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time and the CaCO3 was quantitatively converted to CaO. Polymerizations of L-lactide
were performed over 10 days at 130 oC for the samples pretreated at 400 oC, and over 5
days at 130 oC for the samples pretreated at 600 oC. For all of the reactions with Pro
Osteon 500R, 200 mg of L-lactide was used. For reactions with Pro Osteon 200R, Llactide sample sizes of 100 mg, 150 mg, 200 mg, or 250 mg were used. A representative
1

H NMR of the polymer product formed using Pro Osteon 500R as the initiator is shown

in Figure 2.15. The polymerization of L-lactide is confirmed by the polymer methine
quartet at 5.17 ppm and the absence of the monomer methine quartet at 5.03 ppm. The
percent mass loss after heating, percent mass gain after the CVDP, and the Mp of the Pro
Osteon 500R and 200R samples can be seen in Table 2.2. The compressive strength and
elastic modulus of the samples can be seen in Table 2.3.

Mechanical testing was

performed by Biomet. The reported values are those provided by them. It is unknown
why they tested only half of the samples heated to 400 oC. As expected the Pro Osteon
samples heated to 400 oC lost around 2 % of their mass and the samples heated to 600 oC
lost around 37 %. This additional mass loss is due to the conversion of CaCO3 to CaO.
These additional nucleophiles explain the higher percent mass increase (due to polymer)
that occurred in a shorter reaction time for the samples heated to 600 oC. It was also
observed that as the amount of L-lactide in the reaction vessel was increased, so too did
the percent mass increase of Pro Osteon 200R samples. By limiting the amount of Llactide available for polymerization, I was able to control the mass deposited on the
surface of the Pro Osteon. Of great interest is the compressive strength of the samples in
Table 2.3. Literature values for the compressive strengths of uncoated Pro Osteon 500R
and 200R samples are 6 MPa and 10 MPa respectively.82 Four Pro Osteon 500R samples
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Figure 2.15. Representative 1H NMR spectrum of a Pro Osteon 500R/PLLA composite.
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38.6 ±
1.5

600 (n = 3)

44.1 ±
6.2
49.0 ±
9.9

200
(n = 3)
250
(n = 3)

69.6 ±
5.9

29.1 ±
4.2

150
(n = 3)

200
(n = 3)

22.0 ±
0.6

100 ± 14

53 ± 8

Mass
gain (%)

100
(n = 3)

200

200

L-lactide
(mg)

4000 ± 400

15000 ± 3000

12000 ± 3000

13000 ± 8000

22000 ± 8000

9000 ± 3000

11000 ± 3000
(n = 18)

Peak
molecular
weight (Da)

Table 2.2. Mass loss of Pro Osteon 500R and 200R and mass gain and
molecular weight of Pro Osteon 500R and 200R/PLLA composites prepared
by CVDP. The values listed for the mass loss, mass gain, and peak
molecular weight are the averages with an uncertainty of one SD ( ± 1 SD).

2.2 ±
1.2

400 (n = 12)

36.9 ±
0.6

600 (n = 5)

200R

2.0
±0.4

400 (n = 20)

500R

Mass
loss
(%)

Pretreatment
temperature
(oC)

Pro
Osteon
type
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400 (n = 10)
600 (n = 5)

400 (n = 6)
600 (n = 3)

500R
500R

200R
200R

11.5 ± 10.0

26.0 ± 11.3

5.5 ± 2.7

5.9 ± 2.0

Compressive
strength
(MPa)

0.2 ± 0.09

0.3 ± 0.08

0.1 ± 0.05

0.2 ± 0.05

Modulus
(GPa)

Table 2.3 Compressive strength and elastic modulus of
Pro Osteon 500R and 200R/PLLA composites prepared
via CVDP. The values listed for compressive strength
and modulus are the averages with an uncertainty of one
SD ( ± 1 SD).

Pre-treatment
temperature
(oC)

Pro
Osteon
type
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tested by Biomet had a compressive strength of 2.6 ± 1.0 MPa. The compressive strength
of Pro Osteon 500R/PLLA composites is similar to or double the value for uncoated
samples depending on the value used for uncoated Pro Osteon samples. No difference
was seen between the samples heated at 400 oC and 600 oC. The additional mass loss of
the 600 oC is possibly offset by the larger mass gained during the CVDP due to the
increase in the number of nucleophiles. The compressive strength of Pro Osteon 200R
samples heated to 400 oC are approximately 2.5 times that of uncoated samples. The
samples heated to 600 oC showed compressive strengths similar to uncoated samples.
The data of the individual samples was examined in an attempt to find a correlation
between the compressive strength and the variables of percent mass loss, percent mass
gain, and the molecular weight of the polymer coating. No correlations were observed.
There are two possible reasons for this. First, the structure of coral is anisotropic83 and
the technicians at Biomet who did the mechanical testing did not record the orientation of
the native macroscopic pores in Pro Osteon with respect to the axis along which their
measurements were made. By examining other Pro Osteon samples, I observed that the
orientation of these columnar structures was not the same in each sample. Since the
samples are compressed along the same axis in each mechanical test (the long axis of the
cylinder), the compressive strength of the sample will be different depending on which
way the porous columns run through the sample. This was a possible source of scatter in
the compressive strength values. Second, the variables (percent mass loss, percent mass
gain, and molecular weight) examined were most likely not the best choices when
looking for an explanation into the compressive strength values. As mentioned earlier in
the chapter, the compressive strength of porous scaffolds increases as the porosity
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decreases. A better method for examining the change in porosity would be to examine
how the percent void volume of the sample changes with the deposition of the polymer.
The percent void volume is calculated by first calculating the volume of the sample,
which for a cube is
V = l ∗ w∗h

(2.3)

V =π ∗r2 ∗h

(2.4)

and for a cylinder is

where V is the volume, l is the length of the cube, w is the width of the cube, h is the
height of the cube or the cylinder and r is the radius of the cylinder. Once the volume of
the sample is known, its void volume (Vvoid) can be calculated by subtracting the volume
of the cube or cylinder that is occupied by the HA/CaCO3 scaffold.
Vvoid = V − (

msample
d CaCO3

)

(2.5)

In equation 2.5, msample is the mass of the sample and d CaCO3 is the density of CaCO3 with
units of g/mm3. The percent void volume (%Vvoid) is then calculated by dividing the void
volume from equation 2.5 by the total volume of the cube or the cylinder from equation
2.3 or 2.4 and multiplying by 100.
% Vvoid = (

Vvoid
) ∗100
V

(2.6)

The mass of PLLA (mtotal) needed to fill the void volume can be calculated by
multiplying the density of PLLA (dPLLA) by the void volume of the sample.

mtotal = Vvoid ∗ d PLLA

(2.7)

75
The percent of the void volume that is filled (%Vfilled) with PLLA after the CVDP can be
calculated by dividing the deposited mass of the polymer (mPLLA) by mtotal and
multiplying by 100.

% V filled = (

mPLLA
) ∗100
mtotal

(2.8)

As can be seen by the equations above, the dimensions of the sample are needed to
determine the void volume and therefore the percent void volume filled. Unfortunately
the exact dimensions were not recorded by the technicians who performed the mechanical
studies. Consequently, additional studies were necessary. For the Pro Osteon 500R
blocks used to initiate the CVDP in the next section, the dimensions were known and the
percent void volume was calculated. Additionally the orientation of the porous columns
was noted and was used to interpret the results of the mechanical testing. If a correlation
between the compressive strength and one of the variables can be established, then an
adequate amount of polymer can be deposited to create composites with the desired
properties and compressive strength.
Pro Osteon 500R block/PLLA composites via CVDP: Pro Osteon 500R block
samples were subjected to a variety of pre-reaction conditions as was described in the
experimental section. This was done in an attempt to achieve three things: remove the
residual organic material, maintain the original white/off-white color of the Pro Osteon
samples, and to create a substrate that would initiate the CVDP of L-lactide to deposit
desired quantities of polymer in a relatively short period of time. As before, the overall
goal was to maintain the interconnected porosity of the Pro Osteon while improving the
compressive strength. In addition to varying the pre-reaction conditions, I also varied the
reaction temperatures in attempts to increase the rate of the CVDP. The influence of
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various pre-reaction and reaction conditions on the color of the Pro Osteon 500R/PLLA
samples can be seen in Figure 2.16.

Samples D, R, and Y were dried at room

temperature under vacuum. Samples D and R were reacted at 130 oC for 6 and 27 days
respectively while sample Y was reacted at 160 oC for 6 days. A representative 1H NMR
of a Pro Osteon 500R block/PLLA composite prepared by CVDP is shown in Figure
2.17. Although room temperature drying under vacuum did not remove the organic
material, the samples maintained their original coloration. Sample Y appeared slightly
yellow due to the higher polymerization temperature. Overall, regardless of reaction
temperature and length, little polymer was deposited when the Pro Osteon samples were
dried at room temperature under vacuum. The average percent mass gain for these
samples was 16 ± 15% (n = 16).

The average Mp for the samples dried at room

temperature under vacuum was 5,000 ± 3,000 Da. The remaining samples in Figure 2.16
were all heated to 500 oC. Sample W was heated for 640 hr, samples K and V for 16 hr
in air, and sample H was heated for 16 hr under a flow of O2(g). The samples heated in air
gradually turned grey in color, and the sample heated under a flow of O2(g) turned dark
grey/brown. In addition to being heated at 500 oC, sample K was bleached in a 5.25% by
weight solution of sodium hypochlorite in an attempt to remove the residual pyrolyzed
organic material. This sample appears to be whiter than the others heated to 500 oC. The
percent mass loss appears to support the contention that additional material was removed
through the bleaching process. Samples heated in air or oxygen lost an average of 2.6 ±
0.1% (n = 4) of their mass while samples bleached after heating lost an average of 4.5 ±
1.0% (n = 2). An additional set of samples was heated at 500 oC under vacuum and these
samples lost 6.1 ± 0.2% (n = 2) of their mass. Samples K and V were reacted with L-
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Figure 2.16. Influence of pre-reaction and reaction conditions on the color of the Pro
Osteon 500R/PLLA composites. The page numbers refer to the page in my laboratory
notebook on which the experimental data is recorded.
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Figure 2.17. Representative 1H NMR spectrum of a Pro Osteon 500R block/PLLA composite.
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lactide for 6 days at 130 C and samples W and H were reacted with L-lactide for 4 days
o

at 160 oC. This increased polymerization temperature again resulted in yellowing of the
PLLA. The percent mass gain due to PLLA for all samples that were pretreated at 500 oC
was 53.1 ± 9.1% (n = 8). Polymerizations at 160 oC resulted in similar amounts of
polymer in 4 days (49.9 ± 9.1%, n = 5) as did reactions done at 130 oC over 6 days, 58.4
± 10.6% (n = 3). The average Mp of PLLA for samples pretreated at 500 oC was 6,000 ±
8,000 Da. It appears that room temperature drying is advantageous for keeping the
original color of the samples, but the subsequent CVDP proceeds slowly. Although
heating to 500 oC is desirable for removing the organic material and increasing the rate of
the reaction, it leads to discoloration of the samples. Similarly, carrying out the CVDP at
160 oC increases the rate of the reaction, but PLLA turns yellow at this temperature.
For this set of reactions, I performed mechanical testing of the composites to
determine the compressive strength and the elastic modulus. Examples of compressive
stress-strain curves for several Pro Osteon/PLLA samples prepared via CVDP are shown
in Figure 2.18. Strain is plotted on the x-axis and has units of percent. This is found by
dividing the travel distance by the sample height and multiplying by 100. The y-axis is
compressive stress with units of pressure because it is defined as the applied force
divided by the cross-sectional area of the sample. Due to the high number of pre-reaction
conditions and reaction temperatures, it was not possible to separate the samples into
subsets based on these conditions when analyzing the data. So the samples were treated
as a single data set. This data set was divided into two subsets depending on which face
of the sample the cylindrical pores terminated. All mechanical testing was performed by
aligning the 13 x 17 mm faces parallel to the load cell such that the mechanical properties
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Figure 2.18. Compressive stress-strain curves for Pro Osteon/PLLA composites prepared via CVDP.

0

9

80

81
were measured along the axis between these faces. Samples containing pores terminating
on a face parallel to the load cell (13 x 17 mm) were in one subset and samples with
pores terminating on a face orthogonal to the load cell (14 x 17 mm and 13 x 14 mm
faces) were in the second subset. These categories were necessary to account for the
anisotropic nature of coral83 and the fact not all samples were cut the same. Upon
examination of the data, I saw that there is a strong correlation between the percent of the
void volume filled by deposited polymer and the compressive strength (Figure 2.19).
The method for calculating the percent void volume filled is shown above in equations
2.3 to 2.8. As can be seen in Figure 2.19, as the percent of the original void volume filled
by polymer increases, the compressive strength of the composite also increases.
Extrapolating these results to zero (an uncoated sample), the compressive strength is 3.54 MPa. This value is within the range of reported values for uncoated Pro Osteon 500R
samples.82 Furthermore, compressive strengths were generally higher for samples in
which the cylindrical pores terminated on the face parallel to the load cell. From the best
fit lines in Figure 2.19, the maximum compressive strength of the Pro Osteon
500R/PLLA composites would be 24 or 36 MPa if the pores were completely filled with
PLLA. Because maintaining the interconnected porosity of the sample is also desirable,
filling the macroscopic pores completely is not desirable. Filling the void volume 60 to
70 % produces a composite with a compressive strength of 20 to 25 MPa without closing
the pores completely. The optimum balance between the two properties is unknown at
this time and will depend greatly on the function and the location in which the composite
would be used.
TB/PLLA, TB/PCLM, TB/PG, TB/PCLN composites via CVDP: Until this point
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Figure 2.19. The effect of filling the void volume of Pro Osteon 500R scaffolds with PLLA via CVDP on the compressive
strength of Pro Osteon 500R/PLLA composites.
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in this thesis the focus has been on using porous scaffolds of marine sources that mimic
the structure of trabecular bone (TB) to initiate the CVDP of L-lactide. One downside to
this approach is that additional steps are often required to convert the scaffold from
CaCO3 to HA. During the conversion process CaCO3 is converted to a CaO intermediate
that is quantifiable. An alternative to using a material that mimics the structure of human
trabecular bone is to use a xenograft derived from the trabecular bone of another species
to initiate the polymerization of L-lactide. To this end, described below are my efforts to
deproteinize and strengthen bovine trabecular bone.
Bovine trabecular bone was harvested as described in the experimental section
and thermally pretreated at 600 oC in air for 24, 49, or 66.5 hr before being used to
initiate the polymerization of L-lactide via CVDP. The polymerizations were performed
at 130 oC for 3 or 5 days. A second set of bovine trabecular bone samples were heated at
700 oC in air for 16 hr. The CVDP of L-lactide was performed at 130 oC for 1 or 2 days
using these samples. A representative 1H NMR of a TB/PLLA composite is shown in
Figure 2.20. Integration of the peak areas corresponding to the internal methine protons
of the polymer (5.17 ppm) and the methine protons of the monomer (5.03 ppm) reveal
this sample is greater than 99% polymer. SEM images of an uncoated TB sample and a
TB/PLLA composite prepared via CVDP in Figure 2.21 confirm the presence of a thin
even polymer layer coating the surface of the TB. Also of note, just like the coral and
Pro Osteon samples, the interconnected pores are maintained after the CVDP. Table 2.4
shows the percent mass loss of the TB samples heated to 600 oC or 700 oC, the percent
mass gain of the TB samples after the CVDP of L-lactide and the Mp of the resulting
PLLA coating. The percent mass loss was the same for samples heated at 600 and 700
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Figure 2.20. Representative 1H NMR spectrum of a TB/PLLA composite prepared via CVDP.
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Figure 2.21. Scanning electron microscopy images of (left) uncoated bovine trabecular bone and (right) a trabecular bone/PLLA
composite prepared via CVDP.
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3

49

66.5

66.5

16

16

600

600

600

700

700

11.3 ± 0.6
(n = 10)

10.5 ± 1.0
(n = 9)

8.5 ± 1.4
(n = 4)

10.2 ± 3.2
(n = 4)

11.7 ± 4.7
(n = 4)

11.2 ± 2.8
(n = 4)

TB mass
loss (%)

198 ± 33

135 ± 75

102 ± 18
(n = 10)

127 ± 35
(n = 8)

117 ± 45

131 ± 74

PLLA
mass gain
(%)

11000 ±
5000

14000 ±
5000

13000 ±
5000

7000 ± 5000

14000 ±
7000

Peak
molecular
weight (Da)

Table 2.4. TB/PLLA composite properties prepared by CVDP. The values listed for the
mass loss, mass gain, and peak molecular weight are the averages with an uncertainty of
one SD ( ± 1 SD).
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C. It’s unknown if longer heating times at 700 C would produce additional mass loss.

o

o

The percent polymer mass gained for the 600 oC samples was not significantly different
based on either the heating time or the reaction time. CVDP reactions involving 700 oC
samples produced percent polymer mass gains similar to the samples at 600 oC but in less
time. Longer CVDP reactions involving the samples heated to 700 oC produced larger
mass gains.
Besides L-lactide, HA has also been shown to initiate the ring opening
polymerization of other cyclic lactones such as ε-caprolactone.66, 67 If the nucleophilic
surface of TB and other porous HA scaffolds can also be used to initiate the ring opening
polymerization of L-lactide via CVDP then it seems logical that it could be used to
initiate the polymerization of the other cyclic lactones as well via this method. Figure
2.22 shows a representative 1H NMR spectrum of a TB/poly-ε-caprolactone (PCLN)
composite prepared via CVDP. The TB was heated to 700 oC for 16 hr prior to the
reaction, losing an average of 10.2 ± 0.9 % (n = 5) of its mass. CVDP was performed at
130 oC for 24 hr with an average percent mass gain of polymer of 101 ± 35 % (n = 5). A
1

H NMR spectrum was obtained in CDCl3.

Peak assignments were verified by

comparison to those in the literature.84-87 The 1H NMR spectrum provides confirmation
that the deposited mass is PCLN and not the monomer. The triplet at approximately 4.05
ppm is the methylene protons adjacent to the oxygen in the ester. The corresponding
peak in the monomer, ε-caprolactone, would appear around 4.15 ppm if any monomer
were present. When verifying the polymer/monomer composition of the composites the
area of these peaks are integrated. A second triplet associated with the other methylene
protons adjacent to the ester is at 2.3 ppm. The peak appearing at 3.65 ppm is due to the

Figure 2.22. Representative 1H NMR spectrum of a TB/PCLN composite prepared via CVDP.

Poly-ε-caprolactone
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protons on the carbon adjacent to the hydroxyl of the alcohol end group. The integrated
peak intensity of this hydroxyl end group (g) relative to the internal CH2 group next to the
ester (c) can be used to estimate Mn, the number average molecular weight. Based on an
integrated intensity of 1.000 for the end group (g), 84.7224 for the repeat unit (c), and a
molecular weight of 114.14 g/mol for the repeat group, Mn is determined to be 5,000 Da
for this sample.
TB is also capable of initiating the ROP of glycolide via CVDP. TB samples were
heated at 675 oC for 19 hr in air losing an average of 9.2 ± 1.4 % of their mass. These
samples were then used to initiate the CVDP of glycolide to polyglycolide (PG). The
reaction was performed at 100 oC for varying lengths of time between 16 and 96 hr.
Figure 2.23 shows a representative 1H NMR spectrum of a TB/PG composite made via
CVDP. The 1H NMR spectrum was obtained in a solution of hexafluoroisopropanol
(HFIP) and CDCl3 in a 3 to 1 ratio (v/v). Peak assignments were confirmed with those in
the literature.88-93 The singlet at 4.89 ppm is due to the internal methylene protons of PG.
The small singlet at 4.99 ppm is due to the methylene protons in glycolide. Integration of
these peak areas provides information on the polymer/monomer composition of the
sample. The sample shown in Figure 2.23 is 99.5% polymer. In Figure 2.24 the percent
polymer mass gain is plotted versus reaction time for the CVDP of glycolide initiated by
TB at 100 oC. Note that the percent polymer mass gain is proportional to time. The
linear relationship between the reaction time and the percent mass gain indicates that the
reaction is pseudo zero order. A more detailed explanation of why this and the other
CVDP reactions are pseudo zero order is given in Chapter 3. From the slope of the best
fit line, the rate of the CVDP of glycolide at 100 oC is 0.63 %/hr at 100 oC.

Glycolide

Figure 2.23. Representative 1H NMR spectrum of a TB/PG composite prepared via CVDP.
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Another polymer sometimes used in biodegradable medical devices is the
polyamide, poly-ε-caprolactam. PCLM can be formed through the ROP of the cyclic
lactam, ε-caprolactam. ε-Caprolactam has the same structure as ε-caprolactone, but with
an amide functional group in place of the ester.94 Due to this amide bond, PCLM is
degraded similarly to natural polypeptides.95 The polymers absorb 9-11% water by
weight and degrades by ion-catalyzed surface and bulk hydrolysis.

Hydrolysis by

enzymatic catalysis can also lead to surface erosion.96 Several attempts have been made
to create composites of HA/PCLM by infusing a porous HA scaffold with ε-caprolactam
and initiating the polymerization with various initiators. The ultimate goal of these
studies has been to increase the mechanical strength of the HA scaffold.97-100 But in all
these cases, the surface of HA was not used to initiate the ROP of ε-caprolactam.
Described below is the use of the surface of the TB to initiate the ROP of ε-caprolactam
via CVDP. The ROP of ε-caprolactam initiated by the surface of anorganic bone to
produce composites with a similar morphology to living bone will be discussed in
Chapter 5. TB samples were heated to 675 oC for 19 hr in air and lost an average of 8.0 ±
0.6 % of their mass.

These samples were then used to initiate the CVDP of ε-

caprolactam. The polymerization reactions were carried out at 250 oC for varying lengths
of time between 24 and 144 hr.

1

H NMR was used to confirm the CVDP.

A

representative spectrum can be seen in Figure 2.25. 1H NMR spectra were obtained in a
solvent mixture of trifluoroethanol (TFE) and CDCl3 in a 3 to 1 ratio (v/v).

Peak

assignments were verified by comparison to those in the literature.101, 102 The quartet at
3.14 ppm is due to the polymer internal methylene protons next to the nitrogen in the
amide functional group. The quartet at 3.21 ppm is the monomer methylene protons next

ε-Caprolactam

Figure 2.25. Representative 1H NMR spectrum of a TB/PCLM composite prepared via CVDP.

Poly-ε-caprolactam
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to the nitrogen in the amide. The triplet at 2.14 ppm represents the polymer methylene
protons adjacent to the other side of the amide and the triplet at 2.42 ppm is the monomer
methylene protons in the same position. Integration of the area of these peaks provides
the amount of polymer and monomer in the deposited material.

This sample is

approximately 82% polymer with the remainder being excess monomer. The series of
multiplets between 1.2 and 1.8 ppm represent the remainder of the polymer internal
protons and the remainder of the monomer protons not adjacent to the amide functional
group. The proton attached to the nitrogen atom appears as a singlet around 6.49 ppm.
The large peaks at 4.95 ppm and 3.85 ppm are due to the solvent, trifluoroethanol. For
the series of CVDP reactions carried out for various lengths of time, the polymer percent
mass gained is plotted versus the reaction time in Figure 2.26. As is the case for
glycolide CVDP, the percent mass increase (relative to the original mass of the sample) is
proportional to the reaction time indicating a pseudo zero order process. The intercept is
once again set to zero because there is no polymer deposited on the TB at time t = 0 hr.
The slope of the best fit line, 0.93 %/hr, is the rate of the CVDP of ε-caprolactam under
these conditions.
Conclusion
In addition to initiating the ring opening polymerization of cyclic lactones and
lactams from monomer melts, hydroxyapatite can be used to initiate the polymerization
of these same monomers from the vapor phase. This process is particularly advantageous
for coating porous scaffolds derived from biological sources, such as coral or trabecular
bone, which are often used as bone grafting materials. The CVDP deposits a thin, even
polymer layer on the entire of these materials while at the same time maintaining the
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Figure 2.26. Percent polymer mass gained as the reaction time increases for the CVDP of ε-caprolactam initiated by TB at
250 oC.
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interconnected porosity that is desired for osteoconductivity.
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The polymer layer

improves the compressive strength of the brittle HA scaffold and this improvement is
dependent on the extent to which the pores of the scaffold are filled. The more the pores
are filled with polymer, the larger the compressive strength becomes. Because this
diminishes the porosity of the sample, an optimum balance between the compressive
strength and the porosity needs to be obtained to produce the best possible composite.
In addition to the biologically derived scaffolds mentioned in this chapter, future
work could focus on the use of other materials of biological origin to initiate the
polymerization of cyclic lactones. One such example is nacre. Although not porous like
coral, nacre has layers of CaCO3 plates with organic layers sandwiched in between
holding them together. The remarkable mechanical properties of this material have
intrigued scientists interested in synthetically duplicating the structure or using it as a
bone graft material.103-105 Figure 2.27 shows the result of an exploratory experiment
conducted to investigate the plausibility of using a modified nacre sample to initiate the
ROP of L-lactide.

The SEM images on the top show the original structure of a

cryofractured nacre bead used in jewelry. The images on the bottom show a second nacre
sample in which the organic material was removed (using a Soxhlet extractor and a 80/20
v/v mixture of ethylenediamine and water) and then used to initiate the polymerization of
L-lactide (the nacre bead was not converted to HA as the hydrothermal process destroys
the microscopic structure, Figure 2.28). The original structure is maintained and there is
a suggestion of the presence of PLLA cementing the ceramic layers together. 1H NMR
spectroscopy was used to confirm the presence of PLLA (Figure 2.29). A macroscopic
example of how CVDP can be used to deposit polymers on irregularly shaped scaffolds is

Figure 2.27. (Top) Scanning electron microscopy images of the original nacre structure and (bottom) the
nacre structure after the organic material has been removed and the sample reconstituted with PLLA.
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Figure 2.28. Scanning electron microscopy image of a nacre bead after it was partially
converted to hydroxyapatite via the hydrothermal process. The conversion was
performed at 200 oC for 5 days. In this case the microscopic structure of the nacre seen
in Figure 2.27 is not conserved.

Figure 2.29. Representative 1H NMR spectrum of a nacre/PLLA composite.
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shown in Figure 2.30. The shell is from a young Strombus urceus, a gastropod from the
Indo-west Pacific region. It was identified with the help of Dr. José H. Lead, director and
curator at the Bailey-Matthews Shell Museum (Sanibel, FL). In the upper right and
bottom images is the same shell after it has been hydrothermally converted to HA and
reconstituted with PLLA by CVDP. In addition to the macroscopic structure being
conserved through the hydrothermal and polymerization processes, SEM images of the
cryofractured shell show that the microscopic structure of the shell is largely conserved
(Figure 2.31).106 XRD performed on the entire shell after the hydrothermal process
shows that it was converted from aragonite CaCO3 to HA (Figure 2.32).

1

H NMR

spectroscopy was used to confirm the presence of PLLA (Figure 2.33). The integrated
peak intensity of the methine proton from the hydroxyl end group at 4.36 ppm relative to
the internal methine proton of the polymer at 5.17 ppm can be used to estimate Mn.
Based on an integrated intensity of 0.1455 for the end group, 1.000 for the repeat unit,
and a molecular weight of 144.06 g/mol for the repeat group, Mn is determined to be
1,100 Da for this sample. The overall structure is maintained and the color is similar to
the original shell.
Finally, I would like to note that CVDP of cyclic lactones could potentially be
used to fabricate hydrolyzable coatings for electronic devices.107 A demonstration of this
process is shown in Figure 2.34. A series of uncoated, patterned magnesium oxide
(MgO) substrates on a silicon dioxide wafer are seen in the left SEM image. In the right
image is the same substrate coated with a thin layer of PLLA via CVDP. The CVDP
process enables the deposition of the polymer only on the surface that initiates the
polymerization.

Figure 2.30. Images of (upper left) the shell of a young Strombus urceus in its original state and (upper right,
bottom) the same shell after being converted to hydroxyapatite and reconstituted with PLLA via CVDP.
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Figure 2.31. Scanning electron microscopy images of the
Strombus urceus shell after being hydrothermally
converted to hydroxyapatite and reconstituted with PLLA
via CVDP.
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Figure 2.32. X-Ray powder diffraction pattern of the Strombus urceus shell after it is hydrothermally converted to HA.
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Figure 2.33. 1H NMR spectrum of the Strombus urceus shell/PLLA composite.
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Figure 2.34. Scanning electron microscopy images of (left) patterned MgO substrates (light areas) on a silicon dioxide wafer and
(right) patterned MgO substrates with a thin layer of PLLA via CVDP.
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Chapter Three
Kinetic Analysis of Common Biocompatible Monomers and Polymers with Chemical
Vapor Deposition Polymerization Initiated by Zinc Oxide at Various Temperatures using
a Quartz Crystal Microbalance

Introduction and Background
In the preceding chapter it was established that nucleophilic surfaces of porous,
biologically derived hydroxyapatite scaffolds can be used to initiate the ring opening
polymerization (ROP) of common biocompatible lactones and lactams via the vapor
phase. The result of this process is a biomimetic biocomposite containing a
hydroxyapatite scaffold covered by a thin, even polymer film. For this process to be wellcontrolled, an understanding of the chemical vapor deposition polymerization (CVDP)
kinetics of the reaction occurring at the surface is needed.
The two main factors that control chemical vapor deposition (CVD) processes are
the thermodynamics of the reaction and the kinetics of the entire process.1

It was

demonstrated in the previous chapter that the CVDP of lactones and lactams on the
surface of hydroxyapatite is thermodynamically viable. It has also been shown that
various zinc salts and other metal oxides are sufficiently nucleophilic to initiate the ROP
of L-lactide to poly-L-lactide (PLLA) in bulk melt polymerizations.2-8
The kinetics of the CVD process can be deconstructed into three major steps: the
introduction of the reactant(s) into the reactor, the transport of these species to and from
the surface, and the reaction that occurs at the surface. All three steps can have an effect
on rate of the reaction, where the slowest step is the rate limiting step.9-11 Choosing the

117
proper design of the reactor and adequate conditions inside the reactor enables one to
eliminate the contributions of the first two steps and ensures that the surface reaction is
the rate limiting step.
CVD methods are often described and categorized based on several different
parameters: the gas flow state, activation manner, wall/substrate temperature, pressure,
and temperature.12 There are two types of gas flow systems: the open reactor and the
closed reactor. In the open reactor system, the reactant gas is generated in a chamber
separate from the reactor. Once the reactant is in the vapor phase, it is transported to the
reactor via a carrier gas. The reactant and the carrier gas flow continuously through the
reactor, entering on one side and exiting on the other. As the gaseous reactant flows
through the chamber, some of the reactant diffuses to the surface of the substrate where it
undergoes a reaction. The byproducts then desorb and are carried away by the carrier
gas. In this system, conditions must be controlled to ensure that mass transport and
diffusion of the gases to the surface are not the rate limiting step. Mass transport can be
rate limiting when a boundary layer forms along the walls and substrate surface as the gas
flows through the chamber. The boundary layer is a velocity gradient that develops
because the velocity of the gas near the walls is zero. Its thickness varies with flow rate
and is often defined by the point where the velocity of the gas near the wall or substrate
reaches 99% of the velocity of the bulk gas.

Thick boundary layers can slow the

diffusion of the reactant gases to the substrate. A boundary layer can also form due to
temperature and concentration gradients near the surface. Low pressure (a few mTorr or
lower) and low temperatures can effectively minimize the boundary layer. This allows
the reactant(s) to diffuse to the surface and also slows the reaction at the surface.
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Conversely, the boundary layer is the thickest for high temperatures and high pressures
(i.e., one atmosphere).1, 12-15 In a closed chamber system, the precursor is loaded into the
same chamber as the substrate. The chamber is then tightly sealed and the reactant gases
are generated. The reaction is allowed to run to completion or until the precursor is
depleted. It was traditionally used for purification of metals for chrome plating. Relative
to the open reactor, the reactor for a closed system is a much simpler design that is
largely free from the issues generated by the continuously flowing gas.1, 13, 16, 17
Reactors can also be either hot walled or cold walled. In a hot wall reactor, the
entire chamber is heated to the same temperature as the substrate. While this prevents the
presence of temperature and concentration gradients above the substrate, in some systems
deposition can occur on the walls in addition to the surface of interest. In the cold wall
reactor only the substrate is heated. In addition to this being more a more complex setup,
temperature and concentration gradients may be present in a cold wall chamber.18, 19
The CVD process can also be categorized by the method used to generate the
reactant gas. The most common method is thermal activation using either resistance
heating, radio frequency (RF) heating, or infrared (IR) heating. In cases where heat can
damage sensitive substrates, alternatives such as plasma-enhanced CVD (PECVD), laserinduced CVD (LCVD), and photo CVD (PCVD) can be used. All of these methods can
reduce the temperature needed for deposition.12, 20
The temperature and pressure at which reactions are carried out can also be used
to describe the CVD process. Temperatures range from ultra-high temperature (17001900 oC) processes to high temperature processes (above 1000 oC) and low temperature
(below 300 oC) processes.

Pressures range from atmospheric-pressure CVD to low

-3

pressure CVD (less than 1 Torr) processes and ultra-high vacuum CVD (10
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Torr)

processes.12, 21 As mentioned above, these conditions need to be optimized to give the
best deposition and to ensure that the reaction is not limited by transport of gases to the
surface.22, 23
The reactor design used in this chapter is a closed system. I constructed it. My
system is a hot wall reactor designed to ensure even heating throughout the reactor.
Additionally, it is a low temperature (less than 90 oC) and low pressure (10-4 Torr)
system. The reactions I wished to examine were thermally activated in a straight forward
manner. This reactor design enabled me to study surface initiated CVD polymerization
kinetics occurring at the surface without worrying whether mass transport was rate
limiting. To this end it was also necessary to design and construct my own detection
system, which is described immediately below.
For the CVDP described in this chapter and other such surface polymerizations,
the ideal method for monitoring the kinetics is one that measures the growth of the
polymer film in real time. One such tool that offers good sensitivity and can detect small
mass changes in real time, as low as 1 ng/cm2, is a quartz crystal microbalance (QCM).
QCMs have been used to monitor film deposition or molecule adsorption in a variety of
conditions from vapor or solution phases,24-27 and they have been used to monitor
electrochemical and plasma polymerizations.28-31
The QCM relies on the piezoelectric properties of quartz crystal to gain its
sensitivity. Piezoelectricity was first discovered in 1880 by Pierre and Jacques Curie.32
When mechanical energy is applied to a piezoelectric material, an electric field is
generated, allowing the transformation of the mechanical energy used to deform the

material into electrical energy.

33
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The reverse process was predicted by Lippmann in

1881.34 Applying an oscillating electric field across the thin quartz wafer induces an
acoustic wave which propagates perpendicular to the surface.35 When the crystal is twice
as thick as the acoustical wavelength, a standing wave is established at a frequency called
the resonant frequency, f0. The resonant frequency for a quartz crystal wafer can be
calculated based on equation 3.1,

f0 =

µq
/ 2t q
ρq

(3.1)

where µq is the shear modulus, ρq is the density, and tq is the crystal thickness.36 These
properties of the quartz crystal depend upon the angle at which the wafer is cut from a
single crystal. The most common is the AT cut, which is cut at an angle 35o 15’ from the
Z axis.

This particular cut is often chosen because its temperature dependence is

essentially zero at 25 oC.37
If the thickness of the quartz crystal wafer changes, the resonant frequency also
changes. Sauerbrey was the first to exploit this phenomenon for purposes of measuring
small mass changes.38 He made the assumption that for small mass changes, the addition
of foreign mass could be treated as the addition of an equivalent mass of quartz, and
therefore thickness, of the quartz crystal. Assuming the deposited material is thin, rigid
and even, one can use equation 3.2 to relate the change in resonant frequency to the
change in areal density.
∆f = −C f m f

(3.2)

In equation 3.2, ∆f is the frequency shift, Cf is the mass sensitivity constant for the quartz
crystal, and mf is the areal density of the deposited film. The frequency decreases as the

areal density increases.
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The value of ∆f is calculated by subtracting the resonant

frequency of the quartz crystal from the frequency of the crystal with the deposited
material.
∆f = f c − f 0

(3.3)

Cf is defined as
Cf =

2 f 02
ρ q vq

(3.4)

where f0 is the resonant frequency, ρq is the density of the quartz crystal, and vq is the
shear wave velocity in the quartz crystal. For an AT cut wafer with a 5 MHz resonant
frequency, Cf is 56.6 Hz*cm2/µg.

This means that a 1 Hz change in frequency

corresponds to an areal density change of 17.7 ng/cm2. Areal density is used rather than
mass because the vibrating area of the quartz crystal resonator does not extend all the
way to the edge and can be hard to define. If the density of the deposited film is known,
its thickness, tf, can be calculated.
tf =

mf

ρf

(3.5)

In equation 3.5, mf is the areal density, and ρf is the density of the film. There are two
important and advantageous features of equation 3.2. First, no calibration is needed
because the mass sensitivity and resonant frequency can be calculated from the properties
of the quartz crystal. Second, under the conditions stated above, the mass sensitivity is
independent of the physical properties of the deposited film.39 At greater thicknesses,
equation 3.2 is no longer accurate because the elastic properties of the deposited film
have an influence on the resonant frequency and can no longer be treated as an extension
of the quartz crystal.40 Lu and Lewis41 introduced a formula to account for this. In
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equation 3.6, ρf and ρq are the densities of the film and quartz respectively, vf and vq are
the shear wave velocities in the film and quartz respectively, fc is the resonant frequency
of the film and quartz combined, f0 is the resonant frequency of the quartz, and ff is the
resonant frequency of the freely suspended film.
tan(πf c / f 0 ) = −( ρ f v f / ρ q vq ) tan(πf c / f f )

(3.6)

It should also be noted that a well described frequency shift occurs when one or both
faces of the crystal contact a liquid. This shift was first described by Kanazawa and
Gordon.42 Later, Martin et al. showed how a small mass accumulation on a crystal in a
liquid environment changes the resonant frequency.43 For applications described in this
chapter, the deposited polymer is treated as a thin, rigid layer that is an even extension of
the quartz crystal. Described below is the use of the QCM to study the CVDP kinetics of
the ROP of L-lactide and glycolide by ZnO.
Experimental
Chemicals: Deuterated chloroform (CDCl3, 99.8% D from Sigma-Aldrich, St.
Louis, MO), glycolide (GL, 99.9% from Polysciences Inc., Warrington, PA), 1,1,1,3,3,3hexafluoro-2-propanol (HFIP, 99.5%+, from Acros Organics, Geel, Belgium), and zinc
oxide sputtering target (ZnO, 99.9% from Kurt J. Lesker, Clairton, PA) were used as
purchased from the respective suppliers. L-Lactide (from Purac, Lincolnshire, IL) was
sublimed at 90 oC and then transferred into a N2(g) atmosphere glove box for further use.
Preparation of QCM Reaction Vessel for Kinetic Analyses: All CVDP kinetics
reactions were performed using a Stanford Research Systems (SRS) QCM200 Quartz
Crystal Microbalance (Figure 3.1). Data was acquired using SRS QCM200 LabVIEW
Data Acquisition Software Version 2.0 (SRS, Sunnyvale, CA). Data was analyzed using
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Figure 3.1.
controller.

Stanford Research Systems QCM200 Quartz Crystal Microbalance
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Microsoft Excel. Five MHz, one inch diameter AT-cut quartz crystals with Cr/Au
electrodes from SRS were used in all reactions (Figure 3.2). RF sputtering was used
to deposit a thin layer of ZnO onto the side of the crystal containing the larger of the
two electrodes. Deposition was performed at 100 W for 30 minutes, resulting in a 50
nm thick layer of ZnO. Sputtering was performed with equipment and assistance
from Dr. Natale J. Ianno in the Department of Electrical Engineering at the University
of Nebraska. A two piece CVDP reactor (Figure 3.3) was constructed from Pyrex
glass. The bottom piece was constructed from a glass tube with an outer diameter
(OD) of 40 mm and an inner diameter (ID) of 35 mm. Using a glass working lathe, I
closed one end of the bottom piece to produce an object resembling a test tube 20 cm
in length. In the reactors used to study the CVDP of glycolide, a Teflon reservoir was
placed in the bottom. This reservoir was used to house the glycolide and slow its
polymerization at the surface of Pyrex, which is somewhat nucleophilic.
(Anecdotally, I note that soft glass was much too nucleophilic for my purposes, and
although quartz was not nucleophilic enough to initiate the polymerizations of any of
the cyclic lactones I examined, quartz was not used due to the practical difficulties
associated with quartz “glass working”.) A 40 mm (OD) and 35 mm (ID) glass tube
was also used for the top of my reactor assembly. Because the diameter of the tube
was large and therefore would be difficult to vacuum seal, a glass tube with an OD of
18 mm and an ID of 15 mm was attached to the top. This was achieved by narrowing
the diameter of the top of the larger piece to the diameter of the smaller and joining
them using the glass lathe. At this point in the process electrical feedthroughs were
attached. The feedthroughs provided the electrical connection between the crystal in
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Figure 3.2. Five MHz, one inch diameter, AT-cut quartz crystal with Cr/Au electrodes
from Stanford Research Systems.
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Figure 3.3. Sketch (top) and image (bottom) of the CVDP reactor.
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the vacuum sealed reactor and the outside controller. They were made of either platinum
or copper coated tungsten. Next the ZnO coated quartz crystal was attached to the
feedthroughs. Copper wire was first attached to the feedthroughs using Kester “44” rosin
core solder. At the other end, the copper wire was attached to the electrodes on the ZnO
coated quartz crystal again using the same solder. The length of the copper wire was
approximately 14 cm, far enough from the junction where the two reactor pieces are
fused together that heating during glass working did not affect it. At this point the
stability of the resonant frequency of the crystal in air was checked to ensure no damage
was done when attaching the copper wire. Next the top and bottom pieces were fused
together on the glass lathe. Following this step, the complete reactor was attached to a
high vacuum line to check for leaks and to remove residual water from the reactor. The
stability of the resonant frequency of the crystal was again checked while attached to the
high vacuum line. After a minimum of 16 hours, the reactor was transferred to a N2(g)
atmosphere glove box to be loaded with monomer. Approximately one gram of the
desired monomer was added to the reactor. The exact amount was not crucial, but it was
important to have excess monomer in the reactor so that its evaporation was not rate
limiting. The open end of the loaded reactor was sealed with a rubber stopper and the
entire assembly was removed from the glove box. The bottom of the assembly was
briefly cooled in liquid N2 before attaching the top end to a high vacuum line. The
bottom was kept in the liquid N2 while on the high vacuum line to reduce the vapor
pressure of the monomer. This was necessary to prevent loss of monomer and/or its
pyrolysis during the glassblowing necessary to flame seal the reactor. The reactor was
sealed at a pressure of 10-4 Torr (Figure 3.4). The area of the reactor near the crystal was
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Figure 3.4. Sketch (left) and image (right) of the complete CVDP reactor.
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gently heated with a heat gun to sublime any monomer away from the surface of the
crystal and deposit it in the bottom of the reactor which was maintained at -196 oC in
liquid N2. The reactor was placed in a Yamato DKN402 convection oven (Santa Clara,
CA). Wires attached to the outside feedthroughs were fed through a port in the side of
the oven to the QCM controller (Figure 3.5).
Procedures for Kinetic Analyses: Prior to performing kinetic experiments with
ZnO coated quartz crystals, I performed a control experiment on an uncoated crystal that
was enclosed in a reactor containing L-lactide as described above. This control was
necessary to establish that neither the quartz crystal nor the electrodes could initiate the
polymerization, possibly giving erroneous or misleading results. The uncoated crystal
reactor was heated to several different temperatures between 35 oC and 90 oC and held
constant for two to three hours. No change in the frequency was observed. Consequently
I saw no evidence that the crystal itself could initiate the polymerization of L-lactide.
After the control was complete, I was finally prepared to examine the propensity
of a nucleophilic ZnO coated crystal to initiate the ring opening polymerization of Llactide. The crystal served as a real time monitor of the mass gain due to polymer
deposition, and the time dependence of this mass gain served as a real time (steady state)
indicator of the reaction rate. The ZnO coated crystal was first allowed to stabilize at
room temperature and then the (isothermal) temperature of the reactor and its contents
was raised to 35 oC. For early reactions involving L-lactide this increase in temperature
was not controlled carefully. The increase was allowed to occur as fast as the oven could
make it occur. Later, in polymerizations involving glycolide, this process was controlled
more carefully and the temperature was slowly raised in 5 oC increments over 3 hours.
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Figure 3.5. Images of the complete reaction setup (top), the convection oven with the
CVDP reactor inside (bottom left) and the CVDP reactor inside the oven (bottom
right).
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Although this phenomenon is not observed in L-lactide polymerizations, if the
temperature was increased too quickly for the glycolide polymerizations, monomer
sublimed from the reservoir and was deposited onto the crystal due to the temperature
difference, thus causing instability in the resonant frequency.
For

reactions

involving L-lactide, the resonant

frequency was given

approximately one hour to stabilize after each change in temperature. The temperature
was then held constant for another two to three hours. During this time the frequency and
resistance were recorded. The temperature was then increased in 5 oC increments and the
process was repeated until a maximum temperature of 90 oC was reached.

The

temperature was then decreased in 5 oC increments using the same protocol. This heating
and cooling cycle was repeated until mass loading (due to polymer) on the crystal
reached the critical point at which it could no longer oscillate at its resonant frequency.
For reactions involving glycolide, the temperature was increased in intervals of
either three or five degrees Celsius. At high temperatures (65 to 80 oC) where the
polymerization proceeded quite quickly, data was collected over five to nine hours. At
each of the lower temperatures I had the luxury of collecting data over a much longer
time (up to 21 hours) because the polymerization proceeded so slowly that I had few
concerns about cumulating mass loading preventing the crystal from resonating. At this
point the temperature was decreased in a similarly controlled fashion. The heating and
cooling cycle was repeated for several times until the quartz crystal eventually stopped
oscillating. Some raw data collected during the CVD polymerization of glycolide on ZnO
is shown in Figure 3.6. Over the first three hours (10,800 seconds) shown in this plot, the
temperature was increased from 50 to 55 oC. From three hours to 12 hours (43,200
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Figure 3.6. Raw data from the CVDP of L-lactide initiated by ZnO collected using SRS QCM200
LabVIEW Data Acquisition Software Version 2.0 and plotted in Microsoft Excel.
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seconds) the temperature was held constant at 55 C. The temperature increased from 55
o

o

C to 60 oC over the period from 12 hours to 15 hours (54,000 seconds). From the 15

hour mark until the end of the experiment, the temperature was held constant at 60 oC.
Distinct changes in the slope are clearly observed in Figure 3.6. These slopes are
associated with changes in the rate constants described in more detail later in this chapter.
After the polymerizations were complete, the reactor was opened up and the quartz
crystal was removed. The crystals from the L-lactide polymerizations were placed in
CDCl3. Samples from monomer reservoirs from the glycolide polymerizations were
dissolved in a 3:1 v/v ratio of hexafluoroisopropanol (HFIP) and CDCl3.

1

H NMR

spectra were obtained using a Bruker (Billerica, MA) Avance 400 MHz NMR instrument.
Spectral processing was done using Bruker Topspin 3.0.b.8. Peak assignments for Llactide, glycolide, PLLA, and polyglycolide (PG) were compared to literature values.44-54
Results and Discussion
The ROP of lactones can be initiated by several different initiators. Examples
include anionic initiators such as hydroxide, oxide, alkoxide, and amide,55-58 and neutral
initiators such as alcohols and amines.59-61 Studies on the kinetics of homogeneously
initiated ROPs have shown that they follow the rate law,
Rate = k [ M ] x [ I ] y

(3.7)

where k is the kinetic rate constant, [M] is the concentration of lactone monomer and [I]
is the concentration of initiator. Both x and y are typically one. Because ROPs are living
reactions, each mole of initiator that is consumed creates an equal number of moles of
living polymer chains. This means the number of polymerization sites stays constant

134
throughout the reaction. Because [I] is constant, the rate law in equation 3.7 can be
y

reduced to the following,
Rate = k app [ M ] x

(3.8)

where kapp is equal to k[I]y.62-64 In the CVDP kinetic reactions in this chapter, the lactone
monomer concentration is also constant because there is a large excess of solid monomer
that maintains its vapor pressure at a constant value in the reactor. The rate law in
equation 3.8 can therefore be reduced further to
'
Rate = k app

(3.9)

'
where k app
is equal to k[M]x[I]y. Equation 3.9 can be rewritten as a differential rate law

in terms of the areal density of the deposited polymer.

dm ft
dt

'
= k app

(3.10)

Integration of equation 3.10 produces equation 3.11
'
m f = k app
t + m f0

(3.11)

where m f t is the areal density at time t and m f 0 is the areal density at time zero. Because
the areal density of the deposited polymer at time zero is zero, equation 3.11 reduces to
'
m f = k app
t

(3.12)

This final rate law shows a pseudo zero order relationship. When m f t is plotted against
reaction time, the slope of the resulting line is the pseudo zero order rate constant for the
reaction at a given temperature.
Kinetic Analysis of CVDP of L-lactide initiated by ZnO: The QCM proved to be
the ideal method to quickly and efficiently study the kinetics of the CVDP at various
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temperatures. Recall from equation 3.2 that there is a linear relationship between the
areal density of the deposited film and the frequency at which the crystal oscillates for
thin, rigid, and even films. As the areal density of the film increases the resonant
frequency decreases.

Shown in Figure 3.7 is the dependence of areal density as a

function of time for the CVDP of L-lactide at ZnO. This dependence is shown at 5 oC
intervals ranging from 55 oC to 80 oC. The negative change in frequency is shown on the
second y-axis on the right hand side. Two features are noteworthy in Figure 3.7. First,
the areal density of the polymer increases linearly over time for each temperature. The
pseudo zero order rate constant of the polymerization at each temperature can be obtained
directly from the individual slopes. The rate constants for each temperature are shown in
Table 3.1. Second, it is clear that the polymerization of L-lactide proceeds faster as the
temperature increases.
This increase with temperature is controlled by the vapor pressure and the
temperature dependence of the rate constant. The dependence of the vapor pressure on
temperature is described by the Clausius-Clapeyron equation

Pvap = βe

− ∆H vap / RT

(3.13)

where Pvap is the vapor pressure, β is a constant, ∆Hvap is the enthalpy of vaporization, R
is the ideal gas constant, and T is the temperature. Equation 3.13 can be converted to the
linear form

ln Pvap =

− ∆H vap 1
( )+β
R
T

(3.14)

to provide a linear relationship between the natural log of the vapor pressure and the
reciprocal of temperature.
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Figure 3.7. Change in areal density and negative change in frequency versus time for the CVDP of
L-lactide initiated by ZnO at 55 oC, 60 oC, 65 oC, 70 oC, 75 oC, and 80 oC.
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Reaction Temperature (oC)

Rate Constant (ng cm-2 s-1)

55

3.1 x 10-3 ± 1 x 10-4

60

1.17 x 10-2 ± 1 x 10-4

65

2.83 x 10-2 ± 2 x 10-4

70

7.00 x 10-2 ± 4 x 10-4

75

2.911 x 10-1 ± 3 x 10-4

80

1.041 ± 1 x 10-3

Table 3.1. Rate constants (± 1 SD) and corresponding temperatures for the CVDP of Llactide initiated by ZnO.
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As with many chemical reactions, as the temperature is increased, the number of
molecules capable of overcoming the activation barrier increases. This relationship can
be described by the Arrhenius equation,

k = Ae − Ea / RT

(3.15)

where k is the rate constant, Ea is the activation energy, R is the ideal gas constant, and A
is the pre-exponential factor. Equation 3.15 can be converted to the linear form
− ln k = (

Ea 1
)( ) − ln A
R T

(3.16)

to obtain a convenient linear relationship between the negative natural log of the rate
constant and the reciprocal of temperature. When the negative natural log of the rate
constant at each temperature is plotted versus the reciprocal of reaction temperature
(Figure 3.8), a linear relationship is obtained.

As the temperature of the reaction

increases, so too does the reaction rate, but this rate (and rate constant) is dependent on
both thermal activation and the vapor pressure, both of which exhibit the same
mathematical relationship to temperature (see equations 3.14 and 3.16).

Given the

reported values for the vapor pressures of L-lactide65 and glycolide,66 ln P can be plotted
versus 1/T (Figure 3.9) to give the linear relationship expected from the ClausiusClapeyron equation. By analogy to equation 3.7, we postulated that the rate of the CVD
polymerization could be described by equation 3.17,
y
Rate = kN x Pmonomer

(3.17)

where N is the number of surface nucleophiles (and the number of chain propagation
sites), P is the pressure of the monomer, and x and y are 1. Similarly to equation 3.7, this

0.0028

-1

0

1

2

3

4

5

6

0.00285

0.0029

y = 26215x - 74.064
R2 = 0.9914

1/Temperature (K-1)

0.00295

0.003

0.00305

0.0031

Figure 3.8. Negative natural log of the rate constant versus the reciprocal of temperature for the CVDP of L-lactide initiated
by ZnO.

- ln rate constant (ng cm-2 s-1)

7

139

ln P ressure (P a)

0
0.0027

0.5

1

1.5

2

2.5

3

3.5

4

4.5

5

0.003
1/Temperature (K-1)

0.0029

Figure 3.9. Clausius-Clapeyron plot for L-lactide and glycolide.

0.0028

0.0031

0.0032

L-Lactide y = -10214x + 32.589 R2 = 0.9994

2
Glycolide y = -10456x + 32.419 R = 0.9981

140

141
equation can be reduced to equation 3.9. Based on equation 3.17, k

'
app

in equation 3.9 can

be described by equation 3.18.
'
k app
= k app NPmonomer

(3.18)

'
By dividing k app
in equation 3.18 by the vapor pressure of monomer, which was

determined by Clausius-Clapeyron fits of experimental data (Figure 3.9) found in the
literature,65, 66 we obtained equation 3.19,
'
k app

Pmonomer

= k app N

(3.19)

which indicates that the observed reaction rates at any given temperature should be
pseudo zero order. In other words the observed reaction rate should be independent of
time. The negative natural log of the new rate constants, independent of vapor pressure
can then be plotted versus the reciprocal of temperature to construct an Arrhenius plot
(Figure 3.10). I find from this plot that the activation energy for the CVDP of L-lactide
in this system is 133 ± 10 kJ/mole.
When using the Sauerbrey equation, one makes the assumption that the deposited
film is thin, rigid, and evenly spread across the surface of the crystal. As the film
thickness increases, the viscoelastic properties can lead to acoustic loses and have a
dampening effect on the frequency at which the crystal oscillates.40, 67, 68 This means the
frequency decrease associated with the additional mass is less than it would be at smaller
thicknesses. Viscoelastic dampening was not observed in the CVDP kinetics experiments
described in this chapter. In fact for extremely long reaction times, it appeared that a
gradual increase in the frequency change was observed as the areal density increased
(Figure 3.11). Such a response is inconsistent with equation 3.18. To investigate this
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Figure 3.10. Arrhenius plot for CVDP of L-lactide initiated by ZnO.
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Figure 3.11. Areal density of deposited film over time for CVDP of L-lactide initiated by ZnO at 65 oC.
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unusual behavior, I conducted a relatively simple but time consuming experiment in
which the CVDP was carried out for a very long time at a constant temperature. The
reaction in Figure 3.11 is the CVDP of L-lactide initiated by ZnO at a constant
temperature of 65 oC over a period of 1,400,000 seconds (389 hours or 16 days). For this
isothermal reaction, the polymerization rate is expected to be linear over time. For short
reaction times and small areal density values, less than 600,000 seconds (167 hours or 7
days), the areal density increase is linear as expected. At later times, however, a
progressively increasing deviation from the linear response of short times is observed. So
the question becomes, what is causing this increase? The initiator, ZnO, was present in
the beginning at a fixed amount, and since the CVDP is a living polymerization one mole
of initiator can only produce one mole of polymer chain.

Furthermore, because the

temperature was constant, monomer was present in the vapor phase at a constant
pressure. It is unclear whether the cause of this increase in the deposition rate is due to
an increase in the areal density or the longer reaction times. One plausible explanation
that occurred to us was that the PLLA degraded over the course of the reaction to produce
additional initiation sites. In bulk, melt processes, thermal degradation is known to occur
through random chain scission and unzipping depolymerization reactions.69
scission

can

happen

by

hydrolysis,70

oxidative

degradation,

Chain

cis-elimination,

intramolecular and intermolecular transesterification, and homolysis.71-73

The main

products generated are cyclic oligomers72, 74, 75 and linear oligomers.76 Additionally, it
has been shown that recombination reactions occur.77-79 Other factors that have been
shown to effect thermal degradation include residual catalysts,80, 81 residual monomers,
oligomers82 and other impurities.69, 83 Degradation of PLLA and other polyesters leads to

a decrease in molecular weight.

78
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The H NMR spectra of the polymer coating on the
1

quartz crystal offers strong support for this theory (Figure 3.12). The 1H NMR spectrum
in Figure 3.12 was obtained by dissolving PLLA from the QCM monitored CVDP in
CDCl3. The portion of the spectra shown contains the methine protons of PLLA. The
quartet at 4.36 ppm is attributed to the hydroxyl end group of the polymer. The methine
quartet of the carboxylate end group overlaps with the internal methines quartet
producing a broad set of peaks from 5.28 to 5.10 ppm. There is present a quartet at 5.045
ppm, due to the methine proton of the monomer.44-48 Integration of the internal methines
quartet and the hydroxyl end methine quartet reveals an approximate 2:1 ratio of internal
methines to hydroxyl end methine. This small ratio indicates that the polymer is low
molecular weight. In fact, the deposition is best described as a low molecular weight
oligomer. If the deposited PLLA was high molecular weight polymer, the end group
quartet would be small compared to the internal methines quartet.

To avoid the

increasing deposition rate issue associated with thermal degradation of the polymer, all
L-lactide CVDPs described previously in this chapter were conducted at small areal
densities (below 11 µg/cm2) and at short reaction times (less than 4 days).
Kinetic Analysis of CVDP of glycolide initiated by ZnO: The same QCM setup
and method can be used to study the CVDP of glycolide initiated by ZnO. Figure 3.13
shows the rate of polymerization of glycolide to polyglycolide for seven different
temperatures between 35 oC and 55 oC. The primary y-axis is areal density and the
secondary y-axis is negative change in frequency and both are plotted against time.
Again, as was the case with the CVDP of L-lactide (Figure 3.7), there are two distinct
features that are notable. At all seven temperatures the areal density increases linearly

L-Lactide

Figure 3.12. 1H NMR spectra of PLLA film after CVDP by ZnO at 65 oC for 16 days.
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Figure 3.13. Change in areal density and negative change in frequency versus time for the CVDP of
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with time. Again, this indicates that the reaction is pseudo zero order. Also, as the
temperature is increased, the rate of polymerization increases.

The slope of each

individual trend is the overall rate of the reaction which includes contributions from the
temperature dependent pressure in the reaction vessel, and the temperature dependent
heterogeneous rate constant. These rates are listed in Table 3.2. When compared to the
rates for the CVDP of L-lactide, one can see that the CVDP of glycolide proceeds at
much faster rates. The increased rates were anticipated from reading the literature and
explain my main reason for choosing a lower temperature range. When comparing the
rates at 55 oC, one can see that the rate of the glycolide polymerization is 38.5 times as
fast as the L-lactide polymerization. The glycolide polymerization rate at 35 oC is only
slightly slower than the L-lactide polymerization rate at 55 oC (2.52 x 10-3 ng cm-2 s-1
compared to 3.1 x 10-3 ng cm-2 s-1). This is in agreement with melt polymerization results
in the literature.50, 84 The negative natural log of the rate constant can be plotted versus
the reciprocal of temperature (Figure 3.14). This plot shows a linear relationship. But as
with L-lactide, this rate is due to both the vapor pressure and thermal activation. The
dependence of the vapor pressure can be removed by dividing the rate constant by the
vapor pressure of glycolide. Vapor pressure values were obtained from the literature66
and used to construct Figure 3.9. The negative natural log of the rate constant divided by
the pressure was plotted versus the reciprocal of temperature (Figure 3.15).

This

Arrhenius plot again shows a linear relationship and the slope is Ea/R. More specifically,
I find the activation energy of this process to be 79 ± 11 kJ/mole.
The glycolide CVDP reactions described above were all performed at small areal
densities, less than 12 µg/cm2, and short reaction times, less than six days. at very long

149

Temperature (oC)

Rate Constant (ng cm-2 s-1)

35

2.52 x 10-3 ± 1 x 10-5

40

6.14 x 10-3 ± 1 x 10-5

43

1.738 x 10-2 ± 2 x 10-5

46

3.463 x 10-2 ± 1 x 10-5

49

4.663 x 10-2 ± 4 x 10-5

52

7.439 x 10-2 ± 3 x 10-5

55

1.1916 x 10-1 ± 5 x 10-5

Table 3.2. Rate constants (± 1 SD) and corresponding temperatures for the CVDP of
glycolide initiated by ZnO.
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Figure 3.14. Negative natural log of rate constant versus the reciprocal of temperature for the CVDP
of glycolide initiated by ZnO.
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Figure 3.15. Arrhenius plot for the CVDP of glycolide initiated by ZnO.
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times an increase in the rate of polymerization was also seen for the polymerization of
glycolide. This increase was expected because of the similar structures of glycolide and
L-lactide. It is likely that the increase in rate of each process is caused by the same
factor, probably the thermal degradation of the polymer.85 Unexpectedly at even longer
reaction times, the glycolide polymerizations slowed and eventually stopped propagating.
Upon examination of the Pyrex glass reactor it was noticed that it was no longer clear but
slightly hazy. It appeared the Pyrex reaction vessel had polymerized the glycolide.
Examination of what was supposed to be excess monomer in the bottom of the reactor
confirmed the existence of polymer. The first confirmation was that the material was not
soluble in CDCl3, but it did dissolve in HFIP. Polyglycolide is known to be insoluble in
most solvents, unless they are highly fluorinated.53 In addition the 1H NMR showed the
glycolide had been converted to polyglycolide (Figure 3.16). The 1H NMR was run in a
solvent mixture of HFIP and CDCl3 (3:1 ratio v/v) and referenced to the solvent singlet at
7.27 ppm. In Figure 3.16a, a reference sample of glycolide monomer shows a singlet
peak at 4.97 ppm. This singlet can be attributed to the methylene protons of glycolide.
In Figure 3.16b, a sample of the material from the reactor also shows a singlet peak, but it
appeared at 4.86 ppm. No peak is observed at 4.97 ppm that could be attributed to
monomer. This peak at 4.86 ppm is the internal methylene protons of polyglycolide.
Figure 3.16c is a spectrum of the reactor material spiked with glycolide monomer as a
reference. It is clear that at long reaction times the CVDP at the glass surface consumes
the vast majority of monomer, thus reducing the glycolide vapor pressure causing the
reaction to slow (and ultimately stop) because it is rate limited by mass transfer of
glycolide to the surface of the crystal.
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a

b

c

Figure 3.16. 1H NMR spectra of (a) glycolide, (b) material from the CVDP reactor and
(c) glycolide and reactor material.
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Conclusion
The QCM proves to be an ideal method for studying the CVDP of L-lactide and
glycolide at small areal densities and short reaction times. The polymerization of both
monomers is pseudo zero order and the reaction rate increases as the temperature is
increased. The rate at a given temperature is dependent on both thermal activation and
vapor pressure of the monomer. The activation energies for the CVDP of L-lactide and
glycolide were found to be 133 kJ/mole and 79 kJ/mole respectively. In future work this
method could be applied to the study of the CVDP of other monomers common in
biomedical applications such as the lactones ε-caprolactone and p-dioxanone, and lactams
such as ε- caprolactam.

Different initiators could also be investigated, particularly

hydroxyapatite which was shown in the previous chapter to initiate the CVDP of lactones
and lactams and is a common component of many biocomposites due to it being the
mineral component of bone.
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Chapter Four
Preparation and Characterization of a Demineralized Bone Matrix Simulant (DBMS)
Prepared from Composites of Anorganic Bovine Bone and Polylactones or Polylactams
Introduction and Background
The previous two chapters have focused on the chemical vapor deposition
polymerization (CVDP) of various polylactones and polylactams initiated by the surface
of a porous ceramic scaffold, usually hydroxyapatite, and the kinetics of this reaction.
This process was shown to retain the porosity of the original scaffold and create a
mechanically strong composite that could potentially be used as a bone graft material.
The focus in this chapter will shift to the preparation of a different type of porous scaffold
that could potentially be used for the same purpose. The scaffolds in this chapter will be
prepared by the ultimate removal of the inorganic material from anorganic bone/polymer
composites, leaving a porous polymer scaffold with a structure similar to demineralized
bone matrix (DBM).
Bone grafting is a common reconstructive orthopedic procedure in which large
defects (e.g. non-union in the bone due to fractures, tumors, or other diseases) are
repaired through implantation of various natural and manufactured biocompatible
materials. As stated in Chapter 1, the current gold standard for such procedures is
autogenous bone, due to its osteogenic, osteoconductive, and osteoinductive properties,
plus the lack of disease transmission or immunogenicity. The most important problem
with autogenous bone is its limited supply. Other concerns include variable quality,
operation time and blood loss, increased morbidity, chronic donor site pain, and increased
cost.1-3 Some of these obstacles can be overcome through the use of bone allografts,
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which still provide an osteoconductive matrix but have limited osteoinductive properties.
The disadvantages of using allografts include the possibility of disease transmission,
complications at the host-donor junction, slow replacement times, lack of osteogenesis,
and limited osteoinduction in preserved samples.2,

4

Fresh allografts are rarely used

because the speed at which the grafting transfer must be completed leaves no time for
sterilization or disease testing. Additionally, allografts often evoke an intense immune
response. Freeze drying and deep freezing are the most widely used techniques for the
preservation of allografts. Deep freezing at temperatures below -60 oC decreases the
immunogenicity of the allograft while maintaining the mechanical properties. Freeze
drying has the same effect on the immunogenicity but alters the mechanical properties.5
In countries where power shortages in hospitals are common, preservation is an important
issue.2, 6, 7
DBM is a type of processed allograft that was developed, in part, as a solution to
the above problems.6 It was first used by Nicholas Senn in 1889 in the treatment of bone
cavities.8

DBM is prepared by the removal of the mineral phase of the bone,

hydroxyapatite (HA). This can be accomplished by using acids such as hydrochloric acid
(HCl) to solublize the mineral phase or by using chemicals such as ethylenediamine
tetraacetic acid (EDTA) that dissolve HA by chelating its calcium ions. The organic
matrix that is left behind consists of noncollagenous proteins, bone growth factors, and
collagen.6,

9, 10

Although both methods successfully demineralize the bone, different

noncollagenous proteins are left behind.9,

11, 12

The resulting organic matrix is

osteoconductive and osteoinductive but has virtually no structural strength.6,
Consequently, DBM is often used in powder or putty form.

13

The osteoinductive

properties of DBM where first recognized by Urist in 1965.

14
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Since then it has been

discovered that the osteoinductivity is due primarily to low molecular weight
glycoproteins including bone morphogenic proteins (BMPs).15 The complex mechanism
by which DBM stimulates new bone growth is dependent on many factors, including
extent of demineralization, particle size, donor related effects, preparation of the matrix,
and degradation of the matrix during demineralization.10,

16, 17

Due to these many

variables, the clinical outcome is often difficult to predict.
Synthetic materials made from biodegradable polymers, ceramics, and metals are
increasingly being used in bone graft procedures. While synthetic materials may lessen
the threat of certain forms of rejection, the development of biomaterials with desirable
chemical, physical, and mechanical properties is challenging.

To overcome these

problems, researchers have developed a variety of new materials that are biomimetic and
bioinspired, attempting to copy the blueprint provided by nature.18-22 In previous work,
anorganic bovine bone was reconstituted using the inorganic portion, HA, to initiate the
polymerization of L-lactide.

The resulting product exhibited macroscopic and

microscopic morphologies similar to the original bone.23 I describe below a process to
remove the HA template from these composites to produce DBM simulants (DBMS)
comprised of various polylactones and polylactams. The resulting porous scaffold has
microscopic morphologies similar to that of DBM. Furthermore, the demineralized bone
matrix simulants described below maintain their original macroscopic shape and structure
after demineralization and can exhibit improved mechanical properties over DBM.
Experimental
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Chemicals: Ammonium hydroxide (NH4OH, 28-30% from VWR, Radnor, PA),
deuterated chloroform (CDCl3, 99.8% D from Sigma-Aldrich, St. Louis, MO), disodium
ethylenediamine tetraacetic acid (Na2EDTA, 99% from Fisher, Waltham, MA), εcaprolactam (99%+ from Acros Organics, Geel, Belgium), ε-caprolactone (99% from
Acros Organics), ethylenediamine (99% from Sigma Aldrich), hydrochloric acid (HCl,
from Fisher), polystyrene (PolyCALTM gel permeation chromatography (GPC) standards
from Viscotek, Worchestershire, U.K.), tetrahydrofuran (THF, HPLC grade from Sigma
Aldrich), and 2,2,2-trifluoroethanol (TFE, ≥ 99% from Sigma Aldrich) were used as
purchased from their respective suppliers. L-Lactide (from Purac, Lincolnshire, IL) was
sublimed at 90 oC and then transferred into a N2(g) atmosphere glove box for further use.
Anorganic cortical bone was obtained from bovine femur donated by Premium Protein
Products (Lincoln, NE).
Preparation of anorganic bone (AB)/poly-L-lactide (PLLA), AB/poly-εcaprolactone (PCLN), AB/poly-ε-caprolactam (PCLM) composites: A band saw was
used to remove the distal and proximal ends of the bovine femurs and to cut them into 1.5
to 2 cm thick sections along their length. Cylindrical plugs of cortical bone, with a
diameter of 6 mm and a length between 12 and 20 mm, were machined in the
longitudinal direction from the diaphyseal section of the bovine femur using a 6 mm
diameter dowel tool (Figure 4.1). A Soxhlet extractor was then used to remove the
majority of the organic material. The solvent mixture used for the extraction was 80%
ethylenediamine and 20% deionized water (v/v).24 The solvent was observed to reflux at
119 oC. The samples were extracted for a minimum of 48 hr. Fresh solvent was cycled
through approximately every 10 min. After the extraction period, the solvent mixture
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Figure 4.1. Cylindrical cortical bone plugs cut using an end mill and 6 mm dowel tool.
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was replaced with deionized water. The Soxhlet extraction of the bone cylinders with
water was continued until the water was neutral pH. The water was replaced 3-4 times
during this process. At this stage the bone cylinders, which were greatly whitened, were
removed and allowed to dry at room temperature in air. Samples were then activated by
being heated at either 600 oC for 96 hr or 700 oC for 16 hr in air. They were then placed
in a vacuum desiccator, cooled to room temperature under vacuum, and transferred to a
N2(g) atmosphere glove box for later use.
To begin the polymerization, an anorganic bone plug was placed in a Pyrex glass
tube that was approximately 9.5 mm in diameter. For reactions run with L-lactide and εcaprolactone, the plugs were placed in a ¼” diameter Teflon sleeve that made sample
removal from the reaction vessel easier upon completion of the reaction. An excess of Llactide, ε-caprolactone, or ε-caprolactam was added to the tube. Enough monomer was
added to ensure that the sample was completely covered. The tubes were sealed with a
short section of tygon tubing that was closed with a hose clamp.

They were then

removed from the N2(g) glove box and attached to a rotary vane rough pump. The
samples were maintained under a vacuum for 10 min before the bottom was dipped in
liquid N2 and the vacuum was maintained for an additional 5 min. The tubes were then
sealed at a reduced pressure (~30 mTorr) after placing a slight constriction near the
midsection. L-Lactide and ε-caprolactone reactions were placed in a convection oven at
130 oC. Upon melting, the monomer infused into the pores of the anorganic bone, where
the ring opening polymerization (ROP) was initiated by the surface of the HA.23 After 3
days, the samples were inverted so excess monomer could drain away from the sample.
The constriction kept the sample from sliding to the other end of the tube (Figure 4.2).

Figure 4.2. Method used to create AB/polymer composites. The AB plug is first immersed in the
liquid monomer for several days. At this point it is inverted and excess monomer is allowed to drain
to the bottom while the constriction keeps the sample from doing the same.
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The reaction was allowed to proceed for an additional 3-4 days. ε-Caprolactam samples
were placed in a convection oven at 250 oC. They were immersed for 4 days, then
inverted, and allowed to react an additional 4 days. After this time, the reaction vessels
were removed from the oven and allowed to cool to room temperature. Samples were
then removed from the reaction vessels and excess polymer on the outside of the cylinder
was removed using a Colchester-Clausing lathe. A rotation speed of 800 rpm was used to
machine the samples into cylinders with a height to diameter ratio of 2:1, typically 11
mm x 5.5 mm.
Preparation of DBMS from AB/PLLA, PLCN, PLCM composites: The HA was
then removed from the composites prepared as described above. Samples were extracted
in either a 0.6 M HCl or 0.5 M EDTA solution. The EDTA was dissolved by adding
ammonium hydroxide and then adjusting the pH to 7 using concentrated HCl. Samples
were placed in 40 ml of the HCl or EDTA solution for 7 days. The solutions were
replaced every 2 days. Following their extraction, samples were placed into deionized
water to remove any remaining HCl or EDTA. Samples were then stored in water or
allowed to air dry.
X-Ray powder diffraction (XRD) was performed using a Rigaku (Tokyo, Japan)
D-Max/B Horizontal Q/2Q X-Ray diffractometer (Nebraska Center for Materials and
Nanoscience (NCMN), University of Nebraska-Lincoln (UNL)). X-Rays were produced
by a 2 kW copper target with Kα of λ = 154.4 pm. The acquired diffraction patterns were
referenced to standards from the International Centre for Diffraction Data. Scanning
electron microscopy (SEM) was performed using a Hitachi (Tokyo, Japan) S4700 FieldEmission microscope (Morrison Microscopy Core Research Facility, UNL). Mechanical
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properties of the DBMS were measured using a single-axis Instron 5967
electromechanical machine with a 30 kN load cell (Department of Chemistry, UNL).
Instrument control, data acquisition, and data processing were performed using Blue Hill
version 2.23 software (Norwood, MA).

For mechanical testing, the samples were

machined into rods between 1.0 – 1.2 cm in length and 0.5 – 0.6 cm in diameter. The
specimens were then subjected to compression testing using a 1.0 mm/min crosshead
speed. Molecular weights were estimated using a Viscotek VE 2001 GPC (Department of
Chemistry, UNL). All samples are referenced to polystyrene standards. THF was used for
the mobile phase at a flow rate of 1 ml/min. Detection was accomplished with a Viscotek
VE 3580 refractive index detector. 1H NMR spectra were obtained using a Bruker
(Billerica, MA) 300 MHZ or 400 MHz Bruker DRX Avance spectrometer (Research
Instrumentation Facility (RIF), UNL). Spectral processing was done using Bruker
Topspin 3.0.b.8. PLLA and PCLN samples were dissolved in CDCl3 and all chemical
shifts were reported in ppm referenced to the solvent peak, which was assigned a value of
7.27 ppm. PLCM samples were dissolved in a solution containing a 3:1 ratio (v/v) of
trifluoroethanol and CDCl3. Again, all chemical shifts were referenced to the CDCl3 peak
at 7.27 ppm. Chemical shifts for PLLA,25-29 PLCN,30-33 and PCLM34, 35 were verified by
comparison to values reported previously in the literature.
Results and Discussion
The organic material in bone is the primary source of undesirable immune
response when used as a bone graft.36 The removal of this organic material produces a
porous inorganic template that has the same structure as the original bone. This material
is known as anorganic bone.37

The mineral phase is hydroxyapatite (HA,
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Ca10(PO4)6(OH)2) that is highly substituted, with carbonate (CO3 ) ions often replacing
-2

phosphate (PO4-3) or hydroxyl (OH-) ions, fluoride (F-) and chloride (Cl-) ions replacing
OH- ions, and various metal ions such as magnesium (Mg2+), sodium (Na+), potassium
(K+), or strontium (Sr2+) replacing calcium (Ca2+) ions.38 Previous work has shown that
when the anorganic bone template is heated under vacuum in the presence of L-lactide,
the liquid monomer infuses the pores left behind by the removal of the organic material
and the ring opening polymerization is initiated by the nucleophilic surface of the HA.
The resulting ceramic/polymer composite has a structure that is similar to the original
bone.23 This process can be applied to other similar monomers such as ε-caprolactone,
glycolide, p-dioxanone, or ε-caprolactam to produce similar composites.
If the polymer infuses the pores left behind by the organic material, then
removing the inorganic portion of the composite should produce a porous polymer
scaffold that has a structure similar to DBM.

Figure 4.3 shows SEM images of

cryofractured PCLN DBMS and PCLM DBMS samples prepared by removing the HA
from AB/polymer composites as was described in the experimental section. Removal of
the HA leaves behind a highly porous polymer scaffold that is similar to the microscopic
structure of DBM.39, 40 Similar to the porous scaffolds described in the previous chapters,
this porous polymer DBMS could potentially provide a suitable osteoconductive scaffold
for bone growth, allowing diffusion of nutrients, waste removal, and a place for bone
cells to proliferate.40-43 One major difference between the DBMS described in this
chapter and actual DBM is the DBMS retains its original shape after the removal of HA.
DBM contracts significantly upon drying and therefore is often used as powders, chips or
in gel form in conjunction with other grafting materials.6 Figure 4.4 shows an example of
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Figure 4.3. SEM images of (top) PCLN DBMS and (bottom) PCLM DBMS.
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Figure 4.4. DBMS created from a diaphyseal section of bovine femur that was converted
to anorganic bone, reconstituted with poly-ε-caprolactone, and had the HA removed via
extraction in 0.6 M HCl.
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this remarkable feature of the DBMS. The object in Figure 4.4 began as a section of a
bovine femur. It was first converted to anorganic bone and then used to initiate the ROP
of ε-caprolactone. The HA was removed with 0.6 M HCl. As one can see, after the
removal of the HA, the macroscopic morphology of the section of the femur was retained
despite removing nearly 75% of the original composite’s mass.

If the sample was

allowed to dry, small cracks were observed, but this was avoidable by storing the sample
in water. For smaller samples, cracking was not observed upon drying.
For samples extracted in HCl and EDTA for the same length of time, those
extracted in acid showed a higher percent mass loss. Table 4.1 lists the average percent
mass loss for PLCN DBMS, PLCM DBMS, and PLLA DBMS prepared either by HCl or
EDTA extraction. All extractions were carried out for 7 days. All acid extracted samples
had a mass loss of around 70%. As indicated by XRD analysis (Figure 4.5), this process
resulted in the complete removal of the HA. The samples extracted in EDTA had a wider
range of mass losses, from 24% for PLLA DBMS to 52% for PLCM DBMS. This
clearly indicates that not all of the HA was removed after 7 days. In all cases, the EDTA
extracted samples had smaller mass losses then their acid extracted counterparts. This
observation is consistent with observations from early experiments in which EDTA was
used as an alternative to acid extraction for DBM.44,

45

XRD confirmed the complete

removal of the HA in the acid extracted samples and the partial removal in the EDTA
samples.

Figure 4.5 shows the XRD patterns for an AB/PCLN composite before

demineralization, a PCLN DBMS prepared by demineralization with 0.6 M HCl for 7
days, and a PCLN DBMS prepared by demineralization with 0.5 M EDTA for 7 days.
The composite pattern, confirmed with a reference pattern from the database, was
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Material

Mass Loss (%)
HCl

EDTA

PCLN (n = 5,5)

72 ± 3

33 ± 4

PCLM (n = 5,4)

73 ± 4

52 ± 5

PLLA (n = 5,5)

71 ± 4

24 ± 10

Table 4.1. Percent mass loss of PCLN DBMS, PCLM DBMS, and PLLA DBMS
prepared by HCl and EDTA extraction for 7 days. Mass loss values are reported as the
average with an uncertainty of one standard deviation ( x ± 1 SD).
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consistent with that of hydroxyapatite with the addition of two broad peaks. The broad
peaks at 21.3o and 23.6o can be attributed to the PCLN. When this pattern was compared
to the pattern for the acid prepared PCLN DBMS, the HA peaks were absent, leaving
only the PCLN peaks. The pattern for the PCLN DBMS demineralized with EDTA still
displayed both the HA pattern and the PCLN pattern, but the intensity of the HA peaks
was greatly diminished.
It’s clear from the above results that 7 days was sufficient time to remove all of
the HA using acid extraction.

Not clear from the data was the rate at which the

demineralization was occurring and whether 7 days exceeded the minimum amount of
time needed to completely demineralize the sample. The kinetics of the demineralization
process of bone has been studied by several investigators. The kinetics of the process can
be described using the classic shrinking core reaction model. In this model, there is a
distinct reaction front that separates the demineralized area from the mineralized portion
of the bone.46-51 In other words, the demineralization occurs starting on the outside of the
sample and slowly works its way to the center. The acid concentration and temperature
of the solution have an effect on the demineralization rate, where increases in
concentration and temperature produce faster demineralization rates.52
Figure 4.6 shows the percent mass loss over time for a set of AB/PCLN
composites. Each sample was machined into cylinders that were 11 mm in height and 5.5
mm in diameter. They were demineralized using 0.6 M HCl at room temperature. This
plot indicates that under these conditions the demineralization gave a good fit to a zero
order reaction for which the mass of the composite decreases by approximately 1.3 %/hr.
The demineralization continued at this rate until the mass loss approaches 75%, at which

0

20

40

60

80

0

50

y = 1.2828x + 19.983
2
R = 0.9335

Time (hr)

100

150

200

Figure 4.6. Percent mass loss over time for AB/PCLN composites demineralized with 0.6 M HCl at room
temperature.
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point nearly all of the HA had been removed. This occurred within the first 48 hours of
demineralization. Figure 4.6 serves as an example that the demineralization process
could potentially be controlled, allowing one to make samples with varying amounts of
HA remaining in the core of the sample. The benefits of having a porous outside and
solid core are not yet known, but one can envision that having a porous osteoconductive
outer layer and a solid core to improve the mechanical properties could be advantageous.
Furthermore, it has been demonstrated in DBM that a residual calcium level of 2 % had
the highest osteoinductivity.16
Compressive stress-strain curves were obtained for PCLN DBMS, PCLM DBMS,
and PLLA DBMS samples.

The compressive strength and elastic modulus were

determined for samples that were demineralized in both HCl and EDTA for 7 days. As
noted above, a portion of the HA remained in the EDTA extracted samples.
Additionally, both dry and wet samples were tested. Dry samples were allowed to dry in
air. Wet samples were stored in water until being tested. Figure 4.7 displays the stressstrain plot from the compression testing of the PCLM DBMS samples. The x-axis is the
compressive strain in units of travel distance over sample height. Compressive stress is
plotted on the y-axis with units of pressure because its definition is the applied force
divided by the sample’s cross-sectional area.

A more complete explanation of the

mechanical properties is given in Chapter 5. Table 4.2 displays the compressive strength
and elastic modulus values for all the samples tested. In general, the EDTA extracted
samples had higher compressive strength values than their acid extracted counterparts.
This was expected due to the incomplete demineralization of these samples. Also, the
wet samples exhibited lower compressive strengths than the dry samples, except for the
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Figure 4.7. Compressive stress-strain curves for PCLM DBMS samples prepared by demineralization
with HCl and EDTA.
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8±3

3±1

PCLM

PLLA

500 ± 900

180 ± 50

300 ± 30

Elastic
Modulus
(MPa)

5±3

1±1

3±2

Compressive
Strength
(MPa)

300 ± 200

60 ± 10

200 ± 200

Elastic
Modulus
(MPa)

9±4

46 ± 11

55 ± 8

Compressive
Strength
(MPa)

1500 ± 800

1140 ± 90

1300 ± 400

Elastic
Modulus
(MPa)

Dry Samples

23 ± 14

22 ± 2

12 ± 5

Compressive
Strength
(MPa)

1100 ± 700

300 ± 100

600 ± 600

Elastic
Modulus
(MPa)

Wet Samples

EDTA Extracted Samples

Table 4.2. Mechanical Properties for PLCN, PLCM, and PLLA DBMS samples prepared by extraction in 0.6 M HCl and
0.5 M EDTA. The values reported are the averages with an uncertainty of one standard deviation ( ± 1 SD).
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PLLA DBMS. Between the three different DBMS types, the dry PLLA DBMS was
significantly weaker than the PCLN and PCLM DBMS samples. For the wet samples,
the compressive strength of PLLA DBMS was not significantly different from the other
materials. For comparative purposes, Lin et al. reported the compressive strength of
DBM in phosphate buffer saline (PBS) to be 4.1 ± 0.42 kPa, and heparin crosslinked
DBM (also in PBS) had a compressive strength of 31.4 ± 3.1 kPa.40 Additional values
for the compressive strength of DBM have been reported by Zhao et al.53 The extent to
which the mechanical properties can be controlled by manipulating the degree of
demineralization remains to be investigated.

As mentioned above, it could be

advantageous to have a porous outer layer to improve osteoconductivity and a solid core
to provide greater mechanical strength.
The demineralization process also has an effect on the polymer composition and
molecular weight. Before demineralization, the AB/polymer composites contain a small
amount of monomer.

The 1H NMR spectra for AB/PCLN (Figure 4.8), AB/PLLA

(Figure 4.9), and AB/PCLM (Figure 4.10) composites all show small amounts of
monomer remaining after the polymerization was terminated. The sample in Figure 4.8
contained 98.6% PCLN. This was determined by integrating the areas of the triplet at
4.05 ppm, which represents the internal methylene protons adjacent the oxygen in the
ester of the polymer, and the triplet at 4.15 ppm, which represents the same protons in the
monomer. The sample in Figure 4.9 contained 96.8% PLLA. This was determined by
integrating the areas of the quartet at 5.15 ppm, which represents the internal methine
protons of the polymer, and the quartet at 5.05 ppm which represents the same protons in
the monomer. The sample in Figure 4.10 contained 85.9% PCLM. This was determined

Poly-ε-caprolactone

Figure 4.8. 1H NMR spectrum of AB/PCLN composite before demineralization. Small
amounts of ε-caprolactone are still present.

ε-Caprolactone
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Figure 4.9. 1H NMR spectrum of an AB/PLLA composite before demineralization.
Small amounts of L-lactide are still present.
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Figure 4.10. 1H NMR spectrum of an AB/PCLM composite before demineralization.
Small amounts of ε-caprolactam are still present.
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by integrating the areas of the triplet at 4.15 ppm, which represents the internal methylene
protons adjacent the carbon in the amide functional group of the polymer, and the triplet
at 4.45 ppm which represents the same protons in the monomer. The two large peaks in
the PLCM spectrum are due to the solvent, trifluoroethanol. When Figures 4.8 – 4.10 are
compared to 1H NMR spectra for PCLN DBMS (Figure 4.11), PLLA DBMS (Figure
4.12), and PLCM DBMS (Figure 4.13) after being extracted with HCl, one can see that
the monomer peaks are now absent from the samples. The same is observed after
samples are extracted using EDTA.
The extraction process also decreased the molecular weight of the polymers.
Table 4.3 displays the peak molecular weights (Mp) of AB/PCLN and AB/PLLA
composites before demineralization and after demineralization. The Mp decreased in all
four groups by approximately 60%. Degradation of PLLA, PCLN, PCLM, and other
polyesters and polyamides is due to hydrolysis of the ester and amide linkages. This
occurs randomly along the backbone of the polymer as well as at the chain ends.54-56 The
rate of the degradation is also dependent on the pH of the solution.57, 58 Makino et al.
showed that PLLA degrades the slowest at pH 5.0. The degradation rate increases as the
solution is made more acidic or more alkaline.59, 60 The rate is also influenced by the Mn
and the presence of oligomers and monomer due to the autocatalysis of the hydrolytic
degradation of polyesters which produces carboxylic acid end groups.61-64 It is unclear at
this time what role these various processes play in the hydrolysis of the DBMS samples.
The hydrolytic degradation of polylactones and polylactams can release acidic
products that can lead to a decrease in the pH of the surrounding tissue.65
degradation mechanism is regarded to be bulk erosion, as indicated by the large
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Figure 4.11. 1H NMR spectrum of a PCLN DBMS sample after being extracted with HCl.
The monomer peaks are no longer present.
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Figure 4.12. H NMR spectrum of a PLLA DBMS sample after demineralization with HCl.
The monomer peaks are no longer present.
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Figure 4.13. H NMR spectrum of a PLCM DBMS sample after demineralization with HCl.
The monomer peaks are no longer present.
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Peak Molecular Weight (kDa)

Material
HCl

EDTA

Before

After

Difference

Before

After

Difference

PCLN

40 ± 23

17 ± 5

-57%

54 ± 18

21 ± 9

-62%

PLLA

21 ± 8

8±3

-60%

23 ± 11

11 ± 3

-55%

Table 4.3. Peak molecular weight of AB/PCLN and AB/PLLA composites before and
after demineralization with HCl or EDTA. The values reported are the averages with an
uncertainty of one standard deviation ( x ± 1 SD).

molecular weight decrease that precedes the release of the monomer.
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This release can

lead to local acidosis if there is a large mass of the polymer in a concentrated form, such
as a solid pin.67

One recent study reported that local inflammatory reactions and

intraosseous cysts in the bone where bioresorbable polymer implants are placed.68 These
issues generally do not effect highly porous scaffolds that have a low polymer mass per
unit volume and in general;67 the buffering capacity of biological fluids is thought to
compensate for the acidic products of the degradation and the movement of these fluids
dilutes and diffuses the products away from the implant site.65, 69, 70 Other environmental
factors can affect the degradation and the build up of degradation products, such as fluid
flow71 and degree of loading.72 The polymer composition and physical properties also
play a role in the degradation rate.72, 73
Conclusion
Even though efforts to produce a synthetic, biomimetic substrate similar to DBM
are in their early stages, the present DBMS produced using anorganic bone as a scaffold
exhibited a porous microscopic matrix similar to that of collagen in the original bone.
Despite losing nearly 75% of its mass during the removal of its inorganic framework, the
DBMS maintained its original structure and exhibited mechanical properties that
exceeded those of DBM. Future investigations could more thoroughly explore the extent
of demineralization and the conditions that will produce a product that has good
mechanical properties and osteoconductivity. The use of other monomers such as
glycolide could also be pursued. Combining the DBMS with bone morphogenetic
proteins (BMPs) and other growth factors could be investigated to determine if the
osteoinductive ability of the DBMS can be improved.74-76 Such studies could be done in
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conjunction with in vivo resorption studies to evaluate the biological performance of the
DBMS.77
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Chapter Five
Preparation and Characterization of Anorganic Bone (AB)/Poly-ε-Caprolactam (PCLM)
Biocomposites
Introduction and Background
Previous work in Professor Redepenning’s research group has focused on using
the nucleophilic surface of hydroxyapatite (HA) to initiate the ring opening
polymerization (ROP) of lactones, specifically L-lactide. Composites of anorganic bone
(AB), the inorganic framework left behind when the organic material is removed from
bone, and poly-L-lactide produced using this process exhibited microscopic
morphologies and mechanical properties similar to the living bone.1-3 Since the first
AB/PLLA composites were developed, several additional lactones have been
polymerized using the surface of HA. These include glycolide, ε-caprolactone, and pdioxanone. ε-Caprolactam is structurally similar to ε-caprolactone, with an amide group
taking the place of the ester group (Figure 5.1). Due to this structural similarity, it was
hypothesized that HA would be capable of initiating the ROP of ε-caprolactam. This
chapter describes efforts to prepare an AB/PCLM composite with a microscopic
morphology and mechanical properties similar to living bone.
ε-Caprolactam is a cyclic amide containing six carbons and one nitrogen atom

within a ring (Figure 5.1).4 It is the precursor to the polymer nylon 6. There are two
common ways to initiate the ROP of ε-caprolactam.
temperatures above 250

o

C.

The first is hydrolysis at

Linear polymer chains can be formed through

polycondensation, but the more common route is through polyaddition. The equilibrium
of this reaction results in a 90% conversion to the polymer.5,

6

It is also possible to
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Figure 5.1. Structures of common bioresorbable polymers and their respective monomers
that have been polymerized using the surface of hydroxyapatite.

polymerize ε-caprolactam by anionic polymerization.
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This can be carried out at

temperatures around 150 oC in the presence of a strong base.7-9 In addition to these
common industrial techniques, ε-caprolactam has also been polymerized using metal
oxides as a catalyst,10, 11 alkali metal hydroxides, and carbonates or bicarbonates.12
Nylon has often been used as surgical suture in biomedical applications. Two
examples are EthilonTM and NurolonTM.13 Recently, several attempts have been made to
create composites of HA/PCLM by infusing a porous HA scaffold with ε-caprolactam
and initiating the polymerization with various initiators. The ultimate goal of these
studies has been to increase the mechanical strength of the HA scaffold.14-17 In all these
previous cases, the surface of HA was not used to initiate the ROP of ε-caprolactam, as is
described in this chapter.
Due to the amide bond, nylon and other polyamides are degraded similar to
natural polypeptides.18

They absorb 9-11% water by weight and degrade by ion-

catalyzed surface and bulk hydrolysis. Hydrolysis by enzymatic catalysis is also possible
and leads to surface erosion.19 Longer chain polyamides (polydodecanamide) are more
stable than shorter chain polymers. In one study nylon 6,6 lost 25% of its tensile strength
after 89 days and 83% after 276 days in dogs.20, 21
In addition to safety and biocompatibility, the efficacy and performance of the
bone graft substitute must be evaluated.22 The mechanical properties of a material are
certainly relevant to its efficacy. An ideal bone graft substitute should have mechanical
properties similar to that of the bone it is replacing so that the substitute can withstand the
stress and strain of its environment. If these properties are too dissimilar the implant may
fail mechanically or issues at the bone-implant interface may arise that could affect the

ability of new bone to grow into the implant.

23-25
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In this chapter, a discussion of the

compression and torsional properties of the AB/PCLM composites will be provided in
addition to details concerning their preparation.
Static mechanics deals with the influence of forces on the form of a body at rest or
when there is equilibrium between forces. For the purposes of performing mechanical
characterizations, these forces are generally categorized as compressive, tensile, or shear
force. These forces are defined by the direction and effect of the force on the body. A
compressive force is applied towards the surface of the material and results in shortening
and fattening of the sample. A tensile force is applied away from the surface, resulting in
stretching and elongation of the sample. A shear force is applied perpendicular to the
surface, causing a change in shape to the sample (Figure 5.2). Force is measured in
newtons. One newton is the force needed to accelerate a 1 kg mass at a rate of 1 m/sec2.
A load cell is used to record the applied force, and sample dimensions are indicated by
the load application system.

The resulting load-displacement curve gives the total

deformation in the direction of the applied force. These forces are normalized so that
samples of different shapes and size can be compared. The force and deformation are
normalized by dividing by the dimensions of the sample to give stress and strain, which
form the stress-strain curve. Stress (σ) is the resistance of the material to the force acting
upon it. It is defined as shown below,
σ = F/A

(5.1)

where F is the force and A is the cross sectional area over which the force acts. For a
cylindrical sample, equation 5.1 becomes

σ=

F
π r2

(5.2)

Figure 5.2. Three basic types of force: compressive, tensile, and shear. The symbol ( ) represents the original shape
and (- - -) represents the shape after the force is applied.
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where r is the radius of the cylinder. In a stress-strain plot, stress is plotted on the y-axis
and has units of pressure (Pa = N/m2). Strain (ε) is defined as the geometric change in a
material in response to the applied force. When the sample is compressed, its dimensions
change as it is deformed. Strain is defined as
ε = ∆h/h

(5.3)

where ∆h is the change in the height, or the distance the load cell has traveled, and h is
the height of the sample (Figure 5.3). Strain is dimensionless and is plotted on the x-axis
in a stress-strain curve. Ceramic-polymer composites like the AB/PCLM composite
described in this chapter are usually treated as brittle materials rather than flexible
materials. A simulated stress-strain plot for a brittle material is shown in Figure 5.4. The
linear region of the stress-strain curve is the elastic region. In this region, deformation is
not permanent and the sample will return to its original shape if the load is removed.
Beyond this region, permanent deformation occurs. The slope is known as the elastic
modulus (E), which is a measure of a materials resistance to deformation. Brittle samples
typically have higher moduli than flexible materials.

At the apex of the curve,

catastrophic failure occurs in brittle materials. This is the point when the maximum
stress a sample can withstand is exceeded and the material fails. For this to occur the
force applied on the sample (FD) must exceed the critical force (FC), where the critical
force is defined as26-29

FC =

( Elastic Modulus)(Cross Sectional Area) 2
( Sample Height ) 2

(5.4)

For cylindrical samples this can be rewritten as

FC =

E π 2 r4
h2

(5.5)

Figure 5.3. Diagram of compressive force being applied to a cylindrical sample of
radius (r) and height (h) resulting in a change in the sample height (∆h).
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Figure 5.4. Simulated compressive stress-strain curve for a brittle material.
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For purposes of later comparing the properties of the AB/PCLM composites, the
compressive strength of wet human femoral bone is 167 MPa and the elastic modulus is
17.2 GPa.30, 31 Bovine femoral bone is reported to exhibit a compressive strength as high
as 240-295 MPa and a elastic modulus of 21.9-31.4 GPa.32

Other reports list its

compressive strength as 144 MPa and its modulus as 8.52 GPa.1, 31
In addition to being subjected to compressive forces, composites in certain
applications, such as screws or pins, can be subjected to torsional forces. Torsion is
defined as the twisting of an object due to an applied torque (force).

For solid cylinder

samples, such as the AB/PCLM composites described in this chapter, torsion stress-strain
plots can be constructed similar to the ones constructed for compression testing. For the
measurements performed in this chapter, one end of the cylindrical rod was held fixed in
a static jaw and the other was attached to a drive motor to twist the sample. A load cell
measured the applied torque.

The applied torque produces shearing stresses

perpendicular to the axis of the cylinder. For this experimental setup the shear stress (τ)
on the outside of the cylinder is defined as

τ=

Tr
J

(5.6)

where T is the torque in Nm, r is the radius of the cylinder, and J is the polar moment of
inertia. The term J is a measure of the material’s ability to resist torsion,26 as defined by

J=

π r4
2

=

π d4
32

(5.7)

where d is the diameter of the cylinder. The shear strain (γ), also known as the shear
angle, is dependent on the angle of twist (φ), the radius, and the length (L) of the sample
(Figure 5.5).

Figure 5.5. Diagram of torque (T) being applied to a cylindrical sample of radius (r)
and length (L) and the angle of twist (φ).
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γ=

ϕr
L

(5.8)

Shear strain can be related to the shear stress through the shear modulus (G), also known
as the modulus of rigidity.

γ=

τ
G

(5.9)

The modulus of rigidity is a measure of the stiffness of the sample, where stiffer or more
brittle samples have higher moduli. Determination of G is one parameter of interest in
torsion measurements.

Calculation of G can be accomplished by first substituting

equation 5.8 into 5.9 to give equation 5.10.

ϕr
L

=

τ
G

(5.10)

Next, equation 5.6 can be substituted into equation 5.10 to give equation 5.11.

ϕr
L

=

Tr
JG

(5.11)

Equation 5.11 can be rearranged to equation 5.12.
T=

GJϕ
L

(5.12)

The modulus of rigidity can be calculated from the slope when T, in units of Nm, is
plotted versus φ, in units of radians. The slope of the linear region can then be multiplied
by the sample length and divided by J to yield G in units of Pa.33, 34 A simulation of such
a plot is shown in Figure 5.6. Again, as in the compressive strength plot, the linear region
is known as the elastic region. Deformation is not permanent in this region. At the apex
of the curve, catastrophic failure occurs in brittle materials. This is the point when the

Figure 5.6. Simulation of a torsional torque versus angle plot for a brittle material.
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maximum torque a sample can withstand is exceeded and the material fails.
Alternatively, stress can be plotted against strain, using equation 5.6 to calculate the
stress and equation 5.13 to calculate the strain.

τ=

ϕr

(5.13)

L

The slope of the linear region of this plot is equal to G in units of Pa.
For purposes of later comparison to the torsional data of the AB/PCLM samples,
wet human femoral bone has a torsional strength of 53-71 MPa and a torsional modulus
of 3.1 to 3.7 GPa. Wet bovine femoral bone is reported to exhibit a torsional strength of
62-76 MPa, but a modulus was not listed.32 The broad range of mechanical properties for
bone found in the literature can be attributed to a variety of factors. These factors include

in vivo factors such as age, sex, species, function, and composition and in vitro factors
such as embalming or fixation, boiling and autoclaving, storage, drying and freeze
drying, sterilization, and testing procedure.35
Experimental
Chemicals: Deuterated chloroform (CDCl3, 99.8% D from Sigma-Aldrich, St.
Louis,

MO),

ε-caprolactam

(99%+

from

Acros

Organics,

Geel,

Belgium),

ethylenediamine (99% from Sigma Aldrich), and nylon 6 (from Sigma Aldrich), 2,2,2trifluoroethanol (TFE, ≥ 99% from Sigma Aldrich) were used as purchased from their
respective suppliers. Anorganic cortical bone was derived from bovine femur donated by
Premium Protein Products (Lincoln, NE).
Preparation of anorganic cortical bone: A band saw was used to remove the distal
and proximal ends of the bovine femurs and to cut them into 1.5 to 2 cm thick sections
along their longitude. Cylindrical plugs of cortical bone, with a diameter of 6 mm and a
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length between 12 and 20 mm, were machined in the longitudinal direction from the
diaphyseal section of the bovine femur using a 6 mm diameter dowel tool. A Soxhlet
extractor was then used to remove the majority of the organic material. The solvent
mixture used for the extraction was 80% ethylenediamine and 20% deionized water
(v/v).36 The solvent was observed to reflux at 119 oC. The samples were extracted for a
minimum of 48 hr. Fresh solvent cycled through approximately every 10 min. After the
extraction period, the solvent mixture was replaced with deionized water. The Soxhlet
extraction of the bone cylinders with water was continued until the water was neutral pH.
The water was replaced 3-4 times during this process. At this stage the bone cylinders
which were greatly whitened were removed and allowed to dry at room temperature in
air.
Preparation of AB/PCLM composites: Extracted rods of anorganic bone were
then activated by heating in air at either 600 oC for 96 hr or 700 oC for 16 hr in air.
Activated samples were then placed in a vacuum desiccator and cooled to room
temperature under vacuum, where upon they were transferred to a N2(g) atmosphere glove
box for later use. The preparation of the desired AB/PCLM composite was initiated by
placing an anorganic bone plug in a Pyrex glass tube that was approximately 9.5 mm in
diameter. Excess of ε-caprolactam was added to the tube so that the sample was covered.
The tubes were sealed with a short section of tygon tubing that was closed with a hose
clamp. They were then removed from the N2(g) glove box and attached to a rotary vane
rough pump. The samples were maintained under a vacuum for 10 min before the bottom
was dipped in liquid N2 and the vacuum was maintained for an additional 5 min. The
tubes were then sealed at a reduced pressure (~30 mTorr) after placing a slight
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constriction near the midsection. The polymerizations were carried out by placing the
sealed reaction vessel and its contents in a convection oven at one of three temperatures:
200 oC, 250 oC, or 300 oC. At 200 oC, reaction times varied from 5 to 12 days. At 250
o

C, reaction times varied from 4 to 17 days with the most common length being 7 or 8

days. At 300 oC, reaction times varied from 32 hr to 168 hr with the most common
lengths being 32 or 48 hr. Samples were all immersed for a period of time and then the
reaction vessels were inverted to drain the excess monomer/polymer to the other end of
the reaction tube. At the end of the preselected reaction period, the reaction vessels were
removed from the oven and allowed to cool to room temperature. Samples were then
removed from the reaction vessels and excess polymer on the outside of the cylinder was
removed using a Colchester-Clausing lathe. A rotation speed of 800 rpm was used to
machine the samples into cylinders with a height to diameter ratio of 2:1, typically 11
mm x 5.5 mm. Samples used for torsional strength determination were machined into
cylinders with a recess cut out of the center. The resulting device resembled a dumbbell
(Figure 5.7). The recess was the weakest portion of the sample; hence its dimensions
were used in determining the material’s properties.
Compressive strengths of the AB/PCLM composites were measured using a
single-axis Instron 5967 electromechanical machine with a 30 kN load cell (Department
of Chemistry, University of Nebraska-Lincoln (UNL)).

Instrument control, data

acquisition, and data processing were performed using Blue Hill version 2.23 software
(Norwood, MA). Specimens were subjected to compression testing using a 1.0 mm/min
crosshead speed. Torsional strengths were measured using an Instron MT1 fitted with a
200 in-lb torque load cell (College of Dentistry, Department of Chemistry, UNL).

Figure 5.7. Representative diagram of samples used for (left) compressive and (right) torsional testing.
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Instrument control, data processing, and data acquisition were performed using Partner
version 8.4d software (Norwood, MA). Specimens were subjected to torsional testing
using a 0.5 rev/min turn rate. Scanning electron microscopy (SEM) was performed using
a Hitachi (Tokyo, Japan) S4700 Field-Emission microscope (Morrison Microscopy Core
Facility, UNL). 1H NMR spectra were obtained using a Bruker (Billerica, MA) 300 MHz
or 400 MHz Bruker DRX Avance spectrometer (Research Instrumentation Facility (RIF),
UNL). Spectral processing was done using Bruker Topspin 3.0.b.8. AB/PLCM samples
were dissolved in a solution containing a 3:1 ratio (v/v) of trifluoroethanol and CDCl3.
All chemical shifts are referenced to the CDCl3 peak at 7.27 ppm. Chemical shifts for
PCLM were verified by comparison to values reported previously in the literature.37, 38
Results and Discussion
The specific goal of this chapter of my thesis was to successfully initiate the
polymerization of ε-caprolactam of anorganic bone to produce a composite relevant to
the repair or reconstruction of extremity trauma or craniofacial injuries. To begin with, it
was necessary to determined if hydroxyapatite could even be used to polymerize εcaprolactam to poly-ε-caprolactam, in a manner similar to that described previously to
polymerize various lactones.1-3, 39, 40 Powdered HA and ε-caprolactam were combined in
a 1:1 mass ratio in a glass tube and sealed under a reduced pressure. The tube was placed
in a convection oven at 185 oC. Once the monomer melted, the resulting suspension
exhibited low viscosity, but by 65 hr it was so viscous that little flow was observed upon
tilting the reaction vessel. This observation was a strong and positive indicator that the
desired polymerization was possible. Next 1H NMR spectroscopy was performed on εcaprolactam (Figure 5.8) and nylon 6 (Figure 5.9) to identify and assign the peaks. In

Figure 5.8. 1H NMR spectrum of ε-caprolactam.
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Figure 5.9. 1H NMR spectrum of nylon 6.
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Figure 5.8, the quartet at 3.21 ppm is due to the methylene protons next to the nitrogen in
the amide. The triplet at 2.42 ppm is due to the methylene protons adjacent to the carbon
involved in the amide group. The proton attached to the nitrogen appears as a singlet at
6.49 ppm. The multiplets between 1.5 and 1.8 ppm are the remainder of the protons in
the lactam ring. The two large peaks between 3.5 and 5 ppm are due to the solvent,
trifluoroethanol. In Figure 5.9, the quartet at 3.15 ppm is due to the internal methylene
protons adjacent to the nitrogen in nylon 6. The triplet at 2.15 ppm is due to the internal
methylene protons adjacent the carbon involved in the amide group. The proton attached
to the nitrogen appears at 6.45 ppm. The multiplets from 1.1 to 1.7 ppm are associated
with the remaining internal protons of nylon 6. Again the two large peaks are due to the
solvent.
The next reaction temperature chosen was 200 oC. Although the powder HA
reaction had proceeded relatively quickly at 185 oC, I wished to increase the reaction rate
even further. Samples were heated to 700 oC for 16 hr to activate them prior to their use
as polymerization initiators. During this process, the samples lost 14 ± 2% (n = 10) of
their mass. One set was reacted for 5 days total. At the end of this period of time the
samples gained 26 ± 7% of their mass, but this additional mass was only 35 ± 8%
polymer. The percent polymer was determined from the 1H NMR spectrum (Figure
5.10). The area of the peaks at 2.42 and 2.15 ppm, due to the methylene protons adjacent
the carbon in the amide group for the monomer and polymer, were integrated. The
integrated area of the polymer peak was divided by the total area and multiplied by 100.
These peaks were chosen because they had the greatest separation in the spectrum and
were resolved from other responses due to other protons in the system. In addition to

Figure 5.10. 1H NMR spectrum of an AB/PCLM composite prepared at 200 oC for 5 days.
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being 65% monomer, these samples proved to be extremely brittle and fragile. Another
set of samples were reacted for 12 days total. These samples lost 9.1 ± 0.4% (n = 10) of
their mass when heated to 700 oC for 16 hr. At the end of a 12 day reaction period, a
mass gain of 31 ± 5% was observed. 1H NMR spectroscopy was performed on one of the
samples and revealed it was only 31.4% polymer. It was concluded that 200 oC was not a
desirable reaction temperature, and hopefully not optimal.
Next 300 oC was chosen as the reaction temperature. Anorganic bone samples
were activated at 700 oC for 16 hr and lost 9.5 ± 0.5 % (n = 16) of their mass. The
reaction time at this temperature was either 48 hr or 32 hr. At the end of the preselected
reaction periods, the two sets gained similar amounts of mass, 36 ± 3% (n = 6) for 48 hr
samples and 37 ± 4 % (n = 10) for 32 hr samples. 1H NMR spectroscopy was performed
on one sample from each set and it was shown that the 48 hr sample was 87.8% polymer
and the 32 hr sample was 80.5%. These samples were also observed to turn yellow at
300 oC. This discoloration was not observed for reactions performed at 200 oC where the
polymer was white. To determine the optimum reaction time at 300 oC, I performed a
series of reactions for varying lengths of time between 32 and 168 hr. The results of
these reactions can be seen in Table 5.1. Once again the samples were activated at 700
o

C for 16 hr. During this time they lost 9.4 ± 0.8% of their mass, which is consistent with

results reported immediately above. From this series of reactions it appears that under
these conditions the percent polymer of the resulting composite reaches a maximum
around 50-60 hr before beginning to decline.

A set of samples were prepared for

compression testing based on these results. The samples were heated at 700 oC for 16 hr
and lost 10 ± 1% (n = 6) of their mass. After a 48 hr reaction period the samples gained
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Sample

Mass Gain (%)

53

Reaction Time
(hr)
32

36.9

Organic Material that
was Polymer (%)
80.2

54

32

34.3

66.7

55

36

36.8

84.1

56

36

40.7

74.3

57

40

44.8

88.0

58

40

41.9

83.3

59

44

33.4

77.9

60

44

43.2

83.9

61

48

46.1

92.8

62

48

44.4

92.2

63

52

32.8

89.7

64

56

31.9

90.4

65

60

44.9

91.6

66

72

31.0

80.8

67

72

31.7

81.8

68

96

35.2

80.4

69

120

27.2

76.2

70

144

26.8

75.8

71

168

31.6

74.4

Table 5.1. Results from the polymerization of ε-caprolactam initiated by anorganic bone
at 300 oC for varying lengths of time.
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42 ± 6% of their initial mass and of that mass, 85 ± 3% was PCLM based on H NMR
1

integrations (Figure 5.11). The compressive strength of the samples was found to be 184
± 55 MPa and the elastic modulus was 9.7 ± 1.3 GPa. This compares favorably to the
values listed earlier for human femoral bone,30, 31 and within the broad range of values for
bovine femoral bone.32 This value is also comparable to the values of AB/poly-L-lactide
(PLLA) composites prepared under similar conditions.3 The AB/PLLA composites were
first activated by sintering the bone in air for 16 hr at either 700 oC or 675 oC. Prepared
previously, the activated anorganic bone was then reacted with L-lactide at 130 oC under
reduced pressure until the reaction was deemed complete. The resulting composites have
compressive strengths of 194 ± 26 MPa and 212 ± 62 MPa, and elastic moduli of 8.85 ±
0.49 GPa and 13.2 ± 1.7 GPa, respectively.3
Because discoloration of the PCLM from white to yellow was an issue at 300 oC,
the reaction temperature was lowered to 250 oC. The samples were again activated at 700
o

C for 16 hr and lost 10.2 ± 0.9% of their mass during this period. A series of reactions

were run for periods ranging from 4 to 15 days, to determine the adequate reaction time.
The results are shown in Table 5.2. The percent mass gain due to polymer, as determined
by 1H NMR (Figure 5.12), was found to increase until 8 days after which it remained
fairly constant.

Because the deposited mass of organic material was only 59-77%

polymer, an effort was made to increase this percentage. The samples were machined
into cylinders for later use in compressive strength testing and to remove excess polymer.
They were then reheated for 4 days under reduced pressure at 250 oC. The result was an
increase in the percent polymer present in the composite (Figure 5.13). This increase was
partly due to further conversion of the monomer into the polymer, and partly to removal

Figure 5.11. 1H NMR spectrum of AB/PCLM composite prepared at 300 oC for 48 hrs.
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4

5

6

7

8

9

10

11

12

15

78

79

80

81

82

83

84

85

86

87

0.200

0.173

0.227

0.238

0.270

0.211

0.162

0.128

0.148

0.064

Volume
(cm3)

68.1

73.8

71.6

69.8

75.8

77.1

67.7

65.3

2.02

2.10

2.12

2.14

1.98

2.11

2.01

2.02

1.98

1.77

59.6
62.4

Density
(g/cm3)

(%) Organic
Material
that was
Polymer

0.84

0.83

0.60

1.52

0.47

0.47

2.34

2.23

1.26

2.76

Mass Loss
after
Reheating
(%)

1.6

1.6

1.2

3.0

0.9

0.9

4.3

4.2

2.3

4.5

Void
Volume
(%)

97.4

92.7

98.3

99.5

98.8

90.7

92.6

96.5

96.6

98.1

(%) Reheated
Organic
Material that
was Polymer

2.00

2.08

2.10

2.10

1.97

2.10

1.96

1.98

1.95

1.72

Reheated
Density
(g/cm3)

159.0

128.25

133.9

213.2

167.6

124.5

97.3

94.4

41.1

Compressive
Strength
(MPa)

6.36

5.67

7.14

7.07

6.82

5.40

5.16

4.52

2.10

Modulus
(GPa)

Table 5.2. Results from the polymerization of ε-caprolactam initiated by anorganic bone at 250 oC for varying lengths of time and
the mechanical properties of the resulting composites.

Reaction
Time (d)

Sample
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Figure 5.12. 1H NMR spectrum of AB/PCLM composite prepared at 250 oC for 8 days.
The percent of the mass gain that is polymer is 77.07 % for this particular sample.
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Figure 5.13. 1H NMR spectrum of the AB/PCLM composite from Figure 5.12 reheated under
vacuum for 4 days at 250 oC. The percent of the mass due to polymer is now 90.69%.
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of excess monomer. The loss of excess monomer was first confirmed when I observed
material deposited on the reaction vessel walls after reheating the samples. As can be
seen in Table 5.2, a mass loss was observed for all samples. The mass loss was higher
for the samples that had a higher percentage of monomer originally present.

The

compressive strength and elastic modulus values are also listed in Table 5.2. No value is
listed for sample 85 because it broke after reheating. For the composites listed in Table
5.2, the compressive strength was plotted versus the volume of the sample (Figure 5.14).
This plot showed a linear relationship with a high degree of correlation. Such a result is
unexpected because compressive strength is an intrinsic property of a material, and
therefore should not vary with its composite. Results in the literature suggest strain rate
has an affect on the observed compressive strength of bone.41, 42 Strain rate (έ) is defined
as
έ=

ν
lo

(5.14)

where ν is the speed of deformation and lo is the original length of the sample. The
literature results are at best inconclusive, and often contradictory. It is noteworthy that
my results are not highly correlated with strain rate. For the composites listed in Table
5.2, it is presently unclear what the relationship is between compressive strength and
sample volume. Dr. Mark Beatty, Professor of Dentistry at the University of Nebraska
Medical School, has postulated that the mineral distribution and the content might not be
proportional for each cylinder size.

With bone, as it becomes larger and therefore

supports more weight (or other force), the thickness of the outer annulus increases, the
bone is often denser (corresponding to increased HA content), and the crystalline
microstructure changes to accommodate greater compressive loads. With this in mind, a

Compressive Strength (MPa)

0.0500

0.1000

Volume (cm 3)

0.1500

y = 748.31x - 3.7406
R2 = 0.8745

0.2000

0.2500

0.3000

Figure 5.14. Compressive strength plotted versus the volume for AB/PCLM prepared at 250 oC and reheated for 4 days.
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larger cylinder producing a higher strength may be coincidental - it's not the cylinder
volume that causes the increased strength (even though the two are correlated), but the
quality and quantity of bone (or HA phase in this case) present in the rods, which is also
correlated with volume.
Additional AB/PCLM composites were prepared in the same manner as described
above for torsion measurements. Samples were heated in air at 700 oC for 16 hr and
reacted at 250 oC for a total of 8 days. The torsion plots, torque versus twist angle, for
each sample is shown in Figure 5.15. The peak torque, peak stress and modulus of
rigidity of each sample are shown in Table 5.3. The average peak torque for all 11
samples is 0.23 ± 0.11 Nm, the peak stress is 15.5 ± 6.4 MPa, and the average modulus of
rigidity is 3.1 ± 1.4 GPa. The three samples that exhibited the lowest peak stresses and
moduli (178, 179, and 184) broke at the junction of the large and small diameter. The
remaining samples exhibited a typical break pattern for brittle samples. Brittle samples
typically break along planes perpendicular to the direction in which tension is a
maximum, for example at 45o to the shaft axis (Figure 5.16).33 The average peak torque
for the 8 samples that did not show an anomalous fracture pattern was 0.28 ± 0.07 Nm,
the peak stress was 18.7 ± 3.8 MPa, and the average modulus of rigidity was 3.9 ± 0.5
GPa. The modulus compares favorable to that of human femoral bone, but the peak
stress is about a third of the value.
Finally, different pre-reaction activating conditions were used to prepare a large
set of samples. These samples were sintered in air at 600 oC for 4 days. These samples
lost an average of 8.6 ± 0.8% (n = 16) of their mass during the activation.
Polymerizations were performed at 250 oC for varying lengths of time between 5 and 17
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Figure 5.15. Torque versus twist angle curves for AB/PCLM composites.
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10.44
8.00
7.51
7.52
7.41
8.81
10.02
11.35
6.76
10.51
6.93

176
177
178
179
180
181
182
183
184
191
192

2.06

2.17

2.045

2.165

2.23

2.165

2.10

2.00

2.07

1.98

2.075

Radius
(mm)

0.172

0.413

0.122

0.273

0.308

0.316

0.305

0.089

0.067

0.236

0.233

Peak Torque
(Nm)

12.53

25.73

9.08

17.13

17.68

19.82

20.97

7.08

4.81

19.36

16.60

Peak Stress
(MPa)

3.19

3.86

1.39

4.37

3.30

3.54

3.69

1.25

0.77

4.51

4.42

Modulus of
Rigidity (GPa)

Table 5.3. Torsional properties of AB/PCLM composites.

Length
(mm)

Sample
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Figure 5.16. (Left) AB/PCLM composites with low peak stresses and moduli broke at
the junction of the large and small diameter of the dumbbell. (Right) The remaining
samples broke in a manner typical of brittle materials.
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days. The reaction time was varied because the new activation conditions were expected
to influence the relative rates. As can be seen from the data found in Table 5.4, for this
set of samples differences in final composite properties, percent mass gain, percentage of
the mass gain that is polymer, and the compressive strength, were not correlated with the
reaction time. Figure 5.17 shows a scanning electron microscopy image of a sample
prepared using these conditions. The composite was polished sequentially with 1200 grit
wet sandpaper, 3 µm alumina polishing powder, and 0.5 µm alumina polishing powder.
The sample was then cleaned of any residual alumina by brief ultrasonic cleaning in
water. The dark areas seen in Figure 5.17 are the PCLM and the lighter areas are the HA.
As with previously prepared samples in Professor Redepenning’s group,1-3 the
microscopic morphology of the original bone is conserved.

The PCLM fills the

Haversian canals and the lacunae. The infusion and filling of the pores occurred during
the reaction when liquid ε-caprolactam filled the pores and reacted at the surface of the
HA. It is also noteworthy that these samples show a seamless transition between the
inorganic and polymer phases, which is indicative of a strong electrostatic interaction
between the anionic polymer charges and a cationic inorganic surface.
The reaction time, percent mass gain, percentage of the mass gain that is polymer,
compressive strength, and elastic modulus for the AB/PCLM samples is shown in Table
5.4. The stress strain curves are shown in Figure 5.18. The average mass gain was 54.0
± 10.3%, the average percentage of the mass gain due to polymer was 88 ± 4%, the
average compressive strength was 215 ± 37 MPa, and the average elastic modulus was
6.9 ± 0.6 GPa. The compressive strength was slightly higher than for the samples

5
5
7
7
7
7
7
7
8
8
11
11
14
14
17
17

94

95

88

89

90

91

92

93

96

97

98

99

100

101

102

103

43.2

41.2

51.6

55.6

66.6

61.0

50.6

51.4

51.8

50.0

49.1

49.3

49.8

85.4

55.3

52.1

Mass Gain
(%)

89.7

88.5

87.9

91.3

90.6

83.1

91.4

83.7

96.5

89.9

83.7

86.0

86.4

91.4

83.5

88.9

(%) Organic Material
that was Polymer

250.0

252.4

159.5

169.0

221.7

224.6

194.0

270.7

263.4

239.3

162.4

167.8

226.9

185.0

230.0

222.3

Compressive
Strength (MPa)

7.28

7.59

7.01

5.79

6.46

7.11

6.37

6.90

6.77

7.75

7.55

5.82

6.50

7.16

7.33

7.07

Elastic
Modulus (GPa)

Table 5.4. Physical Properties for AB/PCLM composites prepared by sintering at 600 oC for 4 days and
reacting at 250 oC for varying lengths of time.

Reaction
Time (d)

Sample
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Figure 5.17. SEM image of an AB/PCLM composite.
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Figure 5.18. Compressive stress-strain curves for AB/PCLM composites.
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prepared at 300 C for 48 hr but not statistically different at the 95% confidence level.
o

The modulus was lower and statistically different than the value obtained for those same
samples.

When comparing to previously prepared AB/PLLA composites,1 the

compressive strength was not statistically different at the 95% confidence level, but the
modulus was statistically different. My compressive strength of 215 ± 37 MPa compared
favorably with the compressive strength of 167 MPa reported for human femoral bone.31
My result was higher than the value for human femoral bone at the 99.95% confidence
level.
Conclusion
Like previous reactions involving lactones, anorganic bone proved capable of
initiating the ROP of ε-caprolactam.

The resulting AB/PCLM composite had a

microscopic morphology similar to that of the original bone. The mechanical properties
are comparable to those of human femoral bone. The compressive strength and modulus
of rigidity met or exceeded the reported values for human bone, while the elastic modulus
and peak torsional stress of my materials were slightly lower. It is noteworthy that the
high compressive strength and lower modulus of my samples should result in improved
toughness (defined as the integrated area under the stress-strain curve). The improved
toughness and longer resorption times could prove to be beneficial in certain load bearing
applications where durability is a high priority. The mechanical properties were also
similar to those reported previously for AB/PLLA composites prepared in a similar
fashion.
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Chapter Six
Preliminary in vitro Biocompatibility Studies for Anorganic Bone/Bioresorbable Polymer
Composites
Modern research involving the synthesis of new biomaterials is generally
complement by feedback from some form of biological system. This feedback often
begins by examining a variety of performance parameters obtained from in vitro cell
cultures. Subsequent studies often involve evaluating the performance in animal models,
which can range from subcutaneous implantation of the material in mice to full-scale
double blind studies in humans.
Biological and medical feedback regarding the performance of new biomaterials
often necessitates multi-investigator collaborative research efforts in which research
teams rely on each other’s complementary expertise. The preliminary results described
in this chapter are no exception.

The experimental procedures for conducting cell

cultures described in this chapter were originally supplied by Dr. Paul Wooley, director
of research at Orthopaedic Research Institute at Via Christi Hospital in Wichita, KS.
Wooley’s contribution was part of his contribution to the funded research proposal that
supported my thesis research. Dr. Wooley is a Co-PI on the proposal. The experimental
procedures were then carried out by Wooley’s group, primarily by Dr. Haiying Yu and
Zheng Song at Wichita State University and Via Christ Hospital. Yu and Song also
wrote a first draft concerning their results and forwarded them to Professor Wooley, who
vetted the results and forwarded them to Professor Redepenning who provided them to
me. In this chapter I have lightly edited the wording provided by Wooley’s group and
inserted the resulting text at appropriate spots around which I have supplied scientific
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context and background information. The intent of this exercise was for me to gain
experience providing a first draft of a collaborative manuscript involving the
collaborative research effort focused on the materials I prepared. Chapter 6 of this thesis
serves as my initial contribution to this writing process.
Introduction and Background
As mentioned in Chapter 1, biocompatibility is one of several properties that are
important when creating a material that could potentially be used as a bone graft. Ideally
the material should not be cytotoxic, meaning it should not be toxic to the cells in the
surrounding tissue, and should not produce a prolonged, chronic inflammatory response
known as an undesirable foreign body response (FBR). A FBR occurs when the host
body perceives the implanted material as foreign and attempts to eliminate it or isolate it
from the surrounding tissue. This response can lead to a number of issues including
fibrosis, bone resorption, implant degradation, increased infection rates, delayed healing,
pain, and device failure.1
The general response following implantation of a biomaterial into the body
consists of several stages.

These stages are blood-material interactions, provisional

matrix formation, acute inflammation, chronic inflammation, granulation tissue
development, foreign body reaction, and fibrous capsule development.

Immediately

upon implantation, protein adsorption occurs on the biomaterial surface and a blood clot
subsequently forms at the tissue/material interface.

The clot serves as the initial

provisional matrix that provides structural, biochemical, and cellular components
necessary for wound healing.
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Following deposition of the provisional matrix, acute and chronic inflammation of
the site occurs. Such an inflammatory response can be beneficial if it is not excessive.
Acute inflammation is characterized by the exudation of fluid and proteins and the
emigration of leukocytes. Neutrophils are the first leukocytes to arrive at the wound site.
Additionally, mast cells degranulate and release histamine, interleukin-4 (IL-4), and
interleukin-13 (IL-13) as well as adsorb fibrinogen. Chronic inflammation follows the
acute inflammation stage.

It can be identified by the presence of monocytes,

lymphocytes and macrophages. They are attracted to the wound site by chemokines and
other chemoattractants. The role of these cells is to phagocytose microorganisms and
other foreign material.

Due to the size disparity, biomaterials are generally not

phagocytosed, but cells do attach to the material. Because the cells cannot engulf the
material, “frustrated phagocytosis” occurs, where the leukocytes release products in an
attempt to degrade the biomaterial.2,3 During the inflammatory stage, macrophages also
play a role in the recruitment of other macrophages and regulation of the immune
response to the implant. The release of platelet-derived growth factor (PDGF), tumor
necrosis factor (TNF-α), IL-6, granulocyte-colony stimulating factor (G-CSF), and
granulocyte macrophage colony stimulating factor (GM-CSF) call more macrophages to
the wound site. Additional mediators such as IL-1, IL-6, IL-12, and IL-15 can stimulate
or mediators such as transforming growth factor (TGF-β), IL-10, and prostaglandin E2
(PGE2) can inhibit lymphocyte function. For biocompatible materials, the inflammatory
response usually does not last longer than a couple of weeks.3-5
Macrophages also release cytokines to attract fibroblasts and stimulate
angiogenesis. Fibroblasts are necessary for the production of granulation tissue and the
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synthesis of the extracellular matrix and collagen in an attempt to close the wound. The
continual presence of an implant inhibits the normal healing process. Instead of entering
the remodeling phase, the foreign body response can occur. This is characterized by the
encapsulation of the foreign object by macrophages and foreign body giant cells (FBGC),
which result from macrophage fusion.2,3 Encapsulation occurs around all implants, but if
it releases low molecular weight components or debris, moves, or causes pressure on the
surrounding tissue the fibrous capsule will grow in size. The surface properties of the
implant play a role in the capsule formation. Cells are capable of penetrating porous
implants and a small capsule forms that is incorporated into the implant. If the material
biodegrades rapidly, no capsule is observed. In permanent non biodegradable implants a
small fibrous capsule is observed throughout the life of the implant. Solid implants are
associated with larger capsules.6
Both in vitro and in vivo methods can be employed when studying cell viability
and other related cellular functions. In vitro cell culture models are less complex, provide
a simplified, cost-effective and focused analysis, while utilizing fewer animals and
allowing higher throughput. The downside of in vitro models is that they can be overly
simplistic, only looking at a limited number of cells and their responses, while being
silent regarding cellular signaling that can only be observed in vivo.1 Additionally for
ethical reasons, beginning with in vitro testing can help to limit adverse reactions of
implanted, untested biomaterials in animals.
In this chapter, two in vitro experiments were used to quantify cell viability and
other

related

cellular

functions.

The

3-(4,5-Dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (methylthiazol tetrazolium) assay (MTT assay) was used to
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determine cell viability and real-time reverse transcriptase polymerase chain reactions
(RT-rt-PCR) was used to determine gene expression.

Qualitative morphological

evaluations were done using scanning electron microscopy (SEM).
The MTT assay is a colorimetric assay that measures cell metabolic function,
which serves as an indication of cell viability during culture proliferation on the
composite.

The assay detects the activity of the mitochondrial enzyme, succinate

dehyrogenase in complex II. This enzyme plays a role in oxidative phosphorylation and
the tricarboxylic acid cycle.7-11 If a material is cytotoxic, the activity of this enzyme is
impaired.

When MTT is added to the culture, it is reduced to the purple-colored

formazan. The absorbance can be quantified at a certain wavelength (between 500 and
600 nm) using a spectrophotometer.12
RT-rt-PCR can be used to quantify gene expression by a cell. It simultaneously
amplifies and quantifies the targeted sequence within the DNA molecule. The first step
requires creating a complementary DNA (cDNA) copy of the messenger RNA (mRNA)
using a reverse transcriptase. Amplification of the short DNA sequences is achieved
using a pair of primers, approximately 20 nucleotides in length, that are complementary
to the sequence on each strand of the DNA. They are extended by a DNA polymerase so
that a copy is made of the designated sequence. The same primers are used again to
make another copy of the original DNA and also the short copy that was made in the first
iteration.

This process is repeated and leads to exponential amplification.

The

temperature must be raised between each round to separate the DNA, so a thermo-stable
DNA polymerase must be used. This cycling is usually continued for 30-40 rounds. In
traditional PCR, the reaction products are then analyzed by agarose gel electrophoresis.13
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In real time PCR, a fluorescent dye is used that binds to double stranded DNA but not to
single-stranded DNA.

The fluorescence intensity increases as the amount of DNA

increases and can be measured and quantified after each cycle. The fluorescence of the
target gene is often normalized to an internal standard.13,

14

The internal standard is

typically a housekeeping gene that is present in all cell types because they are necessary
for cell survival. These include glyceraldehyde-3-phosphate dehydrogenase (G3PDH),
albumin, actins, tubulins, cyclophilin, 18S rRNA, or 28S rRNA.15, 16
Several researchers have studied the biocompatibility of HA/bioresorbable
polymer composites both in vitro and in vivo. Previous in vitro studies conducted using
HA/PLLA composites have demonstrated good cell viability and function, especially
compared to pure PLLA materials.17-20

In vivo studies have demonstrated little

undesirable inflammatory response to HA/PLLA composite implants. In addition, bony
ingrowth into the implant has been observed.21, 22
Experimental
Chemicals: Deuterated chloroform (CDCl3, 99.8% D from Sigma-Aldrich, St.
Louis, MO), ε-caprolactam (99%+ from Acros Organics, Geel, Belgium), ε-caprolactone
(99% from Acros Organics), ethylenediamine (99% from Sigma Aldrich), polystyrene
(PolyCALTM gel permeation chromatography (GPC) standards from Viscotek,
Worchestershire, U.K.), tetrahydrofuran (THF, HPLC grade from Sigma Aldrich), and
2,2,2-trifluoroethanol (TFE, ≥ 99% from Sigma Aldrich) were used as purchased from
their respective suppliers.

Anorganic cortical bone was derived from bovine femur

donated by Premium Protein Products (Lincoln, NE).
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Preparation of anorganic bone (AB)/bioresorbable polymer composite samples:
A band saw was used to remove the distal and proximal ends of the bovine femurs and to
cut them into 1.5 to 2 cm thick sections along their longitude. Cylindrical plugs of
cortical bone, with a diameter of 6 mm and a length between 12 and 20 mm, were
machined in the longitudinal direction from the diaphyseal section of the bovine femur
using a 6 mm diameter dowel tool (Figure 4.1). A Soxhlet extractor was then used to
remove the majority of the organic material. The solvent mixture used for the extraction
was 80% ethylenediamine and 20% deionized water (v/v).24 The solvent was observed to
reflux at 119 oC. The samples were extracted for a minimum of 48 hr. Fresh solvent
cycled through approximately every 10 min. After the extraction period, the solvent
mixture was replaced with deionized water. The Soxhlet extraction of the bone cylinders
with water was continued until the water was neutral pH. The water was replaced 3-4
times during this process. At this stage the bone cylinders which were greatly whitened
were removed and allowed to dry at room temperature in air. Samples used to initiate the
polymerization of ε-caprolactone were then activated by being heated at 700 oC for 16 hr
in air. Samples used to initiate the polymerization of ε-caprolactam were activated by
being heated at 600 oC for 96 hr in air. They were then placed in a vacuum desiccator,
cooled to room temperature under vacuum, and transferred to a N2(g) atmosphere glove
box for later use.
To begin the polymerization, an anorganic bone plug was placed in a Pyrex glass
tube that was approximately 9.5 mm in diameter. An excess of ε-caprolactone or εcaprolactam was added to the tube. Enough monomer was added to ensure that the
sample was completely covered. The tubes were sealed with a short section of tygon
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tubing that was closed with a hose clamp. They were then removed from the N2(g) glove
box and attached to a rotary vane rough pump. The samples were maintained under a
vacuum for 10 min before the bottom was dipped in liquid N2 and the vacuum was
maintained for an additional 5 min. The tubes were then sealed at a reduced pressure
(~30 mTorr) after placing a slight constriction near the midsection.

ε-Caprolactone

reactions were placed in a convection oven at 130 oC. Upon melting, the monomer
infused into the pores of the anorganic bone where the ring opening polymerization
(ROP) was initiated by the surface of the HA.23 After 3 days the samples were inverted
so excess monomer could drain away from the sample. The constriction kept the sample
from sliding to the other end of the tube. The reaction was allowed to proceed for an
additional 3-4 days. ε-Caprolactam samples were placed in a convection oven at 250 oC.
They were immersed for 4 days, then inverted, and allowed to react an additional 4-5
days. After this time, the reaction vessels were removed from the oven and allowed to
cool to room temperature.
AB/PCLN composites had a peak molecular weight (Mp) of 71,000 ± 11,000 Da
and were 94.0 ± 2.6% polymer as determined by 1H NMR (Figure 6.1). This was
determined by integrating the areas of the triplet at 4.05 ppm, which corresponds to the
internal methylene protons adjacent the oxygen in the ester of the polymer, and the triplet
at 4.15 ppm which corresponds to the same protons in the monomer.

AB/PCLM

composites were 84.5 ± 3.5% polymer, also determined by 1H NMR (Figure 6.2). This
was determined by integrating the areas of the triplet at 4.15 ppm, associated with the
internal methylene protons adjacent the carbon in the amide functional group of the

Poly-ε-caprolactone

Figure 6.1. Representative 1H NMR spectrum of AB/PCLN composite prepared for cell culture
studies.

ε-Caprolactone

252

Poly-ε-caprolactam

Figure 6.2. Representative 1H NMR spectrum of AB/PCLM composite prepared for cell culture
studies.

ε-Caprolactam
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polymer, and the triplet at 4.45 ppm associated with the same protons in the monomer.
The two large peaks in the spectrum are due to the solvent, trifluoroethanol.
Excess polymer on the outside of the cylinder was removed using a ColchesterClausing lathe. A rotation speed of 800 rpm was used to machine the outside diameter of
the cylinders to 6.0 mm. A parting tool was used to section the cylinder into 1.0 mm
thick discs. The discs were then polished on the lather at a rotation speed of 400 rpm.
The composites were polished sequentially with 1200 grit wet sandpaper, 3 µm alumina
polishing powder, and 0.5 µm alumina polishing powder. The sample was then cleaned
of any residual alumina by brief ultrasonic cleaning in water. This process produced
discs that had a relatively smooth surface, free of tooling marks. Figure 6.3 shows SEM
images of the polished composites. The microscopic morphology of the original bone is
conserved. Additional composites of AB/PLLA and AB/polydioxanone (PDX) were
prepared for the cell culture experiments by Troy Wiegand.24
Scanning electron microscopy (SEM) was performed using a Hitachi (Tokyo,
Japan) S4700 Field- Emission microscope (Morrison Microscopy Core Facility,
University of Nebraska-Lincoln (UNL)). Molecular weights of AB/poly-ε-caprolactone
(PCLN) samples were estimated using a Viscotek VE 2001 GPC (Department of
Chemistry, UNL). All samples are referenced to polystyrene standards. THF was used for
the mobile phase at a flow rate of 1 ml/min. Detection was accomplished with a Viscotek
VE 3580 refractive index detector. 1H NMR spectra were obtained using a Bruker
(Billerica, MA) 300 MHZ or 400 MHz Bruker DRX Avance spectrometer instrument
(Research Instrumentation Facility (RIF), UNL). Spectral processing was done using
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Figure 6.3. Representative SEM images of (top) AB/PCLN composite and (bottom)
AB/PCLM composite for cell culture studies.
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Bruker Topspin 3.0.b.8. PCLN samples were dissolved in CDCl3 and all chemical shifts
were reported in ppm referenced to the solvent peak, which was assigned a value of 7.27
ppm. PLCM samples were dissolved in a solution containing a 3:1 (v/v) ratio of
trifluoroethanol and CDCl3. All chemical shifts were referenced to the CDCl3 peak at
7.27 ppm. Chemical shifts for PLCN25-28 and PCLM29, 30 were verified by comparison to
values reported previously in the literature.
Cell Cultures: All cell culture studies were performed by Dr. Haiying Yu and
Zheng Song at the Orthopaedic Research Institute at Via Christi Hospital in Wichita, KS.
In addition to the four experimental composites, cell viability and gene expression of the
cells was assessed on standard polystyrene (PS) tissue culture plates for comparison
purposes. Prior to seeding all samples were sterilized with a 70% ethanol solution and
allowed to air dry in a biological hood overnight.

The cell lines chosen for these

experiments were Raw264.7, a monocyte-macrophage cell line, and NIH.3T3, a
fibroblast cell line. These lines were chosen because monocytes-macrophages are present
at the site of the implant and are involved in chronic inflammation and FBR. Fibroblasts
are known to attach to the surfaces of implanted materials and are involved in wound
healing.1-3, 31 A total of 4 x 103/10 µl/sample Raw264.7 or 1 x 104/10 µl/sample NIH/3T3
cells were seeded onto each sample examined. The cells were cultured at 37 oC for 7
days under a 5% CO2 atmosphere in a complete media consisting of Dulbecco’s Modified
Eagle’s Medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin.
MTT assay: Cell viability of both the Raw264.7 and NIH/3T3 cells, and therefore
the cytotoxicity of the composites was determined using the MTT assay. After 7 days of
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culture, 0.5 mg/ml MTT was added to the samples and incubated for 6 hrs at 37 C under
o

a 5% CO2 atmosphere. The cells were lysed in 10% sodium dodecyl sulfate (SDS). The
absorbance of the purple color due to the formazan that formed during cell metabolism
was measured at 509 nm using spectrophotometry.

The absorbance reading of the

composites was compared to the reading for the PS standard.
RNA isolation and RT-rt-PCR:

The inflammatory response invoked by the

composites was measured using RT-rt-PCR. This was done by determining the gene
expression of the inflammation-associated genes interleukin-1 β (IL-1 β) and tumor
necrosis factor-α (TNF-α) by the Raw264.7 cells. Macrophages play an important role in
the inflammatory response and also wound healing around the implant. The recruitment
of other macrophages and fibroblasts as well as the regulation of the inflammatory
response are achieved by the production of cytokines, including those listed above.3-5, 32
After 7 days of culture, the cells were harvested and the RNA was extracted using
TRIzol® reagent. A reverse transcription kit was used to make cDNA. SYBR Greenbased RT-rt-PCR analysis was performed using a StepOnePlus Realtime PCR System
(Applied Biosystems, USA). Thermal cycling conditions used were 95 oC for 10 min
followed by 40 cycles of 95 oC for 15 s and 60 oC for 1 min. The amplification primers
sequence for each gene is listed in Table 6.1. Gene expression was determined from the
average cycle threshold (Ct) of three measurements and normalized to the gene
expression of 18s RNA, the internal standard. This ratio is shown in equation 6.1.
Ratio =

(2 ∆Ct ) composite
(2 ∆Ct )18 s RNA

(6.1)

SEM of cell seeded composites: Qualitative determination of cell viability was
assessed using SEM. The morphology of the cells as well as the topography of the
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Gene

Forward and reverse primers

TNF-α

5’- CTGGGACAGTGACCTGGACT
3’- GCACCTCAGGGAAGAGTCTG

IL-1β

5’- GGGCCTCAAAGGAAAGAATC
3’- TACCAGTTGGGGAACTCTGC

18sRNA

5’- CGGCTACCACATCCAAGGAA
3’- GCTGGAATTACCGCGGCT

Table 6.1. DNA sequence of amplification primers used for RT-rt-PCR.
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composites was observed. In addition to the composites seeded with the Raw264.7 and
NIH/3T3 cells, composites that were subjected to the same treatment minus the seeding
were also evaluated using SEM.

This was done to determine if there were any

environmental effects on the topography of the composites when compared to the seeded
samples.

Samples underwent a fixation procedure to preserve the cells for SEM

observation. The fixation was affected by placing the samples in 2% glutaraldehyde for 1
hr, followed by rinsing them in 0.1 M sodium cacodylate buffer. The samples were then
placed in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer for 2 hr. Dehydration
was achieved using a series of ethanol solutions that increased in ethanol composition
(50, 70, 90, 100%) for 2-5 min in each solution. The fixation was completed by exposing
the cells to hexamethyl disilazane (HMDS) for 10 min. The fixed cells were then air
dried, mounted, and sputter coated with gold prior to placing in the SEM.
Results and Discussion
One of the first steps in evaluating the biocompatibility of a potential biomaterial
is to determine the cytotoxicity of the material using in vitro testing.

The

AB/bioresorbable polymer composites were seeded with the Raw264.7 macrophage and
NIH/3T3 fibroblast cell lines and MTT assay was used to determine cell viability based
on the activity of the mitochondrial enzyme succinate dehydrogenase in complex II as
described above. Macrophage and fibroblast cell lines were chosen because they play an
important role in the inflammation and wound healing around an implant. The results of
the MTT assay are shown in Figure 6.4. The cell viability was the highest on the PS
culture plate (the control group). Among the AB/bioresorbable polymer composites,
AB/PCLN showed the highest viability followed by the AB/PLLA composites.

PCLM-AB

Figure 6.4. MTT assay results for the AB/bioresorbable composites (PCLN-AB, PDX-AB,
PCLM-AB, and PLLA-AB) and a PS control. Error bars represent ± 1 standard deviation
(SD).

PCLN-AB
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AB/PCLM and AB/PDX displayed much lower readings in the MTT assay. This is
evidence of low cell viability on these composites, but there is a possibility that the low
viability on AB/PCLM may be due to poor cell adhesion and loss of cells during the
seeding process. The viability of both cell lines appeared similar for each composite.
This indicated that the materials were consistent in their cytotoxicity effect on both cell
lines. SEM images provided confirmation of the cell growth on the materials. Figure 6.5
shows the SEM images of AB/PCLN composites after being cultured for 7 days with the
Raw264.7 and NIH/3T3 cells. The cells maintained their original morphology, spherical
for the Raw264.7 cells33 and spindle-like for the NIH/3T3 cells.34 Additionally, they
covered over 90% of the surface. In contrast, the cells cultured for the same length on
time on the AB/PCLM composites were not evenly distributed and mostly located at the
edges of the sample (Figure 6.6). This experiment will ultimately be repeated because it
was quite surprising. The cells still maintained their morphology. Preliminary results
from soaking the samples in the cell culture medium and comparing them to the original
samples did not show any clear pathways of degradation on this time scale.
My composites were also tested to determine if they would elicit an inflammatory
response. Macrophages play many roles during wound healing and one of them is to
initiate and mediate the inflammatory response. This is done through the production of
various cytokines, including IL-1β and TNF-α. RT-rt-PCR can be used to quantify in

vitro the generation of these cytokines by the Raw264.7 cell line. The results of the PCR
analysis are shown in Figure 6.7. AB/PDX composites were not tested because of the
extremely low cell counts and an adequate amount of RNA could not be extracted. All
the composites and the PS control stimulated the production of IL-1β and TNF-α. In
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Figure 6.5. SEM images of (top) Raw264.7 macrophage cells and (bottom) NIH/3T3
fibroblast cells on an AB/PCLN composite.
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Figure 6.6. SEM images of (top) Raw 264.7 macrophage and (bottom) NIH/3T3
fibroblast cells on an AB/PCLM composite.
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PCLN-AB

PCLM-AB

Biomaterial
Figure 6.7. Expression of IL-1β and TNF-α in Raw264.7 macrophage cells in response to
seeding on various AB/bioresorbable polymer composites and a PS control.
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comparison to the PS, control which is widely used in cell culture plates as a non toxic
material, all three tested composites had lower levels of IL-1β and TNF-α expression.
This indicates lower activation of the macrophages by the composites, which may
indicate the development of a mild inflammatory response when implanted. The results
do not indicate that the inflammatory response is necessarily undesirable. It is also
noteworthy that these results for AB/PCLM are somewhat contradictory to the MTT
results for AB/PCLM. It is unclear that the gene expression ratio for AB/PCLM could be
this low if very few viable cells were present, as was indicated by the MTT assay.
Conclusion
The AB/PCLN and AB/PLLA composites appeared to exhibit reasonable
biocompatibility based on these in vitro tests described in this chapter. Both showed
adequate cell growth, the cells maintained their morphology, and they showed low
production of IL-1β and TNF-α. Due to the lower cell viability on the AB/PCLM and
AB/PDX composites, these materials were less promising than the AB/PLLA and
AB/PCLN composites. Another composite recently developed within the Redepenning
research group is AB/polyglycolide (PG). By comparison to other studies, we anticipate
that the PG in the AB/PG composites will resorb much move quickly than the PLLA in
the AB/PLLA composites. The in vitro biocompatibility of this material is not yet
known, but given the similarity between PG and PLLA it could be expected to behave
similarly.
Regardless of the material chosen for future applications, it is highly likely that
additional in vitro screening will be done. Because these materials are intended for use as
bone graft materials, one good place to start would be to measure osteoclast and
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osteoblast cell activity on the composites. Like the previous in vitro studies, thin discs of
the composites will be seeded with bone marrow-derived stem cells and cultured under
conditions designed to enhance osteoclastogenesis. The osteoclasts will be examined for
cell activation status. The composites will be examined for signs of degradation using
image analysis of culture microphotographs, histological evaluation using trichrome
staining, and assays of bone and polymer breakdown products. This will include calcium
release into the culture medium. This work will be performed in collaboration with
Professor Paul Wooley’s group at Via Christi Hospital in Wichita, KS.
Composites that perform well in the in vitro tests will undergo additional
biocompatibility testing using the murine air pouch model.35 These experiments will use
a mouse osteolysis model. This model mimics the conditions that exist during wound
healing after implantation of a foreign material into the body. Male BALB/c mice will be
injected subcutaneously with 2.5 mL of air to form the air pouch. After 6 days a sterile
saline solution is injected into the pouch and 2 days later the composite is implanted. The
mice are sacrificed 14 days later and the fluid within the pouch is analyzed. Additionally
histological and immunohistochemical evaluations will be conducted to determine the
tissue inflammation status and morphology of the composite. Pathological analysis of the
cell morphology at the interface between the inflammatory tissue and the composite will
also be conducted.

Bone density, bone volume fraction, and bone structure of the

composites will be measured using microcomputerized tomography (MicroCT) imaging.
Based on the biocompatibility results as well as the mechanical properties of the
composite materials, the ultimate goal is to select a material to be used to repair a
segmental bone defect. The defect will be introduced into the femur of a 200-250 g male
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Lewis rat. The same section of bone from a donor rat will be processed and converted
into a composite of AB/bioresorbable polymer using conditions preferred by our group.
This composite rat femur, with dimensions similar to the femoral bone for which it is
being substituted, will be implanted into the defect. The performance of the implant will
be assessed through a variety of tests including histological, immunohistological, and
biomechanical assessments.

268
References
1.
Holt, D.J.; Chamberlain, L.M.; Grainger, D.W., Cell-cell signaling on co-cultures
of macrophages and fibroblasts. Biomaterials 2010, 31, 9382-9394.
2.
Anderson J.M.; Gristina A.G.; Hanson S.R.; Harker L.A.; Johnson R.J.; Merritt
K.; Naylor P.T.; Schoen F.J., Host reactions to biomaterial and their evaluation. In
Biomaterials science: An introduction to materials in medicine, Ratner B.D.; Hoffman
A.S.; Schoen F.J.; Lemons J.E., eds.; Academic Press: San Diego, California, 1996.
3.
Anderson, J.M.; Rodriguez, A.; Chang, D.T., Foreign body Reaction to
biomaterials. Seminars in Immunology 2008, 20, 86-100.
4.
Greenhalgh, D.G., The role of monocytes/macrophages in wound healing. In
Phagocyte Function: A Guide for Research and Clinical Evaluation, Robinson, J.P.;
Babcock, G.F., eds.; Wiley-Liss: New York, New York, 1998.
5.
Valente, J.F.; Ogle, C.K.; Alexander, J.W., Monocytes and macrophages in solid
organ transplantation: Important implications for the future of transplant immunology.
In Phagocyte Function: A Guide for Research and Clinical Evaluation, Robinson, J.P.;
Babcock, G.F., eds.; Wiley-Liss: New York, New York, 1998.
6.
Wound healing. In Biomaterials Science and Biocompatibility, Silver, F.H.;
Christiansen, D.L., eds.; Springer: New York, New York, 1999.
7.
Hatefi, Y., The mitochondrial electron transport and oxidative phosphorylation
system. Annual Review of Biochemistry 1985, 54, 1015-1069.
8.
Chakrabarti, R.; Kundu, S.; Kumar, S., Vitamin A as an enzyme that catalyzes the
reduction of MTT to formazan by vitamin c. Journal of Cellular Biochemistry 2000, 80,
133-138.
9.
Griffiths, G. D.; Lindsay, C. D.; Upshall, D. G., Examination of the toxicity of
several protein toxins of plant origin using bovine pulmonary endothelial cells.
Toxicology 1994, 90, 11-27.
10. Lacy, A.; O'Kennedy, R., Studies on coumarins and coumarin-related compounds
to determine their therapeutic role in the treatment of cancer. Current Pharmaceutical
Design 2004, 10, 3797-3811.
11. Melo, A. R.; Lasunskaia, E. B.; de Almeida, C. M. C.; Schriefer, A.; Kipnis, T.
L.; da Silva, W. D., Expression of the virulence factor, BfpA, by enteropathogenic
Escherichia coli is essential for apoptosis signaling but not for NF-kappa B activation in
host cells. Scandinavian Journal of Immunology 2005, 61, 511-519.

269
12. Mosmann, T., Rapid colorimetric assay for cellular growth and survival:
Application to proliferation and cytotoxicity assays. Journal of Immunological Methods
1983, 65, 55–63.
13. Hunt, M., Real time PCR. http://pathmicro.med.sc.edu/pcr/realtime-home.htm,
July 1, 2010. Accessed August 6, 2011.
14. Ponchel, F.; Toomes, C.; Bransfield, K.; Leong, F.T.; Douglas, S.H.; Field, S.L.;
Bell, S.M.; Combaret, V.; Puisieux, A.; Mighell, A.J.; Robinson, P.A.; Inglehearn, C.F.;
Isaacs, J.D.; Markham, A.F., Real-time PCR based on SYBR-Green I fluorescence: An
alternative to the TaqMan assay for a relative quantification of gene rearrangements,
gene amplifications and micro gene deletions. BMC Biotechnology 2003, 3, 18.
15. Pfaffl, M.W., A new mathematical model for relative quantification in real-time
RT-PCR. Nucleic Acids Research 2001, 29, 2002-2007.
16. Goidin, D.; Mamessier, A.; Staquet, M.J.; Schmitt, D.; Berthier-Vergnes, O.,
Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and
beta-actin genes as internal standard for quantitative comparison of mRNA levels in
invasive and noninvasive human melanoma cell subpopulations. Analytical
Biochemistry 2001, 295, 17-21.
17. Peng, F.; Yu, X.; Wei, M., In vitro cell performance on hydroxyapatite
particles/poly(L-lactic acid) nanofibrous scaffolds with an excellent particle along
nanofiber orientation. Acta Biomaterialia 2011, 7, 2585-2592.
18. Li, J.; Zheng, W.; Zheng, Y.F.; Lou, X., Cell responses and hemocompatibility of
g-HA/PLA composites. Science China Life Sciences 2011, 54, 366-371.
19. Jeong, S.I.; Ko, E.K.; Yum, J.; Jung, C.H.; Lee, Y.M.; Shin. H., Nanofibrous
poly(lactic acid)/hydroxyapatite composite scaffolds for guided tissue regeneration.
Macromolecular Bioscience 2007, 8, 328-338.
20. Marques, A.P.; Reis, R.L.; Hunt, J.A., Cytokine secretion from mononuclear cells
cultured in vitro with starch-based polymers and poly-L-lactide. Journal of Biomedical
Materials Research Part A 2004, 71, 419-429.
21. Hunt, J.A.; Callaghan, J.T., Polymer-hydroxyapatite composite versus polymer
interference screws in anterior cruciate ligament reconstruction in a large animal model.
Knee Surgery, Sports Traumatology, Arthroscopy 2008, 16, 655-660.
22. Hojo, Y.; Kotani, Y.; Ito, M.; Abumi, K.; Kadosawa, T.; Shikinami, Y.; Minami,
A., A biomechanical and histological evaluation of a bioresorbable lumber interbody
fusion cage. Biomaterials 2005, 26, 2643-2651.

270
23. Williams, J.B.; Irvine, J.W., Preparation of the inorganic matrix of bone. Science
1954, 119, 771-772.
24. Wiegand, T.E., Resorbable Polymer-Hydroxyapatite Composites for Bone
Trauma Treatment: Synthesis and Properties, Ph.D. dissertation, University of
Nebraska, Lincoln, Nebraska, 2011.
25. Lee, S. H.; Kim, B. S.; Kim, S. H.; Choi, S. W.; Jeong, S. I.; Kwon, I. K.; Kang,
S. W.; Nikolovski, J.; Mooney, D. J.; Han, Y. K.; Kim, Y. H., Elastic biodegradable
poly(glycolide-co-caprolactone) scaffold for tissue engineering. Journal of Biomedical
Materials Research Part A 2003, 66A, 29-37.
26. Stolt, M.; Viljanmaa, M.; Sodergard, A.; Tormala, P., Blends of poly(epsiloncaprolactone-b-lactic acid) and poly(lactic acid) for hot-melt applications. Journal of
Applied Polymer Science 2004, 91, 196-204.
27. Zhang, J.; Wang, L. Q.; Wang, H. J.; Tu, K. H.; Liu, L., Amphiphilic block
copolymers based on methoxy poly(ethylene glycol) and either crystalline or
amorphous poly(caprolactone-b-lactide): Synthesis, solid-state and aqueous solution
characterizations. Journal of Applied Polymer Science 2007, 105, 915-927.
28. Zhong, Z. Y.; Ankone, M. J. K.; Dijkstra, P. J.; Birg, C.; Westerhausen, M.;
Feijen, J., Calcium methoxide initiated ring-opening polymerization of epsiloncaprolactone and L-lactide. Polymer Bulletin 2001, 46, 51-57.
29. Zhang, Y.; Zhang, Q.; Cheng, K.; Xu, J., Monocarboxyl-end-grouped
polycaprolactam with an adjustable molecular weight. Journal of Applied Polymer
Science 2004, 92, 722-727.
30. Holmes, B.S.; Moniz, W.B.; Ferguson, R.C., NMR study of nylon 66 in solution
(1H, 13C, and 15N NMR using adiabatic J cross polarization). Macromolecules 1982, 15,
129-132.
31. Ziats, N.P.; Miller, K.M.; Anderson, J.M., In vitro and in vivo interactions of cells
with biomaterials. Biomaterials 1988 9, 5-13.
32. ter Steege, J.C.; van de Ven, M.W.; Forget, P.P.; Brouckaert, P.; Buurman, W.A.,
The role of endogenous IFN-gamma, TNF-alpha and IL-10 in LPS-induced nitric oxide
release in a mouse model. Cytokine 1998 10, 115-123.
33. Douglas, S.D.; Tuluc, F., Morphology of monocytes and macrophages. In
Williams Hematology 8th ed., Lichtman, M.A.; Kipps, T.J.; Seligsohn, U.; Kaushansky,
K.; Prchal, J.T., eds.; McGraw-Hill: New York, New York, 2010.

271
34. Dalby, M.J.; Riehle, M.O.; Sutherland, D.S.; Agheli, H.; Curtis, A.S.G., Changes
in fibroblast morphology in response to nano-columns produced by colloidal
lithography. Biomaterials 2004, 25, 5415-5422.
35. Ottaviani, R. A.; Wooley, P. H.; Song, Z.; Markel, D. C., Inflammatory and
immunological responses to hyaluronan preparations using a murine biocompatibility
model. Journal of Bone and Joint Surgery-American Volume 2007, 89, 148-157.

